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1. PRESSURE ULCER DEFINITION AND AETIOLOGY 
Pressure ulcers are defined as “localized injuries to the skin and/or underlying 
tissue, usually over a bony prominence, caused by pressure, or pressure in 
combination with shear” (National Pressure Ulcer Advisory Panel and European 
Pressure Ulcer Advisory Panel (NPUAP & EPUAP), 2009). Pressure ulcers 
develop as a result of the applied external mechanical load, which comprises all 
types of external forces applied to a patients’ skin and underlying tissue due to 
the contact with a support surface (NPUAP & EPUAP, 2009). The extent of the 
skin and/or tissue damage will depend on the duration and magnitude of the 
applied load (pressure and shear). A  high mechanical load for a short period, as 
well as a low mechanical load applied for a long period can lead to tissue 
damage (Loerakker et al., 2011; NPUAP & EPUAP, 2009; Stekelenburg et al., 
2008) 
 
Pressure ulcer development is a complex and multi-factorial process that is still 
not fully understood. When the skin and/or underlying tissue are exposed to 
pressure and shear, a combination of several mechanisms can result in tissue 
damage. The primary mechanisms include oxygen deprivation (NPUAP & 
EPUAP, 2009), direct cell deformation (Ceelen et al., 2008; Gawlitta et al., 
2007a; Stekelenburg et al., 2007), ischemic reperfusion injury (Peirce et al., 
2000; Reid et al., 2004; Tsuji et al., 2005), and impaired lymphatic drainage 
(Miller and Seale, 1981).  
 
Oxygen deprivation or ischemia was recognised as one of the primary etiological 
factors in pressure ulcer development. Pressure and shear cause occlusion of 
the capillary blood vessels, which leads to a decrease or absence of nutrient 
supply and the accumulation of metabolic waste products. Furthermore, the 
capillary permeability will increase, and oedema and cellular infiltration will 
occur, leading to tissue damage and necrosis (Coleman et al., 2014; Daniel et 
al., 1981; Kosiak, 1961; Kottner et al., 2009a; Loerakker et al., 2011). The role 
and effects of oxygen deprivation become more important when there is a 
prolonged exposure to pressure and shear (Loerakker et al., 2011).  
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Direct cell deformation assumes that a mechanical load results in a variety of 
effects, such as local membrane stresses, and cytoskeletal reorganisation. 
These changes of the mechanical and chemical environment of the cell induce 
tissue damage. This tissue damage only occurs if a deformation threshold is 
exceeded. Cell death can occur rapidly (Gefen et al., 2008; Loerakker et al., 
2011). Furthermore, the amount of tissue damage is correlated with the level of 
the deformation (Loerakker et al., 2011). In contrast to oxygen deprivation, the 
effect of direct cell deformation occurs immediately if the deformation threshold 
is exceeded (Gawlitta et al., 2007b; Gawlitta et al., 2007a; Loerakker et al., 
2011).  
 
Ischemic reperfusion injury can be defined as tissue and cellular injury resulting 
from the re-establishment of blood flow and oxygen to a previously ischemic 
tissue (Pretto, 1991). Ischemic reperfusion injury was found to be a causal factor 
for several post-ischemic pathologies, such as myocardial infarction, but their 
role in the development of pressure ulcers is less known and only recently 
discussed (Bosboom et al., 2001; Peirce et al., 2000; Tsuji et al., 2005).  
The role of ischemic reperfusion refers to the activation of damaging processes 
as a result of re-introduction of oxygen generating reactive oxygen species, such 
as unstable and highly reactive free radicals (Peirce et al., 2000; Tsuji et al., 
2005). Gradual reperfusion of ischemic tissue is reported as a possible method 
to prevent an ischemic reperfusion injury (Okamoto et al., 1986). An in-vitro 
study in animals by Unal et al. (2001) found that gradual reperfusion of ischemic 
tissue resulted in a reduction of ischemic reperfusion injury (Unal et al., 2001).  
 
Impaired lymphatic drainage can contribute to pressure ulcer development due 
to the accumulation of anaerobic metabolic waste products as a result of 
occluded and/or ischemic lymph vessels. This accumulation of waste products 
causes tissue necrosis, thereby contributing to the development of pressure 
ulcers (Krouskop et al., 1978). 
Pressure ulcers can develop both superficially (involving the epidermis and 
dermis), or in the deep tissues (affecting fat, muscle and bone) (Bouten et al., 
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2005), and may occur from different pathways.  Both, a bottom-up and top-down 
pathway lead to skin and tissue damage (Bouten et al., 2003; Gefen et al., 2008; 
Kottner et al., 2009a; Kottner and Gefen, 2012; Stekelenburg et al., 2008).  In 
the bottom-up pathway, deep tissue pressure ulcers arise from the muscle 
layers over bony prominences. These pressure ulcers progress towards the 
skin, and are difficult to identify, although considerable damage of the muscle, 
fascia, and subcutaneous fat may be present (Bouten et al., 2003).  In the top-
down pathway, detachment of the superficial skin layers sometimes progress 
into deeper tissue damage. The detachment of the superficial skin is 
predominantly caused by shearing stress (Bouten et al., 2003; Reuler and 
Cooney, 1981). Pressure ulcers that occur from this top-down pathway are 
relatively easily detectable (Bouten et al., 2003). Furthermore, the threshold for 
tissue to resist or recover from periods of pressure and shear, and hence for 
tissue damage to develop, differs for skin, fat and muscle (Daniel et al., 1981; 
Stekelenburg et al., 2006; Bouten et al., 2003). Skin and subcutaneous fat are 
more resistant to pressure than muscle tissue. Furthermore, Lahmann and 
Kottner (2011) have deducted that the aetiology of superficial and severe 
pressure ulcers may differ, because severe pressure ulcers were associated 
with other risk factors compared to superficial pressure ulcers (Lahmann and 
Kottner, 2011). 
 
Specific risk factors can be used to identify patients at risk for pressure ulcer 
development. These factors influence the susceptibility and tolerance of the 
individual for pressure ulcer development, as well as what Coleman et al. (2014) 
referred to as the effects of the mechanical boundary conditions. These 
mechanical boundary conditions represents “the mechanical load applied to the 
skin at the interface with the supporting surface” (Coleman et al. 2014, p. 4), and 
includes the type, duration and magnitude of the mechanical load (Coleman et 
al., 2013; NPUAP & EPUAP, 2009; Coleman et al., 2014). Nine risk factors, 
including impaired mobility and activity, poor perfusion and nutrition, skin and 
pressure ulcer status, moisture, impaired sensory perception and response, 
diabetes and low albumin, were identified as key risk factors (Figure 1)  
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(Coleman et al., 2014). These risk factors were classified as direct and indirect 
causal factors and identified as key elements in a newly proposed pressure ulcer 
conceptual framework (Figure 1) (Coleman et al., 2014). 
 
 
 
 
2. PROBLEM DEFINITION AND IMPACT OF PRESSURE ULCERS ON HEALTH, 
FUNCTIONING AND WELL-BEING 
Pressure ulcers are a common and debilitating health care problem. They occur 
in all healthcare services and can affect patients or residents that are subjected 
to prolonged pressure and shear (Bouten et al., 2003). Pressure ulcer 
prevalence (category I–IV) ranges from 8.8% to 29.9% in nursing homes 
(Gunningberg 2004, Lahmann et al. 2005, Tannen et al. 2006, Muurinen et al. 
2009) and between 7.3% and 23% in hospitals throughout Europe and North-
America (Hurd and Posnett, 2009; Kottner et al., 2009c; Vanderwee et al., 
2007a; Whittington and Briones, 2004). The 2008 Belgian pressure ulcer 
prevalence study revealed that 12.1 % of the patients admitted to hospital had a 
pressure ulcer (category I-IV). Most pressure ulcers occurred at the sacrum 
(48.1%) and heels (38.4%) (Vanderwee et al., 2011). A study conducted in 
Figure 1  New pressure ulcer conceptual framework by Coleman et al. (2014, p.11) 
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Flemish nursing homes, reported a pressure ulcer prevalence of 14.6% 
(Demarré et al., 2012b).   
In hospitals, incidences varied between 0.78 % for pressure ulcers category I-IV 
during the length of stay in Germany and a weekly incidence of pressure ulcers 
category II-IV of 6.2% in the Netherlands (Petzold et al., 2014; Schoonhoven et 
al., 2002). In North American hospitals, pressure ulcer incidence figures during 
the length of stay ranged between 7.0% and 9.0% (Whittington and Briones, 
2004; Bergstrom et al., 1998). In nursing homes, pressure ulcer incidence 
figures between 11.4% and 29% were observed using a follow-up period 
between one week and 21 months (Bergstrom et al., 1998; Horn et al., 2004; 
Ooi et al., 1999). 
 
Pressure ulcers have a profound impact on residents’ and patients’ overall well-
being (Hopkins et al., 2006; Langemo et al., 2000), including a physical, social, 
and financial burden (Hopkins et al., 2006; Langemo et al., 2000).  
 
Studies exploring experiences of living with a pressure ulcer have described 
their impact on a person’s life and well-being (Hopkins et al., 2006; Langemo et 
al., 2000). Accepting compulsory bedrest, immobility, the loss of independence 
and the loss of control were found very tough to deal with (Hopkins et al., 2006; 
Langemo et al., 2000). Moreover, pressure ulcers can initiate a changed body 
image, and create important restrictions for the person and others. Emotions like 
powerlessness, worry, depression and worthlessness have been experienced 
(Hopkins et al., 2006). Furthermore, pressure ulcers have created a feeling of 
dependence from others, and the fear to be a burden to others. Pressure ulcers 
also resulted in restricted interaction with others and has created a feeling of 
social isolation (Gorecki et al., 2009).  
Pain, complications and prolonged hospitalisation have been described as 
additional consequences for patients (Gorecki et al., 2009; Gorecki et al., 2011; 
Hopkins et al., 2006; Langemo et al., 2000). Pain as a result of pressure ulcers 
or related to the treatment of pressure ulcers is a serious and frequent problem 
with a profound impact on the patients well-being (Gorecki et al., 2009; Gorecki 
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et al., 2011; Hopkins et al., 2006; Langemo et al., 2000). The pain contributes to 
sleep disturbance, it negatively impacts mood, and creates feelings of anxiety. 
Furthermore, it interferes with daily living activities and social life (Gorecki et al., 
2011).  
Prolonged length of stay attributable to pressure ulcer development has been 
examined in several studies, with an extra length of stay varying between 4 and 
26 days (Allman et al., 1999; Berthier et al., 2005; Graves et al., 2005). Although 
it has been argued that pressure ulcers are a cause of increased length of stay 
(Allman, 1998), pressure ulcers occur more often in patients with increased age, 
comorbidities and underlying conditions or diseases (Brown, 2003; Moore, 
2009). The length of stay attributable to pressure ulcers, controlled for the 
primary diagnosis or other comorbidities, is less well examined. Furthermore, 
Graves et al. (2005) reported that the distribution of the extra length of stay due 
to pressure ulcers was positively skewed and therefore averages presented in 
some studies, such as 16.3 days by Berthier et al. (2005) and 17.6 days by 
Allman et al. (1999), cannot be compared with the median extra length of stay 
reported by Graves et al. (2005) (4.31 days). 
Evidence on mortality attributable to pressure ulcers remains unclear. As said 
before, pressure ulcers occur more often in patients and residents with another 
primary condition or disease (Brown, 2003; Moore, 2009). Likewise, it has been 
argued that death may be more related to organ failure and underlying 
conditions and diseases (such as spinal cord injury or multiple sclerosis) than to 
the presence of a pressure ulcer alone (Berlowitz and Wilking, 1990; Brown, 
2003; Graves et al., 2005; Berlowitz and Wilking, 1990; Redelings et al., 2005). 
 
Besides their impact on the patients’ overall well-being, pain, and length of stay, 
pressure ulcers also impose a substantial financial burden on all involved parties 
(Gorecki et al., 2009; Hopkins et al., 2006; Langemo et al., 2000). Several 
studies calculated the cost of pressure ulcer prevention and treatment in 
different countries, using different methodologies, and including different 
healthcare services. The development of, mostly avoidable, pressure ulcers is 
causing a considerable extra cost leading to an overall cost ranging between 1% 
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of the health care budget in the Netherlands up to 4% of the health care budget 
in the United Kingdom (Bennett et al., 2004; Severens et al., 2002).  
 
3. PRESSURE ULCER CLASSIFICATION 
The first pressure ulcer classification was proposed in 1975 by Shea (Shea, 
1975). It was primarily used to describe the degree of tissue damage (Dealey 
and Lindholm, 2006). Since then, several pressure ulcer classifications have 
been developed (Ankrom et al., 2005; Dealey and Lindholm, 2006). The best 
known and most used classification is the NPUAP/EPUAP classification system, 
using four stages or categories of pressure ulcers (NPUAP & EPUAP, 2009) 
(Table 1). This system defines non-blanchable erythema of the intact skin as a 
pressure ulcer category I, and partial thickness loss of dermis as a pressure 
ulcer category II. If full thickness tissue loss is present, this is defined as a 
pressure ulcer category III. A full thickness tissue loss with exposed bone, 
tendon or muscle is categorised as a pressure ulcer category IV  (NPUAP & 
EPUAP, 2009). 
 
Observation of non-blanchable erythema (category I pressure ulcer) is 
considered to be an important sign of risk for pressure ulcer development 
(Defloor et al., 2004; Vanderwee et al., 2007b; Schoonhoven et al., 2002). Non-
blanchable erythema is differentiated from blanchable erythema if the blanching 
remains despite pressure being removed. To differentiate non-blanchable from 
blanchable erythema, two methods are frequently used. In the first method a 
finger is pressed on the skin. In the second method a transparent plastic disc is 
used to apply pressure to the skin (Halfens et al., 2001).   
The occurrence of a pressure ulcer category II-IV (skin breakdown) is 
considered as a primary endpoint in effectiveness studies (Defloor et al., 2004; 
Nixon et al., 2006a; Vanderwee et al., 2005). Two additional categories, 
Unstageable/Unclassified and Suspected Deep Tissue injury, are used in the 
United States. Unstageable or unclassifiable pressure ulcers are defined as full 
thickness tissue loss, but the severity cannot be determined because of the 
presence of slough and/or eschar in the wound bed. After removal of the slough 
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Table 1   Pressure ulcer classification (NPUAP & EPUAP, 2009)  
Pressure ulcer category Definition 
Category I Intact skin with non-blanchable erythema of a localised area usually 
over a bony prominence.  A darkly pigmented skin may not have 
visible blanching, but the colour of the skin can differ from the 
surrounding area, which can be painful, firm, soft, warmer or cooler 
compared to adjacent tissue 
Category II Partial thickness loss of dermis. A category II pressure ulcer presents 
as a shallow open ulcer with a red pink wound bed without slough, or 
as an intact or open blister.  The blister can be filled with serum or  
sanguineous serum 
Category III Full thickness tissue loss. Subcutaneous fat may be visible in a 
Category III pressure ulcer, but bone, tendon or muscles are not 
exposed. Slough can be present and the depth of the tissue loss can 
be assessed. Undermining and tunnelling of the wound may be 
present. The depth of a Category III pressure ulcer depends on 
presence and thickness of the subcutaneous tissue, which varies by 
anatomical location. Category III ulcers will be shallow on the nose 
bridge, the ear, occiput and malleolus, whereas they can be extremely 
deep at the sacrum. The bone or tendon should not visible or directly 
palpable 
Category IV Full thickness tissue loss with visible or palpable bone, tendon or 
muscle. Slough or eschar can be present, as well as undermining and 
tunnelling. The depth of a Category IV pressure ulcer varies by 
anatomical location. Category IV ulcer can be shallow at the nose 
bridge, ear, occiput, or malleolus, due to the absence of 
subcutaneous tissue. Category IV ulcers may be complicated with 
osteomyelitis or osteitis  
 
and/or eschar, the pressure ulcer will be classified as a category III or category 
IV pressure ulcer (NPUAP & EPUAP, 2009). 
The differentiation between pressure ulcers and other lesions, especially 
incontinence-associated dermatitis (IAD) and friction lesions, has been found 
difficult (Beeckman et al., 2007; Parish et al., 2007; Defloor et al., 2006). IAD 
can be defined as a reactive response of the skin due to chronic exposure to 
urine and faecal material (Gray et al., 2012). To differentiate pressure ulcers 
from IAD, wound-related characteristics (causes, location, shape, depth, edges, 
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and colour), along with patients related characteristics should be considered 
(Defloor et al., 2005b). Friction lesions can be defined as damage caused by 
“rubbing a part of the body against another part or the force that resists relative 
motion between two bodies in contact and/or material elements sliding against 
each other” (Antokal et al., 2012, p.1). Skills to improve pressure ulcer 
classification and the accurate differentiation from other lesions in clinical 
practice can be improved by education (Beeckman et al., 2008; Beeckman et al., 
2010). 
 
4. PRESSURE ULCER PREVENTION 
An important proportion of the patients in hospitals, nursing homes and in 
community care are at risk for pressure ulcer development. As healthcare 
resources are scarce, risk assessment is essential to establish a pressure ulcer 
prevention policy. Following risk assessment, preventive measures need to be 
allocated striving for a minimal pressure ulcer incidence, as well as limiting the 
associated expenditures. The identification of patients in need of prevention 
needs to be accurate (Defloor and Grypdonck, 2004; Moore, 2009). In this 
section, an overview of risk assessment methods and preventive strategies is 
provided. 
 
4.1 RISK ASSESSMENT 
Risk assessment aims to consistently and correctly distinguish patients who are 
at risk to develop a pressure ulcer, from those not at risk (Defloor and 
Grypdonck, 2004; Moore and Cowman, 2014). Conflicting evidence exists on the 
merits of different risk assessment methods. (Balzer et al., 2013; Balzer et al., 
2014; Schoonhoven et al., 2006). 
Current national and international guidelines advise to include structured risk 
assessment for each patient including the use of a risk assessment scale, the 
nurses’ clinical judgement, and a head to toe skin assessment (Beeckman et al., 
2013a; National Institute for Clinical Excellence, 2005; NPUAP & EPUAP, 2009). 
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Risk assessment scales have been developed to facilitate the identification of 
patients at risk. A risk assessment scale is of interest if it enables a quick, easy 
and valid representation of risk, and if risk can be measured reliably (Kottner and 
Balzer, 2010; Papanikolaou et al., 2007). For research purposes, a risk 
assessment scale is also frequently used to compare baseline patient 
characteristics between studies.  
 
The first scale, developed in 1962, was the Norton scale (Norton et al., 1975). 
The Norton scale includes five items: mobility, continence, mental status, 
general health and activity (Norton et al., 1975). Out of more than 40 
instruments, developed to assess pressure ulcer risk, the Norton and Braden 
scale (Braden and Bergstrom, 1989) are the most commonly used risk 
assessment scales  (Papanikolaou et al. 2007). The Braden scale was published 
for the first time in 1985 and consists of 6 subscales (nutrition, mobility, sensory 
perception, moisture, activity, and friction and shear). Sum scores count up 
between 6 and 23, and here as well lower scores correspond to higher risk 
(Bergstrom et al., 1987; Braden and Bergstrom, 1987; Braden and Bergstrom, 
1994).  
 
A risk assessment scale has a (population-) specific cut-off point. Below this 
point a patient is assumed to be at-risk. There is, however, little and conflicting 
evidence concerning these cut-off points, and no threshold was found to 
outperform another (Beeckman et al., 2013a; Papanikolaou et al., 2007). For the 
Braden scale, a cut-off score of 17 is commonly used in international research 
(Baumgarten et al., 2010; Defloor et al., 2005a; Vanderwee et al., 2005; 
Vanderwee et al., 2007a).   
 
Numerous studies focussed on the validity and reliability of risk assessment 
scales, but these studies support the validity and reliability only to a limited 
extent (Beeckman et al., 2013a; Moore and Cowman, 2014; Papanikolaou et al., 
2007; Kottner and Balzer, 2010; Schoonhoven et al., 2002). Critical concerns 
about the use of risk assessment scales are related to the limited utility of equal-
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weighting scoring of the items (Papanikolaou et al., 2007) and the items included 
in the scales. This has led to problems in sensitivity and specificity of the scales, 
and a lack of evidence that risk assessment scales can decreases pressure 
ulcer incidence (Beeckman et al., 2013a; Moore and Cowman, 2014; 
Papanikolaou et al., 2007; Kottner and Balzer, 2010; Schoonhoven et al., 2002).  
 
Clinical judgement can be defined as the “interpretation or conclusion on a 
patient’s needs, concerns, or health problems and/or judgement to take action” 
(Tanner, 2006). Balzer et al. (2014) found that assessing the risk for pressure 
ulcer development by using clinical judgement was based on a combination of 
multiple patient characteristics. Risk enhancing factors (such as mobility, activity, 
vulnerability enhancing conditions, and care dependency), and protective 
conditions (such as mental capabilities, motivation, and expected duration of 
immobility) were included in clinical judgement (Balzer et al., 2014). 
Clinical judgement is a commonly used approach for risk assessment in care as 
usual, but the prognostic accuracy remains debatable (Saleh et al., 2009; 
Beeckman et al., 2013a). According to Saleh et al. (2009) clinical judgement is 
not less effective than the use of a risk assessment scale in reducing pressure 
ulcer incidence, but neither showed sufficient specificity and sensitivity (Saleh et 
al., 2009).  
 
The skin status, and more specifically the presence of non-blanchable erythema, 
has been identified as a risk factor for the development of pressure ulcers 
category II-IV (Allman et al., 1995; Nixon et al., 2007; Vanderwee et al., 2007b). 
According to Vanderwee et al. (2007b), the number of patients receiving 
preventive measures could be reduced with 50% if prevention is postponed until 
non-blanchable erythema occurs compared to the number of patients assessed 
at risk using the Braden scale. This was achieved without increasing pressure 
ulcer incidence (Vanderwee et al. 2007b). However, pressure ulcers can also 
develop from within the deep tissue and become visible later. Therefore, only 
relying on the presence of non-blanchable erythema for risk assessment is 
insufficient. Nonetheless, when non-blanchable erythema is observed, 
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preventive measures should be started immediately (Vanderwee et al., 2007b). 
Therefore, head to toe skin assessment is recommended as part of a structured 
risk assessment policy in all health care settings (NPUAP & EPUAP, 2009). 
 
4.2 PREVENTION  
Adequate prevention focuses on reducing the amount and the duration of 
pressure and shear (Figure 2).  
 
 
 
A support surface is “a specialised device for pressure redistribution designed 
for management of tissue loads” (NPUAP, 2007, p. 1). The contact area can be 
increased by using reactive support surfaces, such as viscoelastic foam 
mattresses and air-fluidised devices (Figure 3). Increase of the contact area in 
reactive support surfaces is provided by immersion and envelopment (NPUAP & 
EPUAP, 2010). Immersion refers to the ability of the support surfaces to allow a 
patient to sink in the mattress or cushion. The deeper the patient sinks in the 
support surface, the more the patient’s weight is redistributed and the lower the 
Redistribution 
of pressure
Increased contact area
reduces interface pressure
Patient 
postures
to increase 
contact area 
(eg. 30° tilt 
position)
Reactive 
support 
surface
(eg. visco-
elastic foam, 
air-fluidised)
Pressure  relief
removes pressure from 
vulnerable area
Patient 
repositioning 
to remove 
pressure from 
a particular 
anatomical 
location
Active support 
surface 
(eg. 
alternating 
device)
Lifting body 
parts 
(eg. heel 
offloading)
Figure 2   Methods of pressure redistribution  (NPUAP & EPUAP, 2010)  
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pressures will be. Envelopment refers to the moulding of the support surface to 
the patient’s body. The more the patient’s body is enfolded by the support 
surface the larger the contact area and the lower the pressures will be (NPUAP 
& EPUAP, 2010).  
 
               
 
 
 
Another method to increase the contact area is the use of positions that 
decrease pressure over bony prominences. Positions such as the 30° tilt 
position, prone position, or lateral 30° position enables the preservation of 
perfusion and lymph drainage, and minimises cell deformation of the weight 
bearing areas (Figure 4) (Defloor, 2000; Moore, 2009; NPUAP & EPUAP, 2009).  
 
 
 
 
 
 
 
 
 
Pressure redistribution can also be achieved by removing pressure and shear 
from vulnerable areas, defined as pressure relief (NPUAP & EPUAP, 2010) 
(Figure 2). Pressure relief can be established through patient repositioning, the 
application of active support surfaces, and lifting body parts. 
Reactive support surface Active support surface 
Figure 3  Active and reactive support surfaces  (Phillips et al., 2012) 
  
 
 
  
 Lateral 30° 
    
 
 
   
 
 
    
 
 Semi-Fowler 30° - 30° 
    
 
  
 
30° 30° 
 
   
    
 
 Prone 
Figure 4  Patient postures (Defloor, 2000) 
30° 
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Patient repositioning is defined as relieving pressure and shear on particular 
body parts at risk for pressure ulcer development (Beeckman et al., 2013a).  
Providing repositioning for each patient at risk for pressure ulcer development is 
recommended (NPUAP & EPUAP, 2009). Repositioning may vary in terms of 
frequency and positions. Although evidence on the most effective repositioning 
frequency is inconclusive, the repositioning frequency and the posture should be 
determined and adapted based on an individual assessment and should take 
into account patient-related factors as medical condition, skin condition, level of 
activity and mobility, comfort, and plan of care, as well as support surface 
characteristics (Beeckman et al., 2013a; Moore et al., 2013).  
 
Another method to intermittently remove pressure from vulnerable areas is the 
use of an active support surface (NPUAP & EPUAP, 2010).  An active support 
surface is a powered surface that can change load distribution properties, with or 
without body weight of the patient resting on the surface. It provides pressure 
relief via cyclic inflating and deflating air cells (NPUAP, 2007). Differences 
between several types of active support surfaces can be related to differences in 
surface characteristics, such as cycle time, air cell inflation sequence, and 
pressure amplitude.  
 
The pressure amplitude is the difference between the highest and lowest 
interface pressure (Tissue Viability Society, 2010). An example of an active 
support surface is an alternating pressure air mattress (APAM), available as 
APAM overlays and APAM replacement mattresses. The inflation and deflation 
of the air cells of an APAM are characterised by a steep, one-stage inflation or 
deflation. 
 
Alternating Low Air Pressure Mattresses (ALPAMs) are designed to generate 
lower pressures compared to APAMs. Besides shifting pressure or shear to 
other areas of the body, ALPAMs are assumed to improve envelopment and 
immersion of the body in the underlying support surface due to these lower 
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pressures. The ALPAM air cells are also characterized by a steep inflation and 
deflation, and are therefore defined as one-stage ALPAMs.   
 
Recently modified designs have changed this steep transition into a gradual, 
multi-staged inflation and deflation in response to the hypothesis of decreasing 
tissue damage by gradual reperfusion of ischemic tissue (Unal et al., 2001). 
These modified devices are defined as multi-stage ALPAMs.  
 
Both APAMs and ALPAMs are frequently used throughout European health care 
services (Manzano et al., 2013; Nixon et al., 2006a). In Belgium, one third 
(33.3%) of all patients at risk (Bradenscore <17 or pressure ulcer) are allocated 
to such an alternating device (Vanderwee et al., 2011). The use of alternating 
devices is more technical and less labour intensive than repositioning (Moore, 
2009; Schuurman et al., 2009). Furthermore, the use of these alternating 
devices is especially recommended when regular repositioning is contra-
indicated (Vanderwee et al., 2005).  The incidence of pressure ulcers (category 
II-IV) on APAM overlays ranged between 10.7% (Nixon et al., 2006b) and 
15.3% (Vanderwee et al., 2005) in adult populations at risk. Cavicchioli and 
Carella (2007) found an incidence of pressure ulcers (category I-IV) on one-
stage ALPAMs of 2.9 %.  
 
Insufficient evidence is available to guide decision making as to which type of 
alternating device is most effective or the best choice for a specific patient 
(McInnes et al., 2012). Neither systematic reviews nor guidelines could conclude 
on the superiority of a specific alternating pressure device over another 
(Beeckman et al., 2013a; McInnes et al., 2012).  
 
Heel prevention 
Independently of the support surface being used, heel offloading needs to be 
provided. If pressure ulcers occur, heels are frequently affected (Demarré et al., 
2012b; Vanderwee et al., 2011). Due to little adipose subcutaneous tissue at the 
heel, tissue damage may develop quickly and become serious as a result of the 
Chapter 1 
32 
mechanical loading (Gefen, 2010; Wong and Stotts, 2003; NPUAP & EPUAP, 
2009). Evidence on pressure ulcer prevention at the heels is scarce and 
generally not provided by high-quality Randomised Controlled Trials (RCT’s) 
(McGinnis and Stubbs, 2011; Wong and Stotts, 2003).  Heel offloading that can 
realise pressures of 0mmHg at the heel area is the most appropriate and 
effective way to prevent heel pressure ulcers.  
A pillow has been recommended to provide heel offloading (NPUAP & EPUAP 
2009). Vanderwee et al. (2005) questioned if the use of a regular pillow to 
offload the heel from the mattress can be provided in a correct way. Some 
patients tend to push away or relocate the cushion under their legs (Vanderwee 
et al., 2005). Bottoming out of the pillow is another possible disadvantage of the 
use of a regular pillow. When bottoming out occurs, the heels will contact the 
support surface underneath. When using a pillow, efforts must be made to 
educate the patient and health care workers to provide correct heel offloading. 
In a comparative study of Heyneman et al. (2009), based on a pooled database, 
the use of a wedge-shaped cushion was found to be more effective to offload 
the heels than a regular pillow (Heyneman et al., 2009). 
 
Prevention when seated 
Prevention should be provided on a continuous basis during the time an 
individual is at risk (Bergstrom 2005, NPUAP & EPUAP, 2009; Vanderwee et al., 
2009). Besides pressure ulcer prevention while lying in bed, pressure ulcer 
prevention must also be provided when seated. Preventive measures when 
seated are founded on the same principles as pressure ulcer prevention in bed. 
Due to the decreased contact area between the ischium and the underlying 
support surface, pressure and shear will be higher than when lying (Defloor and 
Grypdonck, 1999; Linder-Ganz et al., 2007; Linder-Ganz and Gefen, 2009). 
Therefore the use of a pressure redistributing seat cushion, such as a static air 
cushion or viscoelastic foam cushion is recommended for patients at risk 
(Defloor, 2000; NPUAP & EPUAP, 2009). Little is known about the frequency of 
repositioning while seated in a chair, but as a result of increased mechanical 
load, repositioning must be more frequently provided than when lying in bed 
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(Defloor, 2000; Defloor et al., 2004). When positioning the patient in a chair a 
posture minimizing the pressure and shear to the skin and underlying tissue 
must be applied. In reclined position, the pelvis should be brought in a slightly 
flex forward and the footrest should be adjusted to position the thighs slightly 
lower than horizontal. When sitting upright in a chair, the feet should rest on the 
ground or on a footrest to avoid sliding down (Defloor, 2000; NPUAP & EPUAP, 
2009). 
 
Problems to successfully implement international guidelines in daily practice still 
lead to inadequate and/or incomplete pressure ulcer prevention for (the majority 
of) patients at risk (Baumgarten et al., 2010; Beeckman et al., 2013b; 
Gunningberg, 2005; van Gaal et al., 2011; Vanderwee et al., 2011; Defloor, 
2000; Pieper et al., 1997).  In Belgian hospitals only 10.8% of the patients at risk 
(Bradenscore < 17 or pressure ulcer) received prevention that is fully compliant 
to guidelines in bed and when seated. Correspondingly, 6.9% of nursing home 
residents at risk received prevention fully compliant to guidelines (Demarré et 
al., 2012b; Vanderwee et al., 2011). 
 
Moreover, even when standardised prevention is provided, patients still develop 
new pressure ulcers (McInnes et al., 2012; Nixon et al., 2006a; Theaker et al., 
2005). This indicates that the current preventive measures may still be 
insufficient for some patients that have an increased risk to develop a pressure 
ulcer notwithstanding the preventive measures they receive.  
 
5 PRESSURE ULCERS AND HEALTH ECONOMICS 
Pressure ulcers have, besides an impact on the patients’ overall well-being as 
described above, also a financial impact on all involved parties (Bennett et al., 
2004; Severens et al., 2002). 
Health economics is the discipline which deals with the application of economic 
principles and theories to health and the health sector (Annemans, 2008). 
Different approaches in health economics can be perceived. A frequently used 
approach is the analysis of the cost of illness/injury. With this, the economic 
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burden of an injury or illness is calculated by quantifying the (direct) medical 
costs (Hodgson and Meiners, 1982). A second approach is the budget impact 
analysis. This approach analyses the financial impact of an intervention. A third 
approach consists of health economic evaluations (Ackaert et al., 2010).  A 
health economic evaluation can be defined as a comparative analysis of both 
the costs and health effects of two or more alternative health interventions 
(Annemans, 2008). Three characteristics need to be fulfilled: (1) a systematic 
measurement of costs and health effects, (2) a comparison with alternative 
approaches and, (3) a combination of both costs and effects in the analysis to 
examine the cost-effectiveness (Ackaert et al., 2010). For example, the cost-
effectiveness of pressure ulcer prevention can be calculated by balancing the 
costs of prevention with the achieved patient outcomes. 
 
A growing awareness of the economic impact of pressure ulcers is partly related 
to constrained public and healthcare finances. Insight in the cost related to the 
treatment of mainly avoidable events, such as pressure ulcers is an obvious 
need. Cost-of-illness studies provide insight in the economic burden of pressure 
ulcers for society, healthcare services, insurances, and patients (Larg and Moss, 
2011). These insights can help policymakers and health service management to 
identify the cost drivers for pressure ulcer prevention and treatment. 
Furthermore, it may guide decision making about allocating healthcare 
resources such as materials and nursing staff.  
 
5.1 PERSPECTIVES 
The health economic perspective specifies the chosen focus of the group that 
are bearing the costs (Larg and Moss, 2011). Different health economic 
perspectives can be perceived, such as the societal perspective, government 
perspective, organisational or institutional perspective, insurance perspective 
and patients’ perspective. The terminology to describe health care perspectives 
used is diverse, and the choice of perspective is often not (clearly) reported. 
Besides this heterogeneity in used terminology, the terminology is often not or 
not clearly defined (Larg and Moss 2011). The choice of perspective should be 
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determined based on the research goal and the disease under study, but also 
the available cost data will influence the chosen perspective (Larg and Moss, 
2011). Generally, the societal perspective is preferred as it provides the cost for 
the overall population, including costs outside the health care sector (Byford & 
Raftery 1998, Cleemput et al., 2011; Larg and Moss, 2011). The broader the 
perspective the less chance cost shifts between sectors will affect the outcome, 
thereby minimising the potential biases of more narrow views (Byford & Raftery 
1998, Cleemput et al., 2011; Larg and Moss, 2011). 
 
5.2 COST ITEMS  
Health economic evaluations can comprise direct and indirect costs, as well as 
medical and non-medical costs (Larg and Moss, 2011). Direct medical costs are 
defined as disease related costs, such as prevention, detection, treatment, and 
rehabilitation, which are paid by the patient, healthcare institution, insurances, 
and/or government (Annemans, 2008; Larg and Moss, 2011, Rice, 1967).  
 
Direct medical costs in the field of pressure ulcers can consist of labour cost and 
cost for materials (Dealey et al., 2012; Haalboom, 1991; Schuurman et al., 
2009). Bennet et al. (2004) and Schuurman et al. (2009) found that most of the 
cost of pressure ulcer prevention and treatment is due to nursing time. In the 
study of Bennet et al. (2004) nursing time accounted for 90% of the overall cost 
of pressure ulcer treatment. For pressure ulcers Category I and II this 
percentage increased to 96% of the overall costs. No information was given in 
how nursing time was estimated or calculated. Schuurman et al. (2009) found 
that a more technical approach (such as the use of alternating devices) of 
pressure ulcer prevention was associated with lower costs, compared to a more 
human approach (such as providing repositioning at regular time intervals). 
When using alternating devices, the cost of pressure ulcer prevention was 13 
euro compared to 24 euro when using a turning protocol in the prevention of 
pressure ulcers.  The reported nursing time estimates were calculated based on 
the self-registration of nursing time by the nursing staff. The data on nursing 
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times were part of a standardised case report, which was filled out at during 
prevention or treatment of the patients (Schuurman et al., 2009).  
Direct non-medical costs are disease related costs, which are not part of the 
healthcare service, such as travel costs to the health care provider, or costs 
related to the time that significant others spend to provide care for the patient. 
Indirect medical costs are future costs of general healthcare, such as the 
healthcare costs arising from living longer (Annemans, 2008).  
 
Finally, indirect non-medical costs include costs related to reduced work 
productivity due to morbidity or premature death because of illness (Annemans, 
2008). In general, indirect costs are often more difficult to measure objectively, 
and less easy to attribute to a specific disease (Larg and Moss, 2011). A number 
of published studies have described the cost of illness associated with pressure 
ulcer prevention and treatment. Summarising the costs of pressure ulcer 
prevention can be important for government and health care services to assess 
the impact of prevention on their budget (Schuurman et al., 2009; Severens et 
al., 2002) or when considering the expenditures of new preventive strategies 
(Xakellis et al., 1996b; Makai et al., 2010).  A systematic review summarising the 
available evidence on the cost of pressure ulcer prevention and treatment is 
lacking. 
 
As pressure ulcers represent a serious clinical and economical problem, 
pressure ulcer prevention is important in decreasing the human and also the 
financial burden for all parties involved.  The calculation of the cost of illness of 
current pressure ulcer prevention can stimulate the government, the health care 
organisations, and the health care workers in the implementation and execution 
of a pressure ulcer prevention policies compliant to guidelines. Data on the cost 
of pressure ulcer prevention and treatment in Belgium are lacking.  
 
The aim of this thesis is to fill some of the gaps in the current body of evidence 
related to pressure ulcer prevention. 
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6 OUTLINE OF THIS THESIS 
The research questions in this thesis were grouped in three areas. The first area 
is the effectiveness of support surfaces in the prevention of pressure ulcers, 
more specifically the effectiveness of alternating devices. The aim of a first trial 
is to compare the effectiveness of two types of ALPAMs in an RCT. The central 
goal of this study is to examine the effect of a multi-stage inflation and deflation 
cycle versus a one-stage inflation and deflation cycle in ALPAMs. 
Studies reported pressure ulcer incidences ranging between 10.7% (Nixon et al., 
2006b) and 15.3% (Vanderwee et al., 2005) on APAM overlays in adult at risk- 
populations, compared to an incidence of 2.9 % on ALPAMs (Cavicchioli and 
Carella, 2007). The use of APAM overlays is widespread in Europe. In a second 
study, data from the ALPAM study are pooled with data from an RCT by 
Vanderwee et al.  (2005). The aim of this study is to compare the effectiveness 
of an APAM overlay with a one-stage ALPAM and a multi-stage ALPAM in terms 
of cumulative pressure ulcer incidence and the time to develop a pressure ulcer. 
 
The second area in this thesis relates to the identification of patients at risk for 
pressure ulcer development while receiving standardised preventive measures.  
Once patients are identified as being at risk and preventive measures are 
provided, some patients still develop pressure ulcers. Insight in specific 
predictive factors in this population may help to successfully target preventive 
measures. The aim of the third study is to identify such predictive factors based 
on secondary data analyses performed on the ALPAM database. 
 
The third area relates to the cost of pressure ulcer prevention and treatment.  
Insight in these costs are needed to assist government and institutions to assess 
the impact of prevention and treatment on their budget. Furthermore, it can 
guide the decision process regarding the expenditures for the implementation of 
(new) preventive and treatment strategies. A systematic review is performed to 
summarise the available evidence on cost of pressure ulcer prevention and 
treatment. A subsequent study aims to provide insight into the cost of pressure 
ulcer prevention and treatment in an adult hospital and nursing home population 
Chapter 1 
38 
in Flanders. A mixed perspective is applied and data are collected to estimate 
the cost for pressure ulcer prevention and treatment per patient per day, per 
hospitalisation, as well as the annual national cost of prevention and treatment. 
The structure of this thesis is based on the following research aims:  
1) To compare the effectiveness of an ALPAM with a multi-stage inflation and 
deflation cycle of the air cells with an ALPAM with a one-stage inflation and 
deflation cycle of the air cells (Chapter 2). 
2) To compare the effectiveness of an APAM overlay with a one-stage ALPAM 
and a multi-stage ALPAM  (Chapter 3). 
3) To examine predictive factors associated with the development of pressure 
ulcers in patients at risk while receiving standardised preventive measures 
(Chapter 4). 
4) To provide insight in the available evidence on cost of pressure ulcer 
prevention and treatment in an adult patient population (Chapter 5). 
5) To provide insight in the cost of pressure ulcer prevention and treatment in an 
adult hospital and nursing home population in Flanders using a mixed 
perspective (Chapter 6). 
 
The current chapter addresses the general introduction into the study topic of 
pressure ulcer prevention and health economics. Chapters 2 to 6 include papers 
which have been published, accepted or submitted for publication in peer-
reviewed journals. With respect to the content, some overlap between the 
chapters is present. Finally, Chapter 7 provides an overview of the key findings,  
a general discussion on the results reported in this thesis, a methodological 
discussion, and an overview of the implications for clinical practice and research. 
 
 
  
CHAPTER 2 
 
MULTI-STAGE VERSUS ONE-STAGE INFLATION AND 
DEFLATION CYCLE FOR ALTERNATING LOW PRESSURE 
AIR MATTRESSES TO PREVENT PRESSURE ULCERS IN 
HOSPITALISED PATIENTS: 
A RANDOMISED-CONTROLLED CLINICAL TRIAL 
Based on the article of Demarré L, Beeckman D, Vanderwee K, Defloor T, 
Grypdonck M & Verhaeghe S (2012) Multi-stage versus one-stage inflation and 
deflation cycle for alternating low pressure air mattresses to prevent pressure 
ulcers in hospitalised patients: A randomised-controlled clinical trial.  
International Journal of Nursing Studies 49 (4), 416-426. 
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ABSTRACT 
Introduction: The duration and the amount of pressure and shear must be 
reduced in order to minimise the risk of pressure ulcer development. Alternating 
low pressure air mattresses with multi-stage inflation and deflation cycle of the 
air cells have been developed to relieve pressure by sequentially inflating and 
deflating the air cells. Evidence about the effectiveness of this type of mattress 
in clinical practice is lacking. 
Aim: This study aimed to compare the effectiveness of an alternating low 
pressure air mattress that has a standard one-stage inflation and deflation cycle 
of the air cells with an alternating low pressure air mattress with multi-stage 
inflation and deflation cycle of the air cells. 
Methods and materials: A randomised controlled trial was performed in a 
convenience sample of 25 wards in five hospitals in Belgium. In total, 610 
patients were included and randomly assigned to the experimental group (n = 
298) or the control group (n = 312). In the experimental group, patients were 
allocated to an alternating low pressure air mattress with multi-stage inflation 
and deflation cycle of the air cells. In the control group, patients were allocated 
to an alternating low pressure air mattress with a standard one stage inflation 
and deflation cycle of the air cells. The outcome was defined as cumulative 
pressure ulcer incidence (Grade II–IV). An intention-to-treat analysis was 
performed. 
Results: There was no significant difference in cumulative pressure ulcer 
incidence (Grade II–IV) between both groups (Exp. = 5.7%, Contr. = 5.8%, p = 
0.97). When patients developed a pressure ulcer, the median time was 5.0 days 
in the experimental group (IQR = 3.0–8.5) and 8.0 days in the control group (IQR 
= 3.0–8.5) (Mann–Whitney U-test = 113, p = 0.182). The probability to remain 
pressure ulcer free during the observation period in this trial did not differ 
significantly between the experimental group and the control group (log-rank χ² = 
0.013, df = 1, p = 0.911). 
Conclusion: An alternating low pressure air mattress with multi-stage inflation 
and deflation of the air cells does not result in a significantly lower pressure ulcer 
incidence compared to an alternating low pressure air mattress with a standard 
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one-stage inflation and deflation cycle of the air cells. Both alternating mattress 
types are equally effective to prevent pressure ulcer development. 
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1. INTRODUCTION 
Pressure ulcers are defined as ‘‘localised injuries to the skin and/or underlying 
tissue, usually over a bony prominence, caused by pressure, or pressure in 
combination with shear’’ (NPUAP & EPUAP, 2009). 
Pressure ulcer development is multi-factorial, with applied pressure, or pressure 
in combination with shear being among the primary aetiological factors. 
Pressure and shear result in oxygen deprivation to the affected area (NPUAP & 
EPUAP, 2009). However, the importance of different mechanisms that lead to 
tissue damage, such as impaired lymphatic drainage (Miller and Seale, 1981), 
direct cell deformation (Ceelen et al., 2008; Gawlitta et al., 2007a; Stekelenburg 
et al., 2008), sustained tissue deformation (Daniel et al., 1981; Gawlitta et al., 
2007b; Kosiak, 1961), and ischemic reperfusion injury (Peirce et al., 2000; Reid 
et al., 2004; Tsuji et al., 2005) has not been fully established (Bouten et al., 
2003; NPUAP & EPUAP, 2009).  
 
In European hospitals, pressure ulcer prevalence (Grade I–IV) varies between 
7.3% and 23% (Gunningberg, 2004; Kottner et al., 2009c; Vanderwee et al., 
2007a). In US acute care facilities, Whittington and Briones (2004) found a 
pressure ulcer prevalence (Grade I–IV) of 16% (Whittington and Briones, 2004). 
Pressure ulcers are a burden for the patient as they are painful and negatively 
affect the patient’s quality of life (Gorecki et al., 2009; Hopkins et al., 2006). 
Furthermore, pressure ulcers have an important financial impact for both, 
patients and society (Schuurman et al., 2009; Severens et al., 2002; Xakellis 
and Frantz, 1996). 
 
Adequate pressure ulcer prevention needs to focus on the reduction of the 
duration (removal of pressure) and/or the amount of pressure and shear. The 
removal of pressure and shear on the tissue is defined as pressure relief 
(NPUAP & EPUAP, 2010). Pressure relief can be established through patient 
repositioning, lifting body parts and the application of active support surfaces, 
which are designed for the management of tissue loads (NPUAP & EPUAP, 
2009; NPUAP & EPUAP, 2010). These are powered support surfaces, with the 
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capability to change their load distribution properties (NPUAP, 2007). Alternating 
Pressure Air Mattresses (APAMs) provide pressure relief by sequentially 
inflating and deflating air-filled sacs (McInnes et al., 2008). Incidence figures 
between 10.5% (Nixon et al., 2006a) and 15.3% (Vanderwee et al., 2005) were 
found on APAMs in a hospital setting.  
 
More recently, alternating low pressure air mattresses (ALPAMs) have been 
developed. These support surfaces are supposed to differ from APAMs by 
generating lower pressure amplitudes, which is the difference between the 
highest and lowest interface pressure (Tissue Viability Society, 2010). APAMs 
and ALPAMs both have an alternating cycle, characterised by a steep transition 
during inflation and deflation of the air cells. Studies examining the effectiveness 
of ALPAMs are scarce. Two randomised controlled trials examined pressure 
ulcer incidence on ALPAMs (Cavicchioli and Carella, 2007; Theaker et al., 
2005). Subsequently, ALPAMs have been modified so that the transition from 
deflated air cell to inflated air cell is more gradual or multi-staged. The purpose 
of this trial was to examine the influence of a longer multi-stage inflation and 
deflation cycle, combined with low pressures in the inflated air, on the 
development of pressure ulcers. To date, no clinical studies on the effectiveness 
of ALPAMs with a multistage inflation and deflation cycle of the air cells have 
been reported. Hence, the aim of the current trial was to compare the 
effectiveness of an ALPAM with multi-stage inflation and deflation cycle of the air 
cells with an ALPAM with one stage inflation and deflation cycle of the air cells. 
 
2. METHODS AND DESIGN 
2.1 DESIGN  
A multicentre RCT (allocation ratio 1:1) was conducted between December 2007 
and January 2010. 
 
2.2 PARTICIPANTS 
A convenience selection of 25 wards from five Belgian hospitals participated. 
The selection of hospitals was based on geographical proximity and their 
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willingness to participate. Seven hospitals were invited of whom five consented 
to participate. Per included hospital, a minimum of 4 wards and maximum of 6 
wards were asked to participate in the study. The selection included 8 geriatric 
wards and 17 medical wards in one teaching and four general hospitals. The 
participating medical wards were neurology (n = 6), rehabilitation (n = 3), 
cardiology (n = 2), dermatology (n = 1), pneumology (n = 1), oncology (n = 1), 
and chronic care (n = 1) or a combination of different types of medical conditions 
(n = 2). A consecutive sample was used in this trial. All patients admitted to the 
participating wards were screened for eligibility. Patients were eligible for 
inclusion if they were at risk for pressure ulcer development according to the 
Braden scale. Risk assessment was evaluated by a ward nurse in each patient 
on admission and twice a week during the inclusion period. Patients with a 
Braden score of less than 17 were considered at risk (Defloor et al., 2004; 
Vanderwee et al., 2007a). The Braden scale consists of six subscales: sensory 
perception, moisture, activity, mobility, nutrition and friction and shear (Braden 
and Bergstrom, 1994). Patients having non-blanchable erythema (Grade I 
pressure ulcer) were eligible to be included in the study. Pressure ulcers were 
classified according to the four grades of the European Pressure Ulcer Advisory 
Panel (1999). A pressure ulcer Grade I was defined as non-blanchable erythema 
of the intact skin, a pressure ulcer Grade II as an abrasion or a blister, a 
pressure ulcer Grade III as a superficial ulcer and, a pressure ulcer Grade IV 
was classified as a deep ulcer (European Pressure Ulcer Advisory Panel, 1999). 
Patients were excluded if (1) they had a pressure ulcer Grade II–IV on 
admission, (2) the expected admission time in the hospital was < 3 days, (3) 
they were aged < 18 years, (4) there was a ‘‘do not resuscitate code’’ specifying 
ending all therapeutic interventions, (5) weight was less than 30 kg or more than 
160 kg (mattress specification) and, (6) informed consent could not be obtained 
from the patient or his/her legal representative (Fig. 1). 
Both mattresses were covered with an identical mattress cover. No standard 
repositioning protocol was used in bed. An identical seating protocol was used in 
both groups. All patients were seated on a static air cushion (Hill-Rom Reflex™).  
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  Patients observed 
(n= 7393) 
Patients not eligible (n=6256) 
- Incomplete Braden score (n=214) 
- Patients not at risk for PU(1) development 
(n=6042) 
Patients at risk for PU 
development (2) 
(n= 1137) 
Patients eligible for 
inclusion 
(n= 796) 
Patients excluded (n=341) 
- PU Category II-IV (n=204) 
- Do not resuscitate code (n= 35) 
- <18 years of age (n=6) 
- Weight < 30kg or >160 kg (n= 1) 
- Expected duration of admission < 3 days 
Patients included in the 
study (n= 610) 
No mattress available (n=186) 
Patients randomly assigned to control 
intervention (n= 312) 
Patients randomly assigned to experimental 
intervention (n= 298) 
Patients analysed in experimental group 
(n=298): 
-Follow-up 14 days (n=152) 
-PU Grade II-IV (n= 17) 
-Losses to follow up because of technical 
problems (n=3) 
-Losses to follow up because of discomfort 
(n=11) 
-Losses to follow up: reason not defined (n=3) 
-Discharge to another ward (n=15) 
-Discharge to home (n=40) 
-Death (n=15) 
-Discharge to another institution (n=42) 
-Withdrawal of consent (n=0) 
Patients analysed in control group  (n=312): 
-Follow-up 14 days (n=155) 
-PU Grade II-IV (n= 18) 
-Losses to follow up because of technical 
problems (n=3) 
-Losses to follow up because of discomfort 
(n=16) 
-Losses to follow up: reason not defined (n=5) 
-Transfer to another ward (n=22) 
-Discharge to home (n=41) 
-Death (n=14) 
-Discharge to another institution (n=37) 
-Withdrawal of consent (n=1) 
 
 
Figure 1  Flowchart Sample: Included and excluded patients ALPAM study 
(1) PU: Pressure ulcer; (2) Bradenscore < 17 
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Table 1  Specifications and characteristics of experimental and control group 
 Experimental group 
 
Control group 
 
Cycle amplitude Multi-stage inflation and deflation of 
air cells 
One-stage inflation and 
deflation of air cells 
Cycle Time 10 minutes 10 minutes 
Air cell inflation sequence 1/1 (one air cell is inflated/one air 
cell is deflated) 
1/1 (one air cell is inflated/one 
air cell is deflated) 
Width air cells (diameter) 10 cm  10 cm  
Alternating sequence - Back and sacrum: 10 
cells alternating  low 
pressure (1/1= one air cell 
is inflated/one air cell is 
deflated) 
- Head zone: 3 cells 
continuous low pressure 
(not alternating) 
- Heel zone: 7 cells 
continuous ultra-low 
pressure (not alternating) 
All cells alternate (1/1= one air 
cell is inflated/one air cell is 
deflated)  
 
Sensor 
 
 
Yes 
Continuously measuring the load 
applied at  sacral zone 
No.  
Manually adjustable for weight.  
 
The control unit was disconnected during transport of the patient, resulting in an 
inflated mattress for 2 h without alternating of the air cells. 
2.3 OUTCOMES 
Patient baseline characteristics were collected by the researcher on admission 
in the study: age, weight, length, Body Mass Index, primary diagnosis, 
comorbidities (diabetes, paralysis, cerebrovascular accident), the use of 
tranquilisers/corticosteroids, and nutritional status (using the Mini Nutritional 
Assessment). Data about mobility and activity of each patient were collected as 
part of the Braden risk assessment tool. The primary end point was the 
development of a new pressure ulcer Grade II–IV on any location during the 
period of observation. Daily skin assessment was performed by the ward nurses 
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(qualified nurses and nursing assistants under the supervision of a qualified 
nurse), in each patient, in the morning. 
 
Pressure ulcers were classified according to the EPUAP classification system 
(European Pressure Ulcer Advisory Panel, 1999). The transparent plastic disc 
method was used to observe non-blanchable erythema (Grade I) (Halfens et al., 
2001). Furthermore, a differentiation was made between pressure ulcers and 
incontinence-associated dermatitis (IAD), which was defined as a reactive 
response of the skin to chronic exposure to urine and faecal material (Gray et 
al., 2007). To differentiate pressure ulcers from IAD, wound-related 
characteristics (causes, location, shape, depth, edges, and colour), along with 
patients related characteristics were considered (Defloor et al., 2005b). The 
secondary outcome was the time to develop a pressure ulcer Grade II–IV. Data 
on this outcome were collected between patient inclusion and trial completion. 
Patient acceptability was assessed indirectly by the number of participants 
withdrawing their consent to participate during the period of observation. The 
daily skin observations and the risk assessments were registered by the ward 
nurse in a study file which was attached to the patient chart of all participating 
patients. The study file consisted of a daily observation sheet, used to tick the 
status of the skin per location and on day 5, 10 and 15 a risk assessment was 
included. Each study document included information about pressure ulcer 
classification, differentiation between pressure ulcers and IAD, the standard 
protocol when the patient was seated, and practical instructions for the use of 
the study mattresses. Data on time seated in a chair and time on transport were 
collected. 
 
2.4 SAMPLE SIZE 
The study was powered on the assumption that a 15% pressure ulcer incidence 
(Grade II–IV) (Vanderwee et al., 2005) would be present in the control arm of the 
study and the assumption that a 50% reduction (Nixon et al. 2006; Vanderwee et 
al. 2005) in pressure ulcer incidence (Grade II–IV) in the experimental arm would 
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be present (α = 0.05; β = 0.20; two sided). A sample size of 600 patients (300 in 
each group) was determined. 
 
2.5 RANDOMISATION 
Included patients were randomly assigned to the study groups using simple 
randomisation. The random allocation sequence was based on a computer-
generated list of random numbers. Patients were enrolled by the ward nurses 
after completing the pressure ulcer risk assessment form (Braden scale). When 
the patient was eligible, and a study mattress was available, they were assigned 
to one of the mattresses by contacting the researcher (24 h telephone 
accessibility). The ward nurse received a number of the type of allocated 
mattress (first available on the computer generated list). In total, 610 patients 
were included, of which 298 were allocated to the experimental and 312 to the 
control group (Fig. 1). 
 
2.6 BLINDING 
The study could not be blinded, because of the visible differences of the external 
control unit of the study mattresses. No information was provided to the ward 
nurses about the differences between the experimental and control study device. 
Both were presented as alternating pressure air mattresses. The data-analysis 
was not blinded. 
 
2.7 PROCEDURE 
Prior to the study, all nurses (qualified nurses and nursing assistants) attended a 
theoretical training on (1) pressure ulcer prevention (pathology, classification, 
differentiation between IAD and the use of the Braden scale for risk 
assessment), (2) an introduction to the study aims and protocol, (3) and the use 
of the data collection instrument. The purpose of this training was to certify the 
precision and uniformity of the data collection. Trial completion was defined as: 
(1) development of a pressure ulcer Grade II–IV, (2) 14 days of attending the 
trial (follow up period), (3) transfer to a non-participating ward, (4) discharge 
from the hospital, (5) death or (6) withdrawal of the initial consent to participate. 
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The inter-rater reliability of the observations of the skin at the pressure areas 
and the Braden scores were monitored by the researcher and the study nurse, 
who performed observations weekly, independently of each other. These 
observations and Braden scores were performed unannounced in a random 
sample of patients included in the study. The inter-rater reliability between 
researcher, study nurse and ward nurse was sufficient to very good (Landis and 
Koch, 1977). The inter-rater reliability for the classification of pressure ulcers 
ranged from k = 0.71 (95% CI 0.63 – 0.79) to k = 0.81 (95% CI 0.78 – 0.85). The 
inter-rater reliability for risk assessment based on the Braden scale varied from k 
= 0.64 (95% CI 0.01 – 0.1.28) to k = 0.90 (95% CI 0.81 – 0.99). 
 
2.8 STATISTICAL ANALYSES 
Descriptive data are presented in frequencies (percentages) and means 
(standard deviation) if the data were distributed normally and medians (IQR) if 
data were not distributed normally. Independent sample t-tests were used in 
normally distributed continuous data, Mann–Whitney U-tests were used in not 
normally distributed continuous data, and chi-square and Fisher’s exact tests 
were used in categorical variables. The primary end point was the cumulative 
incidence of a pressure ulcer Grade II–IV, which is the percentage of patients 
developing a new pressure ulcer (Grade II–IV) in the population at risk during 
data collection (Defloor et al., 2005a). Cumulative pressure ulcer incidence 
allows inferences to be made concerning the effectiveness of preventive 
measures (Defloor et al., 2005a). Pressure ulcer Grade II or more was chosen 
as end point, whereas the presence of a pressure ulcer Grade I is commonly 
used as a method for risk assessment for patients in need of pressure ulcer 
prevention in Belgian hospitals (Defloor et al., 2004; Vanderwee et al., 2007b; 
Schoonhoven et al., 2002). This primary end point was compared between 
groups using a chi-square test. Chi-square tests were also used to compare the 
proportions of participants between groups with an existing pressure ulcer Grade 
I and with newly developed pressure ulcers Grade I. Univariate binary logistic 
regression analysis was used to calculate the odds ratio and related 95% 
confidence interval for each variable. To evaluate the independence of the effect 
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of support surfaces on the pressure ulcer incidence, the variables with a value p 
< 0.20 in the univariate analyses were simultaneously entered in a multivariate 
binary logistic regression analysis combined with variables included on 
theoretical grounds. A correlation analysis was performed to test for 
multicollinearity of all independent variables. There was no multicollinearity 
observed between these variables, using a cut-off correlation coefficient < 0.60. 
Intraclass correlation coefficients were assessed to calculate the proportion of 
variance as a result of clustering on ward level and hospital level. Clustering on 
ward and hospital level was not accountable for any variance in pressure ulcer 
incidence,  for the group in total and separately for the experimental and control 
group. To examine differences in the secondary outcome, the time needed to 
develop a pressure ulcer Grade II–IV, a survival analysis with Kaplan Meier plot 
and log rank test was used. A chi-square test was performed to compare the 
proportions of participants between groups of withdrawing consent due to 
dissatisfaction with the support surface under study. Statistical analyses were 
conducted using SPSS1 15.0 (IBM1 Corporation, Route 100 Somers, NY 10589, 
USA). A significance level of p < 0.05 was used. Intention to treat analysis was 
performed. 
 
3. RESULTS 
During recruitment period of 20 months (14 weeks of risk assessment and a two-
week fade-out period for every participating hospital) 7393 patients were 
screened using the Braden scale. Of the patients considered at risk for pressure 
ulcer development (n = 1137), 341 were excluded because of (1) the presence 
of a pressure ulcer Grade II–IV (n = 204), (2) a presumable hospital length of 
stay of less than 3 days (n = 43), (3) the decision to end all therapeutic 
measures (DNR code 3) (n = 35), (4) an age of less than 18 years (n = 6), (5) a 
weight of less than 30 kg or higher than 160 kg (n = 1) and (6) the refusal of 
consent to participate (n = 52). In 186 patients eligible for inclusion there was no 
study surface available. 
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In total, 610 patients were randomised to the control (n = 312) and the 
experimental (n = 298) ALPAM group. Approximately 60% of the patients were 
female and the mean age of the participants was 76.3 years (SD = 14.00). 
Almost half of the patients were incontinent for urine and faeces. The median 
Braden score of the participating patients was 14.0 (IQR = 12.0–15.0). In both 
groups, 15.4% of the patients were admitted in the study having a pressure ulcer 
Grade I (χ² = 0.00; df = 1, p = 0.99). Experimental and control group were 
comparable for all baseline characteristics (Table 2). 
 
In the total group, the cumulative incidence of pressure ulcers Grade II–IV was 
5.7%. The pressure ulcer incidence density (Grade II–IV) was 0.54/100 
observed days (35 pressure ulcers/6453 observed days) (CI 95% = 0.39–0.75). 
Most pressure ulcers Grade II–IV occurred at the sacral zone (cumulative 
incidence = 3.4%) and nine patients developed a heel pressure ulcer 
(cumulative incidence = 1.7%). The incidence of IAD was 11.1% (Table 3). 
In the experimental group, 5.7% of the patients developed a pressure ulcer 
Grade II–IV, compared to 5.8% in the control group. Univariate analysis showed 
no significant difference between the two groups (χ² = 0.001; df = 1, p = 0.97). In 
the experimental group, newly developed non-blanchable erythema (pressure 
ulcer Grade I), was observed in 17.1% of the patients compared to 12.2% in the 
control group (χ² = 2.98; df = 1, p = 0.08). 
 
Theoretically, pressure ulcers observed before day 4 could have been caused 
by tissue damage prior to the start of the study, as the time between the onset of 
pressure ulcer development and the external appearance can be 3 days (Reddy, 
1990). When excluding pressure ulcers (Grade II–IV) occurring in the first 3 days 
after admission in the study, the results remained comparable, 3.4% incidence in 
the experimental group versus 4.2% in the control group (χ² = 0.257; df = 1, p = 
0.61). Based on univariate analysis, Braden score, non-blanchable erythema at 
the start of the study and corticosteroids were included in the binary logistic 
regression analysis. This was completed with variables included on theoretical 
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grounds, as gender, paralysis, diabetes, tranquilisers, incontinence (urine and 
faeces), and the maximum time seated in a chair or on transport.  
 
The analysis revealed no significant difference in the development of pressure 
ulcers Grade II–IV between the groups (OR = 1.17; 95% CI 0.553–2.455; Wald χ
² = 0.16, df = 1; p = 0.687) (Table 4). An equal number of patients developed a 
pressure ulcer Grade II–IV at the pelvic area (hip and sacral) in the experimental 
group (3.7%) compared to the control group (3.5%) (χ² = 0.01; df = 1, p = 0.91). 
No significant difference in pressure ulcer incidence at the heel/ankle was found 
between the experimental (1.3%) and the control group (1.9%) (χ² = 0.32; df = 1, 
p = 0.57). Seven severe pressure ulcers (Grade III and IV) occurred in the 
control group (2.2%), compared to four in the experimental group (1.3%) (χ² = 
0.70; df = 1, p = 0.40). At the heel area, one Grade III–IV pressure ulcer 
occurred in the experimental group (0.3%), compared to five (1.6%) in the 
control group (Fisher Exact; df = 1, p = 0.22). In the experimental group, no 
Grade IV pressure ulcers at the heel area occurred at all, compared to 4 (1.3%) 
patients in the control group (Fisher Exact; df = 1, p = 0.12). However, none of 
those differences in severe pressure ulcers between the experimental and the 
control group were significant. 
 
When patients developed a pressure ulcer, the median time was 5.0 days (IQR 
= 3.0–8.5) in the experimental group and 8.0 days in the control group (IQR = 
3.0–8.5) (Mann–Whitney U-test = 113, p = 0.182). The probability to remain 
pressure ulcer free during the observation period in this trial did not differ 
significantly between the experimental group and the control group (log-rank χ² = 
0.013, df = 1, p = 0.911, Fig. 2). The acceptability of the devices was 
comparable for both groups. Eleven patients in the experimental group withdrew 
their consent to participate in the study due to discomfort, compared to 
seventeen in the control group (1.8 versus 2.6%; χ² = 3.85; df = 9, p = 0.92). In 
both groups, an equal number of patients were lost to follow-up due to technical 
problems of the study device (Figure 1). 
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Table 2  Baseline characteristics of included patients 
 
 
 
 
Total 
(n=610) 
mean (SD)(1) 
Control group 
(n=312) 
mean (SD) 
Experimental 
group (n= 298) 
mean (SD) 
t (2) p(3) 
Age 76.3 (14.00) 76.50 (13.20) 76.15 (14.82) - 0.31 0.76 
Weight  (kg) 65.8 (15.00) 66.50 (15.16) 65.08 (15.38) - 1.16 0.25 
Length  (m) 1.7 (0.095) 1.66 (0.09) 1.65 (0.1) - 1.36 0.17 
BMI (4) 23.8 (4.65) 23.95 (4.66) 23.70 (4.64) - 0.65 0.51 
Braden score 
Median (IQR) 
 
14.0 (12.0-
15.0) 
 
14.0 (12.0-
15.0) 
 
14.0 (12.0-15.0)  
 
* 
 
0.66 
Maximum time sitting &/or 
transport (hours) (5) 
 
2.4 (3.13) 
 
2.3 (3.18) 
 
2.5 (3.08) 
 
0.73 
 
0.46 
 
Total 
(n=610) 
% (n) 
Control group 
(n=312) 
% (n) 
Experimental 
group 
(n= 298) 
% (n) 
Χ²(6) p 
Gender 
Male 
Female 
 
39.4 (241) 
60.6 (369) 
 
41.7 (130) 
58.3 (182) 
 
37.2 (111) 
62.8 (187) 
 
1.24 
 
0.26 
Wards 
Geriatric  
Neurology 
Pneumology 
Dermatology 
Rehabilitation 
Chronic Care 
Internal medicine 
(combination) 
Oncology 
Cardiology 
 
32.3 (197) 
28.2 (172) 
4.6 (28) 
5.2 (32) 
7.4 (45) 
4.1 (25) 
8.5 (52) 
4.3 (26) 
5.4 (33) 
 
14.4 (88) 
15.7 (96) 
2.5 (15) 
2.8 (17) 
3.8 (23) 
2.1 (13) 
5.1 (31) 
2.1 (13) 
2.6 (16) 
 
17.9 (109) 
12.5 (76) 
2.1 (13) 
2.5 (15) 
3.6 (22) 
2.0 (12) 
3.4 (21) 
2.1 (13) 
2.8 (17) 
 
6.53 
 
0.59 
Incontinence 
Urinary 
Fecal 
Urinary/Fecal 
 
66.3 (389) 
53.9 (318) 
49.5 (302) 
 
65.9 (197) 
54.7 (164) 
50.6 (158) 
 
66.7 (192) 
53.1 (154) 
48.3 (144) 
 
0.04 
1.14 
0.33 
 
0.84 
0.70 
0.57 
Braden- activity      
Bedfast 27.6 (165) 14.4 (86) 13.2 (79) 5.55 0.14 
Chairfast 61.3 (366) 30.0 (179) 31.3 (187)   
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(1) SD= standard deviation; (2) t= t-value, unless mentioned else; (3) p= p-value; (4) BMI= Body Mass 
Index; (5) Maximum time sitting &/or transport= maximum time seated in a chair on a static air 
cushion and the time the power of the mattress was switched off because of transport; (6) χ²: Chi-
square; (7) Corticosteroids= systemic use of corticosteroids; (8) PU: pressure ulcer present at the start 
of the study; (9) IAD= Incontinence associated dermatitis present at the start of the study; * Mann-
Whitney U-test. 
 
Total 
(n=610) 
% (n) 
Control group 
(n=312) 
% (n) 
Experimental 
group 
(n= 298) 
% (n) 
Χ²(6) p 
Braden- Moisture 
Always moistures 
Mostly moistures 
 
13.6 (81) 
31.0 (185) 
 
14.4 (44) 
29.1 (89) 
 
12.7 (37) 
33.0 (96) 
 
2.44 
 
0.49 
Diabetes 22.1 (135)  22.8 (71) 21.5 (64) 0.15 0.70 
Cerebrovascular  
disorder 
 
12.5 (76) 
 
11.9 (37)  
 
13.1 (39) 
 
0.21 
 
0.65 
Paralysis 11.6 (71) 10.9 (34) 12.4 (37) 0.34  0.56 
Medication 
Tranquilizers 
Corticosteroids(7) 
 
46.4 (283) 
12.5 (76) 
 
48.5 (142) 
10.9 (34) 
 
47.5 (141) 
14.1 (42) 
 
0.05 
1.43 
 
0.81 
0.23 
PU(8) Grade I present at 
start 
15.4 (94) 15.4 (48) 15.4 (46) 0.00 0.99 
IAD(9) present at start 6.4 (39) 7.7 (24) 5.0 (15) 1.80 0.18 
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(1) Χ² (df=1): Chi-square (degrees of freedom); (2) p: p-value; (3) Fisher Exact test; (4) PU: Pressure 
Ulcer; (5) IAD: Incontinence-Associated Dermatitis 
Table 3  Overview of the incidence of pressure ulcers (Grade I-IV) and incontinence-
associated dermatitis(5)  
 Total  
(n=610) 
% (n) 
Control  
(n= 312) 
% (n) 
Experimental 
(n=298) 
% (n) 
Test Χ² 
(df=1)(1) 
p(2) 
PU Grade I (4) 
(Newly developed) 
 
14.6 (89) 
 
12.2 (38) 
 
17.1 (51) 
 
Χ² 
 
2.98  
 
0.08 
PU Grade II 3.9 (24) 3.5 (11) 4.4 (13) Χ² 0.28 0.60 
Pelvic Area 
Sacral 
Hip 
3 (18) 
2.8 (17) 
0.2 (1) 
3.2 (10) 
2.9 (9) 
0.3 (1) 
2.7 (8) 
2.7 (8) 
0 (0) 
Χ² 
Χ² 
F.E. (3) 
0.14 
0.02 
_ 
0.70 
0.88 
1.00 
Heel Area 
Heel 
Ankle 
0.7 (4) 
0.7 (4) 
0 (0) 
0.3 (1) 
0.3 (1) 
0 (0) 
1 (3) 
1 (3) 
0(0) 
F.E. 
F.E. 
_ 
_ 
_ 
_ 
0.36 
0.36 
_ 
Other 0.3 (2) 0 (0) 0.7 (2) F.E. _ 0.24 
PU Grade III 1.0(6) 0.6 (2) 1.3 (4) F.E. _ 0.44 
Pelvic Area 
Sacral 
Hip 
0.7 (4) 
0.7 (4) 
0 (0) 
0.3 (1) 
0.3 (1) 
0 (0) 
1.0 (3) 
1.0 (3) 
0 (0) 
F.E. 
F.E. 
_ 
_ 
_ 
_ 
0.36 
0.36 
_ 
Heel Area 
Heel 
Ankle 
0.3 (2) 
0.2 (1) 
0.2 (1) 
0.3 (1) 
0 (0) 
0.3 (1) 
0.3 (1) 
0.3 (1) 
0 (0) 
F.E. 
F.E. 
F.E. 
_ 
_ 
_ 
1.00 
0.49 
1.00 
Other 0.0 (0) 0.0 (0) 0.0 (0) _ _ _ 
PU Grade IV 0.8 (5) 1.6 (5) 0.0  (0) F.E. _ 0.06 
Pelvic Area 
Sacral 
Hip 
0.0 (0) 
0.0 (0) 
0.0  (0) 
0.0  (0) 
0.0  (0) 
0.0  (0) 
0.0  (0) 
0.0  (0) 
0.0  (0) 
_ 
_ 
_ 
_ 
_ 
_ 
_ 
_ 
_ 
Heel Area 
Heel 
Ankle 
0.7 (4) 
0.7 (4) 
0.0  (0) 
1.3 (4) 
1.3 (4) 
0.0  (0) 
0.0  (0) 
0.0  (0) 
0.0  (0) 
F.E. 
F.E. 
_ 
_ 
_ 
_ 
0.12 
0.12 
_ 
Other 0.2 (1) 0.3 (1) 0.0  (0) F.E. _ 1.00 
PU Grade II-IV 5.7 (35) 5.8 (18) 5.7 (17) Χ² 0.001 0.97 
Pelvic Area 3.6 (22) 3.5 (11) 3.7 (11) Χ² 0.01 0.91 
Heel Area 1.7 (10) 1.9 (6) 1.3 (4) F.E. _ 0.75 
Other 0.4 (3) 0.3 (1) 0.7 (2) F.E. _ 0.62 
PU Grade III-IV 1.8 (11) 2.2 (7) 1.3 (4) Χ² 0.70 0.40 
Pelvic Area 0.7 (4) 0.3 (1) 1.0 (3) F.E. _ 0.36 
Heel Area 1 (6) 1.6 (5) 0.3 (1) F.E. _ 0.22 
Other 0.2 (1) 0.3 (1) 0 (0) F.E _ 1.00 
IAD(5) (newly 
developed) 
11.1 (68) 13.5 (42) 8.7 (26) Χ² 3.45 0.063 
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Table 4  Binary Logistic regression with pressure ulcer Category II-IV as dependent variable 
and risk factors as independent variables 
 B (s.e.) (1) Wald OR (2) 95% CI p-
value 
Standard  ALPAM(3) 0.15 (0.38) 0.16 1.17 (0.553-2.455) 0.687 
NBE* (4) 1.53 (0.40) 14.50 4.63 (2.103-10.173) <0.001 
Braden score* -0.22 (0.08) 7.74 0.80 (0.684-0.936) 0.005 
Corticosteroids* (5) -1.76 (1.04) 2.85 0.17 (0.022-1.329) 0.092 
Diabetes (6) 0.49 (0.42) 1.31 1.63 (0.708-3.731) 0.252 
Tranquillizers(7) 0.20 (0.39) 0.27 1.22 (0.574-2.593) 0.606 
Paralysis (8) 0.21 (0.53) 0.16 1.23 (0.440-3.451) 0.691 
Maximum time sitting &/or 
transport (9) 
0.04(0.06) 0.42 1.04 (0.921-1.178) 0.518 
Incontinence (urine & faeces) (10) -0.11(0.39) 0.08 0.90 (0.418-1.922) 0.779 
Gender (11) -0.39 (0.40) 0.98 0.68 (0.311-1.468) 0.322 
(1) B(s.e.): regression coefficient (standard error);  (2) OR: odds ratio; (3) Standard ALPAM: control 
group is reference category; (4) NBE at the start of the study: absence of Non- Blanchable Erythema 
is reference category; (5) Corticosteroids (systemic): absence of corticosteroids is reference category; 
(6) Diabetes: absence of diabetes is reference category; (7) Tranquillizers: absence of tranquillizers is 
reference category; (8) paralysis: absence of paralysis is reference category; (9) Maximum time sitting 
and/or transport= maximum time seated in a chair on a static air cushion and the time the power of 
the mattress was switched off because of transport; (10) Incontinence: absence of double incontinence 
is reference category; (11)Gender: male is reference category;  
*Variables in Univariate analysis p<0.2 
 
4. DISCUSSION 
The aim of this clinical trial was to compare the effectiveness of an ALPAM with 
multi-stage inflation and deflation cycle of the air cells (experimental mattress) 
with the effectiveness of an ALPAM with a standard one-stage inflation and 
deflation cycle of the air cells (control mattress). The primary outcome was the 
cumulative incidence of pressure ulcers Grade II–IV. Both mattresses resulted in 
a low pressure ulcer incidence. The experimental mattress did not result in a 
significantly lower pressure ulcer incidence compared to the control mattress. 
Both mattresses were equally effective to prevent pressure ulcers. The time to 
develop a pressure ulcer was comparable in both groups. This discussion will 
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compare the results of this study with those from similar trials and will account 
for possible explanations for the observed effects. 
 
4.1 COMPARISON WITH SIMILAR TRIALS 
Clinical trials on the effectiveness of APAMs (using a similar design and 
methodology) reported incidence figures between 10.5% (Nixon et al., 2006b) 
and 15.3% (Vanderwee et al., 2005). Those results are considerably higher than 
the results found in the current trial (cumulative pressure ulcer incidence = 
5.7%). The incidence density was found to be lower [0.54/100 observed days 
(95% CI = 0.39–0.75)], compared to the APAM study by Vanderwee et al. (2005) 
[1.46/100 observation days (95% CI = 0.98–1.97)]. These findings are supported 
by the study of Cavicchioli and Carella (2007) on pressure ulcer incidence on 
ALPAMs, using a comparable patient population and study methodology. In the 
trial of Cavicchioli and Carella (2007), with a smaller sample size, even a lower 
pressure ulcer incidence was found (cumulative pressure ulcer incidence 
including Grade I = 2.9%). Different reasons may account for the differences 
found in pressure ulcer incidence between APAMs studies and the current 
ALPAM study.  
A first reason might be related to the use of different inclusion criteria in the 
trials. In the study by Nixon et al. (2006a), a large proportion of the patients 
(79%) were bedbound, compared to 27.6% in this trial (61.3% was chairbound). 
No reference was made to the use of a standardised protocol for patients at risk 
when they were sitting in a chair. The fact that the patients were less mobile and 
the possible lack of a standardised protocol when seated in a chair may have 
resulted in these considerably higher pressure ulcer incidences. Compared to 
Vanderwee et al. (2005), considerably fewer patients entered the study with non-
blanchable erythema (15.4% versus 33.6%). As non-blanchable erythema is 
considered as an independent risk factor for pressure ulcer development (Nixon 
et al., 2007) the population in the current study was probably less at risk for 
pressure ulcer development compared to the trial by Vanderwee et al. (2005). 
A second reason may be related to the differences in observer training regarding 
the clinical differences between pressure ulcers and IAD. Difficulties related to 
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pressure ulcer observation and differentiation between pressure ulcers and IAD 
have been reported in multiple studies (Beeckman et al., 2007; Kottner et al., 
2009b). Beeckman et al. (2007) found that only 22% of the nurses correctly 
assessed IAD, which were often misclassified as a pressure ulcer Grade II or 
Grade III. Although a considerable proportion of the included patients in the 
Nixon trial (15%) had a moist skin according to the Braden scale (Nixon et al., 
2006a), the researchers did not mention the organisation of a training to observe 
the difference between pressure ulcers and IAD. This lack of training may have 
caused an overestimation of pressure ulcers in their study. In this trial, all 
observers were intensively trained to correctly differentiate between pressure 
ulcers and IAD. Furthermore, the correctness of the skin observations was 
regularly assessed by introducing inter-observer checks between the 
observations of the ward nurses, the study nurses and the researcher. The inter-
rater reliability was sufficient to good (Landis and Koch, 1977). 
A third reason for the difference in pressure ulcer incidence between the APAM 
studies and this ALPAM study may be the lower interface pressure and the 
higher pressure redistribution index of the ALPAM, which suggests a 
hypothetical advantage of this support surface. Large and methodological sound 
clinical trials are needed to confirm the existence of a clinical advantage.  
 
4.2 POSSIBLE EXPLANATIONS FOR THE OBSERVED EFFECTS 
No differences in pressure ulcer development were found between the 
experimental and the control mattress. A first possible explanation may be 
related to the gradual inflation and deflation cycle of the experimental mattress. 
The possible role of this gradual inflation and deflation cycle of the air cells, in 
pressure ulcer development is not yet clear and needs to be clarified. It is 
possible that this modification of the inflation/deflation cycle only is not able to 
impact pressure ulcer incidence significantly.  
Secondly, despite the fact that this is one of the largest trials of this kind, the lack 
of effect may also be related to the power of the study. The study was powered 
on the assumption of a pressure ulcer incidence of 15% on an APAM 
(Vanderwee et al., 2005), because there were no data available on incidence on 
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ALPAMs at the start of the study. In the current study, only 5.7% of the included 
patients developed a pressure ulcer. These lower incidence figures resulted in a 
decrease in power. Moreover, with the minimal differences in pressure ulcer 
incidence found between both groups, it is likely that significance could not be 
achieved by the recruitment of more patients. An assessment based on the 
figures found in this study suggest the need of an unrealistic, not feasible 
sample size to find a significant result between the two groups, if this difference 
would even exist.  
Thirdly, the lack of difference found between the two study groups can be due to 
the fact that the control group performed better than expected. A pressure ulcer 
incidence on ALPAMs with a one-stage inflation and deflation cycle was 
assumed to be comparable with the incidence on APAMs, which was not found 
in this study. As mentioned above, there are several possible explanations for 
this difference. 
 
At the heel area the experimental mattress included an ultra-low continuous 
pressure zone and the control mattress included an alternating low pressure 
zone. Pressure ulcers Grade II–IV still occurred on both devices with an 
incidence of 1.7% at the heel area. However, no differences in heel pressure 
ulcers were observed between both mattresses and we observed a non-
significant difference in the severity of heel pressure ulcers between the 
mattresses. More patients developed a severe pressure ulcer (Grade III–IV) the 
heel area in the control group compared to the experimental group. However, 
this is based on a small number of pressure ulcers. Continuous ultra-low 
pressure at the heel zone is not adequate to prevent the development of heel 
pressure ulcers, but can have an additional role in the effective prevention. 
Nevertheless, offloading the heels in accordance with the latest NPUAP/EPUAP 
guidelines (2009) remains the most appropriate and effective way to prevent 
heel pressure ulcers. Further research needs to clarify the possible additional 
value of continuous very low pressure at the heel area when combined with 
offloading the heels. 
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5. LIMITATIONS 
The lack of a blinded outcome assessment is a first limitation of this study. 
However, the nurses were not informed about the differences in the mattresses 
in order to minimise the effect of non-blinding. Furthermore, inter-rater 
observations were conducted to assure the reliability of the observations. A 
second limitation is related to the limited predictive value of the Braden scale to 
assess risk for pressure ulcer development. Risk assessment, and particularly 
the use of risk assessment scales, has always been a controversial issue in 
practice and in scientific debates. This controversy is linked to the limited 
predictive validity of the available risk assessment scales. In 2002, 
Schoonhoven and co-workers concluded that the Braden scale is only able to 
predict the development of pressure ulcers to some extent. This issue might 
have resulted in the inclusion of patients who were thought as being at risk, but 
who were not. 
 
Although the cumulative pressure ulcer incidence on ALPAMs found in this study 
can be seen as representative for a population of geriatric and medical patients, 
these results cannot be generalized to other patient populations. 
 
6. CONCLUSION 
Based on the results of this study, we can conclude that ALPAMs with multi-
stage inflation and deflation cycle of the air cells and standard ALPAMs are 
equally effective in pressure ulcer prevention. Both ALPAMs generate a low 
pressure ulcer incidence and consequently seem to be good and effective 
preventive measures. 
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CHAPTER 3 
 
THE EFFECTIVENESS OF THREE TYPES OF 
ALTERNATING PRESSURE AIR MATTRESSES IN THE 
PREVENTION OF PRESSURE ULCERS IN BELGIAN 
HOSPITALS 
Based on the article of Demarré L, Verhaeghe S, Van Hecke A, Grypdonck M, 
Clays E, Vanderwee K & Beeckman D (2013) The effectiveness of three types of 
alternating pressure air mattresses in the prevention of pressure ulcers in 
Belgian hospitals.   
Journal of Research in Nursing and Health 36(5), 439-452. 
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ABSTRACT 
To compare the effectiveness of multi-stage and one-stage alternating low-
pressure air mattresses (ALPAM) and alternating pressure air mattress (APAM) 
overlays in preventing pressure ulcers among hospitalised patients, data were 
pooled (N=617) from a study of patients allocated to multi-stage ALPAM (n=252) 
or one-stage ALPAM (n=264), and another study of patients allocated to APAM 
overlay (n=101). Cumulative pressure ulcer incidence was 4.9% (n=30) over 14 
days. Fewer ulcers developed on multi-stage ALPAM compared with APAM 
overlay (OR=0.33; 95% CI [0.11, 0.97]), but no difference was found between 
one-stage ALPAM and APAM overlay (OR=0.40; 95% CI [0.14, 1.10]). Time to 
develop ulcers did not differ by mattress type.  
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1. INTRODUCTION 
Pressure ulcers remain a significant health problem for patients and healthcare 
providers. Pressure ulcer development is a complex phenomenon. Exposure to 
pressure and/or shear, a combination of ischemia, direct cell deformation, 
ischemic reperfusion injury, and impaired lymphatic drainage may lead to 
damage to the skin or the underlying tissues and structures (Ceelen et al., 2008; 
Loerakker et al., 2011; NPUAP & EPUAP, 2009; Reed, et al., 2003; Tsuji, et al., 
2005). 
 
In 2004, the prevalence of pressure ulcers in US hospitals was 16.0% 
(Whittington & Briones, 2004), and similar results (prevalence of 18.1%) were 
found across Europe (Vanderwee, et al., 2007a). In 2009, pressure ulcer 
prevalence in US hospitals was reduced to 6.7% (Gunningberg, et al., 2012). 
Changes in reimbursement policy, hospital staffing, and increased awareness of 
the negative patient outcomes of hospital-acquired pressure ulcers may have 
prompted more systematic risk assessment and timely start of preventive 
measures. 
 
Paramount to the prevention of pressure ulcers is reducing the amount and 
duration of pressure or shear, which can be achieved by the use of patient 
repositioning or by a support surface, “a specialized device for pressure 
redistribution designed for management of tissue loads” (NPUAP, 2007, p. 1). 
Pressure redistribution can be achieved by temporarily shifting contact between 
the support surface and vulnerable areas or pressure points to other areas 
(NPUAP, 2007), either by repositioning the patient or by using an active support 
surface (NPUAP 2007; NPUAP & EPUAP, 2010). 
 
An active support surface is a powered surface that achieves load distribution by 
cyclic inflation and deflation of air cells, with or without body weight of the patient 
resting on the surface (NPUAP, 2007). Active support surfaces differ in their 
duration of cycle time, rate of change of air cell inflation, and pressure amplitude 
(NPUAP, 2007). Pressure amplitude is defined as the difference between the 
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highest and the lowest interface pressure (Tissue Viability Society, 2010). An 
example of an active support surface is an alternating pressure air mattress 
(APAM), available as APAM overlays (used atop a standard bed mattress) and 
APAM replacement mattresses. The inflation and deflation of the air cells of an 
APAM are characterized by a steep, one-stage inflation or deflation. 
 
Pressure redistribution also can be achieved with a support surface that enables 
the patient to sink into the mattress, thereby increasing the contact area 
between the patient and the support surface. Alternating low pressure air 
mattresses (ALPAMs) generate lower pressures than APAMs, enabling them not 
only to shift pressure or shear to other areas of the body but to better envelop 
the body in the underlying support surface. One-stage ALPAMs have air cells 
that inflate and deflate in a single step. The air cells of more recent multi-stage 
ALPAMs have gradual, stepwise inflation and deflation, in response to the 
hypothesis that tissue damage is decreased by gradual reperfusion of ischemic 
tissue (Unal et al., 2001). 
 
The use of different types of pressure redistributing surfaces varies 
internationally. Based on limited reports, in US acute care settings, 57% of 
patients with a hip fracture, a population of patients considered at risk for 
pressure ulcers, are placed on pressure-redistributing surfaces (Baumgarten et 
al., 2010). The absence of studies of APAM overlays from the United States 
suggests that these devices may be less common in US healthcare institutions. 
However, their use is widespread in Europe (Manzano et al., 2013; Nixon et al., 
2006b), where the incidence of pressure ulcers on APAM overlays ranged 
between 10.7% (Nixon et al., 2006b) and 15.3% (Vanderwee, et al., 2005) in 
adult populations at risk. The incidence of pressure ulcers on one-stage 
ALPAMs has ranged between 2.9% and 5.8% (Cavicchioli & Carella, 2007; 
Demarré et al., 2012; Theaker, et al., 2005). Pressure ulcer incidence on multi-
stage ALPAMs was 5.7% (Demarré et al., 2012a). Demarré et al. (2012a) found 
one-stage and multi-stage ALPAMs equally effective in terms of pressure ulcer 
incidence and time to develop a pressure ulcer. 
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Costs for purchase and maintenance of support surfaces vary widely. The 
purchase price for an APAM overlay is estimated at $1,500 (Nixon et al., 2006). 
Estimated purchase costs for a one-stage ALPAM range from $2,500 to $3,500, 
and from $6,000 to $7,000 for a multi-stage ALPAM. Given these cost 
differences, health systems may take an interest in their comparative 
effectiveness. In a systematic review and meta-analysis, McInnes et al. (2012) 
did not find any one specific alternating pressure device more effective than 
others, but no comparisons of the effectiveness of an APAM overlay with a one-
stage or multi-stage ALPAM have been reported. 
 
To help determine whether more complex technology leads to more effective 
devices, data from two previously conducted randomised controlled trials (RCTs) 
were pooled to compare the effectiveness of the less expensive APAM overlay 
with one-stage and multi-stage ALPAMs. The main outcome was cumulative 
incidence of all pressure ulcers (Category/ Stages II–IV). Subgroup analyses 
examined predictors of superficial (Category/Stage II) and severe 
(Category/Stages III–IV) pressure ulcers. The secondary outcome was the time 
to develop a pressure ulcer. 
 
2. METHODS 
2.1 DESIGN  
A comparative design was used to pool the data from two RCTs (Demarré et al., 
2012a; Vanderwee et al., 2005). In the study by Vanderwee et al. (2005) 
(hereafter referred to as “APAM overlay study”), data were collected from May 
2000 until August 2002. In the study by Demarré et al. (2012a) (hereafter 
referred to as “ALPAM study”), data were collected from December 2007 until 
January 2010. 
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2.2 RANDOMIZED CONTROLLED TRIALS USED FOR THE POOLED DATABASE  
APAM overlay study.  
The APAM overlay study included 447 patients admitted to 1 of 19 surgical, 
medical, and geriatric wards in a convenience sample of seven Belgian 
hospitals. Risk assessment was conducted in consecutive patients admitted to 
the participating wards during the study period. The Braden score was assessed 
on admission and every 3 days, and the presence or absences of non-
blanchable erythema was assessed daily. The Braden scale is a risk 
assessment scale that consists of six items: sensory perception, mobility, 
activity, nutrition, friction, and shear. The lowest score on the Braden scale is 6 
(high risk) and the highest is 23 (no risk). A patient was classified as at risk for 
pressure ulcer development if the Braden score was less than 17 or when non-
blanchable erythema was present. This cut-off score is commonly used in 
Belgian health care institutions (Defloor, et al., 2004; Vanderwee et al., 2005) 
and was chosen to enhance comparability with other studies (Baumgarten et al., 
2010; Defloor, et al., 2005; Vanderwee et al., 2005, Vanderwee et al., 2007). 
Patients at risk were randomly assigned to an APAM overlay with no 
repositioning protocol or to a viscoelastic polyethylene-urethane foam mattress 
with a standardised repositioning protocol every 4 hours. In both groups, a pillow 
supporting the calf of the leg was used for heel offloading. All patients used a 
static air cushion for pressure redistribution when seated (Vanderwee et al., 
2005). 
 
ALPAM study. The ALPAM study included a consecutively identified sample of 
610 patients from a convenience sample of five Belgian hospitals. Eight geriatric 
wards and 17 medical wards participated in the study, the latter consisting of 
neurology (6), rehabilitation (3), cardiology (2), dermatology (1), pulmonology 
(1), oncology (1), chronic care (1), or mixed medical conditions (2). Patients with 
Braden scores less than 17 were classified as at risk for pressure ulcer 
development (Baumgarten et al., 2010; Defloor et al., 2005; Vanderwee et al., 
2005, 2007). The patients at risk were randomly assigned to a one-stage 
ALPAM (n=312) or to a multi-stage ALPAM (n=298). No standard protocol for 
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repositioning in bed was used in either group, and all patients used a static air 
cushion to redistribute pressure when seated (Demarré et al., 2012a). An equal 
number of one-stage and multi-stage ALPAMs were available during the study 
period. Further information on the two studies is available in previous 
publications (Demarré et al., 2012a; Vanderwee et al., 2005). 
 
2.3 INCLUSION CRITERIA USED FOR THE POOLED DATABASE 
Patient data were pooled if the following criteria were met (see Figure 1): 
 Allocation to an alternating pressure air device (APAM overlay, one-
stage or multi-stage ALPAM). 
 Braden score of less than 17 (Baumgarten et al., 2010; Defloor et al., 
2005; Vanderwee et al., 2005, Vanderwee  et al., 2007). 
 No pressure ulcer of any category/stage at the start of the study. 
Patients with pressure ulcers Category/Stage I (n=175) were excluded 
for this pooled analysis, as the presence of a pressure ulcer 
Category/Stage I was only an inclusion criteria in the APAM overlay 
study. 
 Admitted to a geriatric or internal medicine ward. 
 
The first 14 observation days were examined. This 14-day period was chosen 
based on the mean length of stay in Belgian hospitals (6 days on medical wards 
to 18 days on geriatric wards) (Flemish Agency for Care and Health in Trybou, 
2011). 
 
2.4 INTERVENTIONS: ALTERNATING PRESSURE SUPPORT SURFACES 
Table 1 provides an overview of the characteristics of the support surfaces in 
this study. The three support surfaces were comparable with respect to the 
diameter of the air cells (10 cm), rate of change of inflating/deflating air cells 
(sequence of one cell inflated/one cell deflated), and time needed to complete 
one cycle (between 10 and 12 minutes). No standard repositioning protocol was 
used for any patient. All patients used a static air cushion when seated in an 
armchair.  
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Figure 1  Flowchart of pooling process.  
PU =  Pressure ulcer; APAM = Alternating Pressure Air Mattress; ALPAM = Alternating Low-Pressure Air Mattress 
APAM overlay study 
(n = 447) 
ALPAM study 
(n = 610) 
Pooling based on following inclusion criteria (n = 617): 
Allocated to alternating device, 
 Braden Score < 17, 
Pressure ulcer free at the start of the study, 
Admitted to a geriatric or internal medicine ward 
Excluded from analysis (n = 346): 
Not on alternating device (n = 225), 
Braden score ≥17 (n = 37), 
Non-blanchable erythema at the start of 
the study (n = 81), 
Admitted to a surgical ward (n = 3) 
Excluded from analysis ( n =  94): 
Non-blanchable erythema at the start 
of the study 
ALPAM-group 
(n = 516) 
Excluded for not meeting inclusion criteria (n = 6256): 
-incomplete Braden score (n = 214) 
-patients not at risk for PU development (n = 6042) 
Patients excluded (n = 341): 
-PU category II-IV (n = 204), 
-do not resuscitate code III (n = 35), 
-< 18 years of age (n = 6), 
-weight < 30kg or > 160 kg (n = 1), 
-expected duration of admission < 3 days (n = 43), 
-no informed consent (n = 52) 
Excluded for not meeting inclusion criteria (n=1549): 
-patients not at risk for PU development (n=1549) 
Patients excluded (n = 612): 
-PU category II-IV (n = 131), 
-repositioning contra-indicated (n = 113), 
-weight > 140 kg (n = 3), 
-expected duration of admission < 3 days (n = 242), 
-no informed consent (n = 123) 
 
APAM study 
Assessed for eligibility (n= 2608) 
Vanderwee et al. (2005) 
 
ALPAM study 
Assessed for eligibility (n= 7393) 
Demarré et al. (2012) 
 
Patients at risk for PU development 
(n = 1059) 
Patients at risk for PU development 
(n = 1137) 
Patients analysed in the One-
stage  ALPAM group  
(n = 264): 
-Follow-up 14 days (n = 143) 
-PU category II-IV (n = 12) 
-technical problems or 
discomfort (n = 11) 
-reason to end the study not 
defined (n = 12) 
-transfer to another ward (n = 
20) 
-discharge to home (n = 29) 
-death (n = 11) 
-discharge to another 
institution (n = 26) 
Patients analysed in the Multi-
stage ALPAM group (n = 252): 
-follow-up 14 days (n = 131), 
-PU category II-IV (n = 9), 
-technical problems or 
discomfort (n = 9), 
-reason to end the study not 
defined (n = 6), 
transfer to another ward (n = 
11), 
discharge to home (n = 35), 
death (n = 12), 
discharge to another institution 
(n = 39) 
 
Patients analysed in the APAM overlay group (n = 
101): 
-follow-up 14 days (n = 62), 
-PU category II-IV (n = 9), 
-redraw of consent because of technical problems or 
discomfort (n = 0), 
-reason to end the study not defined (n = 5), 
-transfer to another ward (n = 2), 
-discharge to home (n = 6), 
-death (n = 3), 
-discharge to another institution (n = 14) 
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The main differences among the three groups were: (1) the type of support 
surface (overlay vs. replacement), (2) the air cell pressures, (3) the method of 
inflating and deflating the air cells, (4) the use of a sensor, and (5) the preventive 
measures at the heels (Table 1). 
A detailed description of these differences is provided below. 
 
APAM overlay. The overlay was placed atop a standard mattress. The inflation 
and deflation of the APAM overlay air cells was steep and one-staged. All air 
cells except three at the head zone alternated inflation and deflation. The 
surface was manually adjusted to the patient’s weight via an external control 
unit. The heels of the patients were offloaded, using a pillow supporting the calf 
of the leg. 
 
One-stage ALPAM. The one-stage ALPAM replaced the standard mattress. The 
air cell cycle of the one-stage ALPAM was characterised by steep inflation and 
deflation. All air cells alternated. The mattress was manually adjusted to the 
patient’s weight via an external control unit. No heel offloading was provided. 
Multi-stage ALPAM. The multi-stage ALPAM was also a mattress replacement. 
The air cells of the multi-stage ALPAM were gradually inflated and deflated. The 
air cells at the spine and the sacrum alternated. A sensor at the sacrum 
continuously measured weight distribution and adjusted the pressure in the cells. 
The air cells at the head and heels did not alternate but had continuous low 
pressure. No heel offloading was provided. 
 
2.5 OUTCOME MEASURES AND SUBGROUP ANALYSES 
Main and secondary outcomes were compared in APAM overlay, one-stage 
ALPAM, and multi-stage ALPAM groups. The primary outcome was cumulative 
pressure ulcer incidence of Category/Stages II–IV on any location of the body 
during the 14-day period of observation. The secondary outcome was the time in 
days to develop a pressure ulcer of Category/Stages II–IV. 
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Table 1  Specifications and Characteristics of Experimental and Control Group 
 Support Surface 
 ALPAM  
Characteristic Multi-stage One-stage APAM overlay 
Cycle amplitude Multi-stage inflation 
and deflation of air cells 
One-stage inflation 
and deflation of air 
cells 
One-stage inflation 
and deflation of air 
cells 
Cycle Time 10-12 minutes 10 minutes 10 minutes 
Air cell inflation 
sequence 
1/1  1/1  1/1  
Width air cells 
(diameter) 
10 cm  10 cm  10 cm  
Alternating sequence (1) Head zone: 3 cells 
continuous low 
pressure (not 
alternating) 
(2) Back and sacrum: 
10 cells alternating low 
pressure (1/1) 
(3) Heel zone: 7 cells 
continuous ultra low 
pressure (not 
alternating) 
(1) All cells alternate, 
except from 3 cells at 
the head zone (1/1)  
 
(1) All cells alternate, 
except from 3 cells at 
the head zone (1/1)  
 
Heels Continuous ultra low 
pressure zone  
Alternating low 
pressure zone 
Heel offloading using 
a pillow 
Sensor 
 
 
Yes 
Continuously 
measuring the load 
applied on sacral zone 
No 
Manually adjustable for 
weight.  
No 
System Mattress replacement Mattress replacement Mattress overlay 
 
  
ALPAM = Alternating Low-Pressure Air Mattress; APAM = Alternating Pressure Air 
Mattress; 1/1 = one air cell is inflated/one air cell is deflated 
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Pressure ulcers were categorized according to the classification system of the 
NPUAP and EPUAP (2009), in which pressure ulcer severity ranges from non-
blanchable erythema (Category/Stage I) and partial thickness skin loss 
(Category/Stage II) to full thickness skin loss (Category/Stage III) and full 
thickness tissue loss (Category/Stage IV). To differentiate between blanchable 
and non-blanchable erythema, a transparent plastic disc was used (Halfens, et 
al., 2001). Pressure ulcers were distinguished from incontinence-associated 
dermatitis (IAD) and friction lesions. An IAD was defined as a reactive response 
of the skin to chronic exposure to urine and faecal material (Beeckman, et al., 
2009; Gray et al., 2012). No data were collected on the use of incontinence 
briefs or the prevention and treatment of IAD. A friction lesion was defined as 
damage caused by “the rubbing of  one body against another or the force that 
resists relative motion between two bodies in contact and/or material elements 
sliding against each other” (Antokal et al., 2012, p. 1). 
A subgroup analysis of patients who developed pressure ulcers was done to 
examine group differences in cumulative incidence of superficial versus severe 
pressure ulcers. In addition, because tissue damage could have developed in 
underlying tissue prior to the patients’ inclusion in the study (Berlowitz & Brienza, 
2007; Gefen, 2009), cumulative pressure ulcer incidence was analysed 
excluding patients who developed severe pressure ulcers in the first 3 days 
(Reddy, 1990). 
 
2.6 PROCEDURE 
Baseline variables from both studies were age, gender, diagnosis, type of ward 
(geriatric or medical), and Braden risk assessment score (Table 2). Both studies 
had an identical procedure. Skin assessment was performed by the ward nurses 
on a daily basis during morning care. To enhance the precision of the 
observations and the uniformity of data collection, all nurses attended a training 
session on aetiology, pressure ulcer classification, differentiation from IAD and 
friction lesions, differentiation of blanchable and non-blanchable erythema, and 
the use of the Braden scale. The training also clarified the aim of the study and 
the protocol. 
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The inter-rater reliability of the skin observations and the Braden score was 
assessed weekly. These observations and Braden scores were performed 
unannounced in a random sample of patients in the study. The inter-rater 
reliability among researcher, study nurse, and ward nurse ranged between 
k=0.71 (95% CI [0.63, 0.79]) to k=0.94 (95% CI [0.91, 0.97]) for skin 
observations, and between k=0.64 (95% CI [0.01, 1.28]) to k=0.90 (95% CI 
[0.81, 0.99]) for risk assessment (Demarré et al., 2012a; Vanderwee et al., 
2005). 
Data from the first 14 days after study inclusion were used in analysis. No data 
were collected after patients developed a pressure ulcer Category/Stages II–IV, 
or withdrew their consent, died, or were discharged to a non-participating ward, 
home, or nursing home (see Figure 1). 
 
2.7 STATISTICAL ANALYSES 
The variables included in analyses in addition to group assignment were those 
that were identical in both studies: age, gender, diagnosis, type of ward (geriatric 
or medical), and the Braden risk assessment. Frequencies (percentages) and 
medians (interquartile range) were used to present descriptive data. To compare 
non-normally distributed continuous data, Kruskal–Wallis tests were conducted. 
For categorical variables, Chi-square and Fisher’s exact tests were used. 
Univariate binary logistic regression analyses were conducted to calculate the 
odds ratio and related 95% CIs for each variable. Only Braden risk assessment 
and the age of the patient were associated with pressure ulcer development 
(p<0.10) in univariate analyses, and both variables were included as covariates 
in multivariate analyses. The total Braden score was entered in the multivariate 
analyses rather than the separate Braden items, as the total score had the 
lowest p-value in univariate analyses.  
No multicollinearity was detected between the independent variables. 
Multivariate logistic regression was used to examine the influence of support 
surface type, risk category, and age on pressure ulcer development and 
pressure ulcer severity. A log-rank test analysis and a Kaplan–Meier survival plot 
were used to examine differences in time to develop pressure ulcers. Statistical 
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analyses were conducted using SPSS 15.0 (IBM Corporation, Somers, NY), and 
a significance level of p<0.05 was set. 
 
3. RESULTS 
3.1 BASELINE CHARACTERISTICS 
The data of 617 patients were analysed (multi-stage ALPAM: n=252, one-stage 
ALPAM: n=264, and APAM overlay: n=101). The median age of the patients was 
80 years (IQR=71–86), and 60.1% (n=365) were female. Patients were most 
frequently admitted with neurological diagnoses (25.9%), rehabilitation disorders 
(23.4%), or pulmonary disorders (17.9%). The median Braden score was 14 
(IQR=12–15). Baseline patient characteristics are presented in Table 2. Activity 
level, gender, primary diagnosis, and Braden score were comparable among 
groups. Patients were significantly older (p=0.03) in the APAM overlay group 
(Mdn=81), compared with the one-stage ALPAM (Mdn=79) and multi-stage 
ALPAM (Mdn=80). More patients in the APAM overlay group than in the one-
stage and multi-stage ALPAM groups were cared for in geriatric wards 
(p<0.001). 
 
3.2 PRIMARY OUTCOME: CUMULATIVE INCIDENCE OF PRESSURE ULCERS 
OUTCOMES IN SUPPORT SURFACE GROUPS.  
In the sample as a whole, the cumulative pressure ulcer incidence was 4.9% 
(n=30). Pressure ulcer incidence was significantly lower in the multi-stage 
ALPAM group (3.6%) compared with the APAM overlay group (8.9%) (p=0.047). 
The difference between the APAM overlay group (8.9%) and the one-stage 
ALPAM group (4.5%) was not significant (p=0.126). More patients developed 
non-blanchable erythema in the APAM overlay group (23.8%) compared with the 
one-stage ALPAM group (14.4%) (p=0.045). Most pressure ulcers occurred in 
the pelvic area, either sacrum or hip (n=17, 2.7% of sample). No significant 
differences in pelvic area ulcer incidence were found between the multi-stage 
ALPAM (2.0%) and APAM overlay (5.8%) groups (Fisher’s exact; p=.088), or  
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Table 2  Baseline characteristics of included patients 
  Type of Support Surface   
  ALPAM    
 
 
 
Total 
Mdn (IQR) 
Multi-stage 
Mdn (IQR) 
One-stage 
Mdn (IQR) 
APAM overlay 
Mdn (IQR) 
Kruskall 
Wallis-test 
p 
 Continuous Variables 
Age 
 
80 (71-86)  80 (70-86) 79 (70-85) 81(75-89)    7.0        0.03 
Braden score 14 (12-15) 14 (12-15) 14 (12-15) 15 (13-15.5)    5.8 0.05 
  Type of Support Surface   
  ALPAM(2)    
 
Total 
% (n) 
Multi-stage 
% (n) 
One-stage 
% (n) 
APAM 
overlay(3) 
% (n) 
χ²  p 
 Categorical variables 
Gender* 
     Male 
     Female 
*10 missings 
 
39.9 (242) 
60.1 (365) 
 
39.7 (100) 
60.3 (152) 
 
42.8 (113) 
57.2 (151) 
 
31.9 (29) 
68.1 (62) 
 
3.4 
 
0.18 
Ward 
     Geriatrics 
     Internal medicine 
 
37.4 (231) 
62.6 (386) 
 
34.1 (86) 
65.9 (166) 
 
29.2 (77) 
70.8 (187) 
 
67.3 (68) 
32.7 (33) 
 
47.4 
 
<.001 
 
Activity level 
     Bedfast 
     Chair fast 
     Ambulatory 
 
27.2 (167) 
62.4 (383) 
10.5 (64) 
 
26.2 (66) 
65.1 (164) 
8.7 (22) 
 
25.3 (66) 
61.7 (161) 
13.0 (34) 
 
34.7 (35) 
57.4 (58) 
7.9 (8) 
8.1 0.23 
Diagnosis* 
     Neurologic  
     Pneumologic 
     Rehabilitation  
     Cardiac 
     Gastrologic  
     Urogenital 
     Other 
*19 missings 
 
25.9 (155) 
17.9 (107) 
23.4 (140) 
7.4 (44) 
14.2 (85) 
4.2 (25) 
7.0 (42) 
 
29.8 (75) 
17.9 (45) 
24.6 (62) 
7.9 (20) 
11.5 (29) 
4.4 (11) 
4.0 (10) 
 
25.8 (67) 
19.2 (50) 
21.5 (56) 
6.5 (17) 
15.8 (41) 
3.1 (8) 
8.1 (21) 
 
15.1 (13) 
14.0 (12) 
25.6 (22) 
8.1 (7) 
17.4 (15) 
7.0 (6) 
12.8 (11) 
20.1 0.07 
Total 617 252 264 101   
 IQR = Inter Quartile Range; ALPAM = alternating low pressure air mattress;  APAM  overlay = alternating 
pressure air mattress overlay;  p = p-value; χ² = Chi-square test;  
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between the one-stage ALPAM (2.3%) and APAM overlay group (5.8%) 
(Fisher’s exact; p=0.106). Seven (1.1%) patients developed pressure ulcers on 
the heel. Pressure ulcer incidence on the heel was comparable among the three 
groups (Fisher’s exact for comparisons above; p=1.00; p=1.00) (Table 3). 
 
3.3 INDEPENDENT EFFECTS OF SUPPORT SURFACE, AGE AND RISK CATEGORY ON 
INCIDENCE OF PRESSURE ULCERS IN MULTIVARIATE ANALYSES.  
Multivariate analyses confirmed that pressure ulcer development was lower in 
the multi-stage ALPAM group compared with the APAM overlay group, when 
controlling for Braden score category and age (OR=0.33; 95% CI [0.11, 0.97]) 
(see Table 4). No significant differences in pressure ulcer development were 
found between patients on an APAM overlay and those on a one-stage ALPAM 
(OR=0.40; 95% CI [0.14, 1.10]). The results were similar when excluding severe 
pressure ulcers occurring in the first 3 days after admission to the study.  Age 
was not associated with pressure ulcer incidence in multivariate analyses. Fewer 
severe pressure ulcers developed in the multi-stage ALPAM group compared 
with the APAM overlay group (OR=0.08; 95% CI [0.01, 0.83]). No difference in 
incidence of superficial pressure ulcers was found among the three study 
groups. 
More pressure ulcers developed in higher risk patients, with Braden scores 
between 6 and 9, than those with Braden scores between 15 and 16 (OR=5.23; 
95% CI [1.67, 16.32]), due to higher incidence of superficial pressure ulcers 
among the higher-risk patients (OR=6.89; 95% CI [1.84, 25.75]). Risk category 
based on the Braden scale was not associated with severe pressure ulcers 
(OR=2.28; 95% CI [0.22, 23.32]) (Table 4). 
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Table 3  Overview of the cumulative pressure ulcer incidences 
  Support Surface Multi-stage 
ALPAM 
vs APAM 
p 
One-stage 
ALPAM 
vs APAM 
 
p 
  ALPAM  
 
Pressure ulcers 
Total 
% (n) 
Multi-
stage 
% (n) 
One-
stage 
% (n) 
APAM 
% (n) 
Category  I 18.3 (113) 20.2 (51) 14.4 (38) 23.8 (24) 0.550 0.045 
 Category II 3.2 (20) 3.2 (8) 2.7 (7) 5 (5) 0.532* 0.325* 
Category III 1.0 (6) .4 (1) .4 (1) 4 (4) 0.025* 0.022* 
 Category IV .6 (4) 0 (0) 1.5 (4) 0 (0) - 0.579* 
Category II-IV 4.9 (30) 3.6 (9) 4.5 (12) 8.9 (9) 0.047 0.126 
     Pelvic Area  2.7 (17) 2.0 (5) 2.3 (6) 5.8 (6) 0.088* 0.106* 
     Heels  1.1 (7) 0.8 (2) 1.5 (4) 1.0 (1) 1.000* 1.000* 
     Other 1.0 (6) 0.8 (2) 0.8 (2) 1.9 (2) 0.583* 0.317* 
 
 
 
 
  
ALPAM = alternating low pressure air mattress; APAM = alternating pressure air,  p = p-value, Pelvic Area 
= Sacrum and Hips; * Fisher-Exact test 
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Table 4  Multivariate analysis with pressure ulcer severity as dependent variable  
Variable Wald OR  95% CI p 
Pressure ulcer category II-IV 
Multi-stage ALPAM  (1) 
One-stage ALPAM (1) 
4.10 
3.18 
0.33 
0.40 
[0.11,0 .97] 
[0.14, .1.10] 
0.043 
0.103 
Braden moderate risk (13-14) (2) 
Braden high risk (10-12) (2) 
Braden very high risk (6-9) (2) 
0.01 
2.09 
8.11 
0.96 
2.13 
5.23 
[0.30, 3.00] 
[0.76, 5.93] 
[1.67, 16.32] 
0.938 
0.148 
0.004 
Age  1.06 0.99 [0.96, 1.01] 0.303 
Pressure ulcer category II 
Multi-stage ALPAM  (1) 
One-stage ALPAM (1) 
0.97 
1.98 
0.52 
0.38 
[0.15, 1.89] 
[0.10, 1.46] 
0.324 
0.159 
Braden moderate risk (13-14) (2) 
Braden high risk (10-12) (2) 
Braden very high risk (6-9) (2) 
0.070 
0.55 
8.23 
1.19 
1.67 
6.89 
[0.31, 4.54] 
[0.43, 6.43] 
[1.84, 25.75] 
0.799 
0.458 
0.004 
Age  0.24 0.99 [0.96, 1.02] 0.627 
Pressure ulcer category III-IV 
Multi-stage ALPAM  (1) 
One-stage ALPAM (1) 
4.47 
1.49 
0.08 
0.39 
[0.01,0 .83] 
[0.08, 1.78] 
0.035 
0.223 
Braden moderate risk (13-14) (2) 
Braden high risk (10-12) (2) 
Braden very high risk (6-9) (2) 
0.32 
1.82 
0.49 
0.52 
2.92 
2.28 
[0.05, 5.13] 
[0.62, 13.84] 
[0.22, 23.32] 
0.574 
0.174 
0.486 
Age  1.27 0.98 [0.93, 1.02] 0.259 
 
 
  
OR = odds ratio; CI = Confidence Interval; ALPAM = alternating low pressure air mattress;  
(1) APAM overlay group is reference category, (2) Braden mild risk (15-17) is reference category; p = p-
value. 
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3.4 SECONDARY OUTCOME: TIME TO DEVELOP A PRESSURE ULCER 
Overall, the median time to develop a pressure ulcer was 8 days (IQR=4.00–
12.25). No difference in time to ulcer was found among the three groups (multi-
stage ALPAM=6 days [IQR= 3.50–8.50], one-stage ALPAM=11.5 days 
[IQR=4.0–14.0], and APAM overlay=8 days [IQR=4.50–8.50], Kruskal–Wallis test 
χ²=5.749, p=0.056). The probability of remaining pressure ulcer-free did not 
differ among the three groups (log-rank X²=3.167, df=2, p=0.205, Figure 2). 
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Figure 2  Kaplan Meier plot of the time to develop pressure ulcers Category II-IV.  
 (1) APAM = Alternating pressure air mattress; (2) Multi-stage ALPAM = Multi-stage Alternating low-
pressure air mattress; (3) One-stage ALPAM = One-stage Alternating low-pressure air mattress 
APAM (1) 
One stage ALPAM (3) 
Multi-stage ALPAM 
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4. DISCUSSION 
4.1 EFFECT OF SUPPORT SURFACE ON PRESSURE ULCER INCIDENCE AND 
SEVERITY 
In this comparison of the effectiveness of an APAM overlay with a one-stage and 
a multi-stage ALPAM, a reduced incidence of pressure ulcers was found in the 
multi-stage ALPAM group compared to the APAM overlay group. The median 
time to develop a pressure ulcer was similar among groups.  
 
Pressure ulcer incidence on APAM overlays in this study was comparable with 
the incidence on APAM overlays found by Nixon et al. (2006b), who examined 
the effectiveness of various types of APAM overlays compared with various 
types of APAM replacements and found that they were equally effective (Nixon 
et al., 2006b). Similarly, our analyses did not identify differences in effectiveness 
between APAM overlays and one-stage ALPAMs. No studies were found 
comparing the effectiveness of one-stage and multi-stage ALPAMs with APAM 
overlays. A thorough comparison of our results with others was hampered by 
heterogeneity in type of support surfaces (Cavicchioli & Carella, 2007; Nixon et 
al., 2006; Theaker et al., 2005), study population (Theaker et al., 2005), 
inclusion criteria (Cavicchioli & Carella, 2007; Theaker et al.,2005), and 
outcomes (Cavicchioli & Carella, 2007; Theaker et al., 2005). The incidence of 
pressure ulcers was significantly lower in the multi-stage ALPAM group 
compared with the APAM overlay group. Others found that overlays and 
replacements (Nixon et al., 2006b), but also multi-stage and one-stage ALPAMs 
(Demarré et al., 2012a), were equally effective at preventing pressure ulcers. 
The contrasting findings of the current study may be due to the features of the 
two mattresses that had significantly different outcomes. The main 
characteristics that distinguish multi-stage ALPAMs from APAMs are: (1) lower 
pressures, (2) use of a sensor continuously adjusting the body weight applied to 
the mattress, and (3) gradual inflation and deflation of the air cells. The 
development of a pressure ulcer is thought to be caused by a combination of 
mechanisms (Loerakker et al., 2011; Nixon, et al., 2005). Similarly, the 
effectiveness of a multi-stage ALPAM at preventing pressure ulcers may be due 
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to the combined performance of several features, acting on different aetiological 
mechanisms. 
 
Subgroup analyses showed that the incidence of severe pressure ulcers was 
lower on multi-stage ALPAMs compared to APAMs. Damage to the deeper 
tissue structures may be not visible because of intact skin, and therefore 
adequate treatment or secondary prevention may be delayed (Berlowitz & 
Brienza, 2007; Black, 2005; Gefen, 2009). This delay may lead to longer 
hospitalisations, more frequent need for surgery, and higher costs (Berlowitz & 
Brienza, 2007; Dealey, Posnett, & Walker, 2012; McNair et al., 2010). If multi-
stage ALPAMs would be able to reduce the incidence of severe pressure ulcers, 
costs related to the purchase and maintenance of these sophisticated devices 
may be warranted by their benefits. An RCT is needed to confirm the 
advantages of multi-stage ALPAMs over other support surfaces, and a cost-
effectiveness analysis would provide further insight on performance in relation to 
costs. An a priori sample size calculation needs to take into account the low 
event rate of severe pressure ulcers. 
 
The median time to develop a pressure ulcer was 8 days and was comparable in 
all groups. A similar result was found by Theaker et al. (2005), who found the 
median time to develop a pressure ulcer in an intensive care population to be 7 
days, but did not report separate results for each study mattress (a one-stage 
ALPAM and a low-air-loss bed). As is true for incidence rates, comparing the 
time to develop a pressure ulcer in our study with those of other studies was 
hampered by several factors. First, the time to develop pressure ulcers is not 
often reported in effectiveness studies (Cavicchioli & Carella, 2007), perhaps 
because preventing pressure ulcers is more important than delaying the onset of 
a pressure ulcer. Furthermore, an accurate analysis of the time to develop an 
ulcer demands reliable daily registration of skin observations, which is often 
difficult to achieve (Cavicchioli & Carella, 2007; Nixon et al., 2006). 
 
Chapter 3 
85 
4.2 PRESSURE ULCER PREVENTION AT THE HEEL SITE 
The one-stage ALPAM had low alternating pressure air cells at the heel site, 
whereas the multi-stage ALPAM had an ultra-low continuous pressure zone. In 
the APAM overlay group, a pillow was used to support the heel. Pressure ulcers 
at the heel occurred on all three devices. To prevent pressure ulcers at this body 
site, 0 mm/Hg is the ideal pressure, which can be achieved only by heel 
offloading (NPUAP & EPUAP, 2009). Vanderwee et al. (2005) suggested that 
the use of a regular pillow to offload the heel may be less effective because 
patients push away or relocate the cushion beneath their legs, or because the 
pillow flattens out, allowing the heels to rest on the support surface.  
Studies of the effectiveness of devices to prevent heel pressure ulcers are 
scarce. In a comparative study by Heyneman et al. (2009) using a pooled 
database of patients positioned on viscoelastic foam mattresses, a wedge-
shaped cushion was more effective than a regular pillow at offloading the heel. 
Well-conducted RCTs are needed, however, to confirm these findings. In the 
meantime, when using a pillow, continuous attention and education of both 
patients and nurses are needed to provide correct heel offloading. Further 
research should focus on the development of devices that are simultaneously 
effective and well tolerated by patients. 
 
4.3 STRENGTHS AND LIMITATIONS 
RCTs are the gold standard to compare the effectiveness of support surfaces, 
but they are also expensive and time-consuming. We used pooled data from two 
previous studies to compare the effectiveness of an APAM overlay, a one-stage, 
and a multi-stage ALPAM. The use of pooled databases of original patient data 
has clinical and statistical advantages, compared to meta-analyses based on 
reported data (Hudgens et al., 2013), such as the ability to correct for known 
covariates or differences in inclusion criteria, and the creation of a larger sample 
by combining several databases. The main limitation is the lack of randomisation 
within the pooled sample, which may lead to an unequal distribution of baseline 
characteristics. In spite of the similarities in inclusion criteria and settings of both 
studies from which our pool was drawn, patients were older in the APAM overlay 
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group than in the one-stage and multi-stage ALPAM groups. This difference may 
be due to the inclusion of more geriatric patients in the APAM group compared 
with the one-stage ALPAM or multi-stage ALPAM group. Furthermore, only a 
few characteristics were identical in both studies and available for analysis (age, 
gender, diagnosis, type of ward, and the Braden risk assessment). In a 2013 
review, Coleman et al. (2013) identified other risk factors, including skin status, 
diabetes, haematological measures, and general health status, as predictors of 
pressure ulcer development. As we were unable to adjust for these, the results 
of this study must be interpreted with caution. 
A second limitation is the choice of the cut-off Braden score of 17 for inclusion. 
The score of 17 was chosen to enhance comparability with other studies 
(Baumgarten et al., 2010; Cavicchioli & Carella, 2007; Defloor et al., 2005; 
Gunningberg, 2004; Vanderwee et al., 2007), but some of the patients in the 
current study at the lower pressure ulcer risk levels of 15–16 may have been 
relatively mobile and therefore at less risk for pressure ulcer development. In a 
recent review by Beeckman et al. (2013), authors could not determine a clear 
cut-off point, as no Braden threshold outperformed another as a predictor of 
pressure ulcers. 
A third limitation of the study is the time lapse of 7 years between the APAM 
overlay study and the ALPAM study. Patients admitted to hospitals more 
recently (ALPAM study, 2007–2010) may have been more care-dependent or 
more severely ill than a decade ago (APAM study, 2000–2002). The trend 
toward lower Braden risk scores (higher risk) in the ALPAM groups compared to 
the APAM overlay group may reflect a higher acuity level. Although pressure 
ulcer prevention protocols evolved over those 7 years, confounding due to 
updated prevention protocols was avoided by using a comparable and strict 
study protocol. 
A fourth limitation was the absence of twice daily re-assessment of non-
blanchable erythema. The release of pressure/shear from a vulnerable area 
produces an increased blood flow through hypoxic tissue, defined as reactive 
hyperaemia. As this reactive hyperaemia can continue for 1/2 to 3/4 of the 
observed arterial or capillary occlusion time (Khan, et al. 1991; Nixon, 2001), the 
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incidence of non-blanchable erythema may have been overestimated in the 
current study. 
A final limitation was the lack of blinded skin assessment because of the visible 
differences in support surfaces. This is a well-known and common limitation in 
this type of study. Interrater reliability checks were conducted to minimise 
potential bias due to the lack of blind assessment and to enhance accuracy and 
reliability of the observations. 
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CHAPTER 4 
 
FACTORS PREDICTING THE DEVELOPMENT OF 
PRESSURE ULCERS IN AN AT RISK POPULATION WHO 
RECEIVE STANDARDISED PREVENTIVE CARE: 
SECONDARY ANALYSES OF A MULTICENTRE 
RANDOMISED CONTROLLED TRIAL  
Based on the article of Demarré L, Verhaeghe S, Van Hecke A, Clays E, 
Grypdonck M & Beeckman D (2014). Factors predicting the development of 
pressure ulcers in an at risk population receiving standardised prevention: 
secondary analyses of a multicentre randomised controlled trial.   
Journal of Advanced Nursing. In Press. doi/10.1111/jan.12497
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ABSTRACT 
Aims: To identify predictive factors associated with the development of pressure 
ulcers in patients at risk who receive standardised preventive care.  
Background: Numerous studies have examined factors that predict risk for 
pressure ulcer development. Only a few studies identified risk factors associated 
with pressure ulcer development in hospitalised patients receiving standardised 
preventive care.  
Design: Secondary analyses of data collected in a multicentre randomised 
controlled trial. 
Methods: The sample consisted of 610 consecutive patients at risk for pressure 
ulcer development (Braden Score < 17) receiving standardised preventive care 
measures.  Patient demographic information, data on skin and risk assessment, 
medical history, and diagnosis were collected during a 20 month period. 
Predictive factors were identified using multivariate statistics.  
Results: Pressure ulcers in category II-IV were significantly associated with non-
blanchable erythema, urogenital disorders, and higher body temperature. 
Predictive factors significantly associated with superficial pressure ulcers were 
admission to an internal medicine ward, incontinence-associated dermatitis, 
non-blanchable erythema, and a lower Braden score. Superficial sacral pressure 
ulcers were significantly associated with incontinence-associated dermatitis. 
Conclusions: Despite the standardised preventive measures they received, 
hospitalised patients with non-blanchable erythema, urogenital disorders, and a 
higher body temperature were at increased risk for developing pressure ulcers.  
Relevance to clinical practice: Improved identification of at-risk patients can be 
achieved by taking into account specific predictive factors. Even if preventive 
measures are in place, continuous assessment and tailoring of interventions is 
necessary in all patients at risk. Daily skin observation can be used to 
continuously monitor the effectiveness of the intervention. 
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1. INTRODUCTION 
Pressure ulcers are internationally accepted as an important indicator of the 
quality of care. They are considered to be a preventable adverse event 
(Gunningberg and Stotts, 2008; Van den Heede et al., 2007). Targeted 
prevention must consist of the identification of patients at risk and the 
introduction of tailored preventive care. A structured approach for risk 
assessment should include the use of a reliable and valid risk assessment scale 
(NPUAP & EPUAP, 2009), the observation of non-blanchable erythema (Defloor 
et al., 2004; Schoonhoven et al., 2002), and  clinical judgment of the nurse 
based on a profound knowledge of key risk factors (National Institute for Clinical 
Excellence, 2005; NPUAP & EUAP, 2009).  A risk factor can be defined as a 
variable associated with pressure ulcer development (Kraemer, 2010; 
Woodward, 2005). The identification of these risk factors allows a more accurate 
and precise judgment about the risk to develop pressure ulcers (Kottner et al., 
2011).  
 
2. BACKGROUND 
Pressure ulcer development is a complex and multi-factorial process. Several 
mechanisms may lead to tissue damage as a result of exposure to pressure 
and/or shear. Oxygen deprivation, direct cell deformation (Ceelen et al., 2008; 
Gawlitta et al., 2007a; Stekelenburg et al., 2007), ischemic reperfusion injury 
(Peirce et al., 2000; Reid et al., 2004; Tsuji et al., 2005), and impaired lymphatic 
drainage (Miller and Seale, 1981) are mechanisms that might lead to pressure 
ulcer development. Pressure ulcers can develop both superficially or in the deep 
tissues (Bouten et al., 2005). Skin and subcutaneous fat are more resistant to 
pressure than muscle tissue. The threshold for tissue damage resulting from 
periods of pressure and shear differs for skin, fat, and muscle (Daniel et al., 
1981; Stekelenburg et al., 2006; Bouten et al., 2003). Lahmann & Kottner (2011) 
suggested that the aetiology causing superficial (category II) and severe 
(category III-IV) pressure ulcers may differ. This hypothesis was based on 
findings that severe pressure ulcers were associated with complete immobility, 
whereas superficial pressure ulcers  were associated with friction and shear, 
Chapter 4 
94 
both items on the Braden scale (Lahmann and Kottner, 2011). It is not yet clear 
if other risk factors for developing a superficial pressure ulcer are different from 
those for a severe ulcer.  
 
Numerous studies identified risk factors predicting pressure ulcer development 
(Beeckman et al., 2013a; Coleman et al., 2013). Several studies considered 
preventive measures when examining risk factors in a population of hospitalised 
patients (Beeckman et al., 2013a; Coleman et al., 2013; Schoonhoven et al., 
2006). Only a few studies examined specific predictive factors in a population of 
at-risk hospitalised patients who received preventive care (Manzano et al., 2013; 
Nixon et al., 2006a).  These studies identified predictive factors such as non-
blanchable erythema, existing wounds, diabetes, low haemoglobin level on 
admission or before surgery (Nixon et al., 2006a), and age in high-risk 
hospitalised patients (Manzano et al., 2013; Nixon et al., 2006a).   
 
A first and necessary step for successful pressure ulcer prevention is the correct 
identification of patients who are at risk for pressure ulcer development. 
Identification using a structured approach that combines several risk 
assessment methods is recommended (Defloor and Grypdonck, 2004; NPUAP 
& EPUAP, 2009; Schoonhoven et al., 2002; Vanderwee et al., 2007b). When 
patients are assessed as being at risk, preventive care should be provided in 
accordance with international guidelines and institutional standards. However, 
even when standardised prevention is implemented, patients may develop new 
pressure ulcers (McInnes et al., 2012; Nixon et al., 2006a; Theaker et al., 2005).  
Knowledge about predictive factors identifying patients at risk of developing 
pressure ulcers even when preventive measures are applied may help to 
successfully tailor preventive measures to further decrease the development of 
pressure ulcers, thus improving patient outcomes. 
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3. THE STUDY 
3.1 AIM 
To examine predictive factors associated with the development of pressure 
ulcers in patients at risk while receiving standardised preventive care.   
 
3.2 DESIGN 
Secondary data analyses were performed on a cohort of 610 patients included in 
a multicentre Randomised Controlled Trial (RCT). 
Data were collected as part of a larger study examining predictive factors for 
pressure ulcer development and the effectiveness of alternating low-pressure air 
mattresses (Demarré et al., 2012a).  
 
3.3 SAMPLE  
Data were collected in five Belgian hospitals. Patients were recruited in a 
convenience sample of 8 geriatric wards and 17 internal medical wards: 
neurology (n = 6), rehabilitation (n = 3), cardiology (n = 2), dermatology (n = 1), 
pneumology (n = 1), oncology (n = 1), chronic care (n = 1), and wards with 
combined internal medicine pathology (n = 2).  All patients admitted to the 
participating wards (n = 7393) were screened for eligibility. Patients were eligible 
for inclusion if their Braden score was less than 17 (n = 1137).  The reliability 
and validity of the Braden scale has been extensively studied (Braden and 
Bergstrom, 1994; Schoonhoven et al., 2002; Kottner et al., 2009b), and it is often 
used internationally as a tool for risk assessment (Baumgarten et al., 2010; 
Lahmann and Kottner, 2011; Vanderwee et al., 2011; NPUAP & EPUAP, 2009).  
Exclusion criteria were the presence of a pressure ulcer category II-IV (n = 204), 
a presumed hospital length of stay of less than 3 days (n = 43), the decision to 
end all therapeutic interventions (Do Not Resuscitate code 3) (n = 35), age less 
than 18 years (n = 6), bodyweight less than  30kg or more than  160 kg (n= 1), 
no standardised preventive measures available (n = 186), and no consent to 
participate (n = 52). Patients with non-blanchable erythema were eligible for 
inclusion. If patients were excluded, they received preventive measures 
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compliant with the hospital protocol. In total, 610 patients comprised the sample 
(Figure 1).  
 
3.4 VARIABLES 
The selection of potential predictive variables was based on the PrePURSE 
study of Schoonhoven et al.  (2006), including variables obtained from literature 
(Schoonhoven et al., 2006). Data  were collected for the following potential 
predictive factors: patient characteristics (age, gender, weight, length, 
incontinence, presence of urinary catheter, body temperature, and blood 
pressure),  items included on the Braden scale, medical characteristics 
(diabetes, paralysis, medication), primary diagnosis, ward type (internal 
medicine ward and geriatric ward), and skin status (non-blanchable erythema 
and incontinence-associated dermatitis (IAD)).  
 
3.5 DATA COLLECTION 
Prior to the start of the study, the researcher trained the ward nurses in pressure 
ulcer prevention (pathology, classification, differentiation between IAD, and the 
use of the Braden scale for risk assessment), and gave an introduction to the 
study aims, protocol, and the use of the data collection instrument. The purpose 
of this training was to ensure precision and uniformity of data collection.  
Patient characteristics, medical history, and primary diagnosis were assessed at 
baseline by the researcher.  Skin assessment, including specific assessment of 
the pressure points and IAD, was performed daily by the ward nurse during 
morning care. Pressure ulcers were classified according to the NPUAP/EPUAP 
classification system.  Non-blanchable erythema was defined as a pressure 
ulcer category I, partial thickness skin loss as a pressure ulcer category II, full 
thickness skin loss as a pressure ulcer category III, and full thickness tissue loss 
was classified as a pressure ulcer category IV (NPUAP & EPUAP, 2009). The 
transparent plastic disc method was used to differentiate between non-
blanchable erythema and blanchable erythema (Halfens et al., 2001). The 
reactive response of the skin to chronic exposure to urine and faecal material 
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was defined as IAD. Wound-related characteristics (causes, location, shape, 
depth, edges, and colour) and patient-related characteristics were evaluated to 
differentiate pressure ulcers from IAD (Defloor et al., 2005b). Data were 
collected between December 2007 and January 2010. 
The researcher and a tissue viability nurse affiliated with the hospital (study 
nurse), performed skin assessments independently, unannounced and at least 
once a week, in a random sample of patients. The inter-rater reliability for 
pressure ulcer classification ranged between к= 0.71 (95% CI 0.6 - 0.8) and к= 
0.81 (95% CI 0.8 - 0.9) among the researcher, the study nurse, and ward 
nurses.  
 
3.6 STANDARDISED PREVENTION 
All patients received standardised preventive care when lying in bed and when 
seated. The patients were randomly allocated (allocation sequence of 1:1) to a 
one-stage or multi-stage alternating low-pressure air mattress when lying in bed. 
The two types of alternating low-pressure air mattresses were found to be 
equally effective in terms of pressure ulcer incidence (respectively 5.8% and 
5.7%; p = 0.97), and probability to remain pressure ulcer free (log-rank Χ² = 
0.013, p = 0.911) (Demarré et al., 2012a).  A static air cushion was used in both 
groups to prevent pressure ulcer development when seated in an armchair. A 
standardised repositioning protocol was not used in any group. (Demarré et al., 
2012a). 
 
3.7 ETHICAL ASPECTS  
The study was approved by the Ethical Committee of Ghent University Hospital 
(B/ 67020071976) and by the Ethical Committee of each participating hospital. 
Informed consent was obtained from the participating patients or their legal 
representatives. 
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Figure 1  Flowchart Sample: Included and excluded patients  
(1) PU: Pressure ulcer; (2) Bradenscore<17;  (3) standardised preventive measures =  an Alternating 
Low Pressure Air Mattress was used to provide standardised preventive measures in bed and a 
static air cushion to provide standardised prevention when seated in an armchair 
Patients observed 
(n= 7393) 
Patients not eligible (n=6256) 
- Incomplete Braden score (n=214) 
- Patients not at risk for PU(1) development (n=6042) 
 
Patients at risk for PU 
development (2) 
(n= 1137) 
Patients eligible for inclusion 
(n= 796) 
Patients excluded (n=341) 
- PU Category II-IV (n=204) 
- Do not resuscitate code (n= 35) 
- <18 years of age (n=6) 
- Weight < 30kg or >160 kg (n= 1) 
- Expected duration of admission< 3 days (n=43) 
Patients included in the study 
receiving standardised 
preventive measures 
(n= 610) 
No standardised preventive measures available (n=186) 
PU category II-IV (n=35) 
 
The end the study was due to 
- Follow-up 14 days (n=307) 
- Technical problems with ALPAM (n=6) 
- Discomfort on standardised preventive measures (3) (n=27) 
- Reason not defined (n=8) 
- Transfer to another ward (n=37) 
- Discharge to home (n=81) 
- Death (n=29) 
- Discharge to another institution (n=79) 
- Withdrawal of consent (n=1) 
All patients (n=610) were included in the analyses 
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3.8 DATA ANALYSES 
Categorical variables were presented as frequencies (percentages). Continuous 
variables were described as medians (IQR). Mann-Whitney U-tests were used 
for continuous data; chi-square and Fisher’s exact tests were used for the 
categorical variables. Purposeful selection of variables was used for the multiple 
binary logistic regression as described by Bursac et al. (2008).  Univariate binary 
logistic regression analyses were performed on all potentially predictive factors 
using a cut-off point of p < 0.25 (Table 1). The retained variables were 
simultaneously entered in the multivariate binary logistic regression; variables 
were removed from the model if they were not significant (cut off point of p < 
0.10) (Bursac et al. 2008). The odds ratios and 95% confidence intervals were 
calculated. No multicollinearity was observed among variables in the multivariate 
model. If the total score on the Braden scale and the items on the scale were 
significantly associated, the total score was included in the model. The variation 
in the development of pressure ulcers explained by the multivariate models was 
provided by the Nagelkerke R Square. Additional univariate and multivariate 
sub-analyses were performed to identify factors associated with the 
development of superficial pressure ulcers (category II) at the sacrum and heels, 
and severe pressure ulcers (category III-IV). Statistical interaction to assess 
whether the effect of IAD on the development of pressure ulcers was dependent 
on the presence of non-blanchable erythema was conducted using multivariate 
logistic regression. No statistical interaction was found. Statistical analyses were 
conducted using SPSS® 15.0 (IBM® Corporation, NY, USA). A significance level 
of p < 0.05 was applied.   
 
4. RESULTS 
4.1 CHARACTERISTICS OF THE PARTICIPANTS 
The median age of the patients was 80 years (IQR = 71-86) and 60.5% of the 
patients were female. Almost half of the patients were incontinent for urine and 
faeces. The median Braden score was 14.0 (IQR = 12.0-15.0), 27.5% (n = 167) 
of the patients were bedbound and 61.3% (n = 373) were chairbound. Fifteen 
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percent (n = 94) were admitted with non-blanchable erythema, and 14.6% (n = 
89) developed non-blanchable erythema during the study. The cumulative 
pressure ulcer incidence was 5.7% (n = 35), including 3.9% (n = 24) superficial 
(category II) and 1.8% (n = 11) severe (category III-IV) pressure ulcers.  
Pressure ulcers occurred more frequently at the sacrum (3.4%, n = 22), 
compared to the heels (1.7%, n = 9). A pressure ulcer category II-IV developed 
in 13.7% (n = 25) of the patients with non-blanchable erythema (Table 2). IAD 
was present in 6.4% (n = 39) of the patients at the start of the study; another 
6.7% (n = 49) developed IAD during the study.  
 
4.2 PREDICTIVE FACTORS FOR THE DEVELOPMENT OF PRESSURE ULCERS 
(CATEGORY II-IV) 
Patients developing pressure ulcers category II-IV had a higher body 
temperature (p = 0.041), had higher rates of urinary catheterisation (p = 0.006), 
and were more frequently admitted with a primary diagnosis of a urogenital 
disorder (p = 0.048), compared to patients who did not develop a pressure ulcer 
(Table 2).   
In the multivariate analysis, non-blanchable erythema (OR = 5.36; 95% CI 2.4 – 
12.0), having a urogenital disorder (OR = 3.76; 95% CI 1.0 - 13.7), and higher 
body temperature (OR = 1.65; 95% CI 1.0 - 2.7) were independent predictive 
factors for the development of pressure ulcers category II-IV (Table 3). The 
percent of variance explained for developing a category II – IV pressure ulcer by  
predictors included in this model was 23% (Nagelkerke R² = 0.23). 
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Table 1  Univariate binary logistic regression analyses of potentially predictive factors 
Variables   
 
OR1 
All PU 2 
(n=35) 
95% CI 
 
 
p-value 
 
 
OR 
Superficial  
PU 3 (n=24) 
95% CI 
 
 
p-value 
Patients’ characteristics 
Age 
Gender4 
Weight 
Length 
BMI 
Incontinence for urine5 
Incontinence for faeces5 
Double incontinence5 
Presence of urinary catheter5 
Body temperature  
Fever (>38°Celcius) 5 
Systolic blood pressure  
Diastolic blood pressure 
 
0.99 
0.75 
1.00 
1.04 
0.96 
1.30 
0.75 
1.04 
2.68 
1.88 
0.57 
0.99 
0.99 
 
0.97-1.02 
0.39-1.52 
0.98-1.02 
1.00-1.07 
0.89-1.04 
0.63-2.66 
0.36-1.53 
0.53-2.06 
1.29-5.51 
1.23-2.86 
0.19-1.68 
0.97-1.00 
0.97-1.02 
 
0.769 
0.440 
0.889 
0.046 
0.348 
0.480 
0.428 
0.909 
0.008 
0.004 
0.305 
0.197 
0.566 
 
0.99 
0.64 
1.01 
1.04 
0.98 
1.53 
0.89 
1.16 
1.89 
1.81 
0.80 
0.98 
0.98 
0.97-1.02 
0.28-1.46 
0.98-1.03 
1.00-1.09 
0.89-1.07 
0.66-3.57 
0.38-2.05 
0.51-2.64 
0.76-4.71 
1.10-2.99 
0.18-3.54 
0.96-1.01 
0.95-1.01 
 
0.577 
0.287 
0.584 
0.051 
0.576 
0.316 
0.797 
0.714 
0.203 
0.020 
0.804 
0.128 
0.246 
Skin assessment 
Non-blanchable erythema5 
IAD5 
 
4.12 
1.44 
 
2.02-8.44 
0.67-3.08 
 
<0.001 
0.002 
 
3.71 
4.40 
1.57-8.77 
1.86-10.44 
 
0.004 
0.001 
Braden score  
Sensory perception6 
Activity7 
Mobility8 
Moisture9 
Nutrition10 
Friction and shear11 
0.83 
0.76 
0.47 
0.71 
0.95 
0.63 
0.00 
0.72-0.95 
0.37-1.55 
0.11-1.99 
0.25-2.06 
0.48-1.89 
0.31-1.27 
0.00- 
0.006 
0.446 
0.301 
0.531 
0.889 
0.191 
0.998 
0.77 
0.66 
0.69 
0.79 
0.95 
0.28 
0.00 
0.66-0.90 
0.28-1.53 
0.16-3.04 
0.23-2.69 
0.42-2.15 
0.10-0.76 
0.00- 
0.001 
0.330 
0.653 
0.703 
0.899 
0.012 
0.998 
Medical characteristics       
Diabetes5 
Paralysis5 
Use of sleep medication and 
tranquilizers5 
Systemic use of 
corticosteroids5 
1.44 
1.29 
0.94 
 
0.41 
0.67-3.08 
0.48-3.43 
0.47-1.88 
 
0.09-1.75 
0.347 
0.616 
0.864 
 
0.228 
0.51 
0.70 
1.38 
 
0.29 
0.15-1.75 
0.16-3.05 
0.59-3.19 
 
0.04-2.21 
0.256 
0.636 
0.433 
 
0.237 
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Table 1  Univariate binary logistic regression analyses of potentially predictive factors 
Variables   
 
OR1 
All PU 2 
(n=35) 
95% CI 
 
 
p-value 
 
 
OR 
Superficial 
PU 3 (n=24) 
95% CI 
 
 
p-value 
Primary diagnosis5 
Pulmonary diagnosis 
Hart and vascular disorders 
Neurology 
Physiology  
Gastroenterology 
Urogenital disorders 
Endocrinology 
Immunology 
Sensory diagnosis 
Dermatology 
 
 
1.10 
1.09 
1.14 
0.66 
0.54 
3.40 
1.18 
0.00 
- 
0.00 
 
 
0.49-2.48 
0.37-3.18 
0.55-2.38 
0.27-1.61 
0.16-1.80 
1.10-10.53 
0.15-9.23 
0.00- 
0.00- 
0.00- 
 
 
0.818 
0.879 
0.729 
0.357 
0.317 
0.033 
0.876 
0.999 
1.000 
0.999 
 
 
1.53 
0.77 
1.24 
0.83 
0.52 
2.39 
0.00 
0.00 
0.00 
0.00 
 
 
0.62-3.77 
0.18-3.34 
0.52-2.96 
0.31-2.27 
0.12-2.27 
0.53-10.88 
0.00- 
0.00- 
0.00- 
0.00- 
 
 
0.357 
0.723 
0.624 
0.722 
0.388 
0.257 
0.999 
0.999 
1.000 
0.999 
Characteristics related to the 
study 
Internal medicine ward12 
Maximum time sitting &/or 
transport (hours) 
Standardised preventive 
measures13 
0.51 
 
0.99 
 
0.99 
0.22-1.18 
 
0.88-1.11 
 
0.50-1.96 
0.115 
 
0.839 
 
0.973 
3.46 
 
0.99 
 
1.24 
1.02-11.73 
 
0.87-1.13 
 
0.55-2.81 
 
0.047 
 
0.876 
 
0.612 
 
   
  
1 OR: odds ratio; 2 All PU: pressure ulcers category II-IV;  3Superficial PU: pressure ulcer category II;   4 Male is reference 
category;  5 The absence of the dichotomous variable is reference category; 6 Completely and very limited is reference 
category compared to slightly limited and no impairment; 7 Bedfast and chairfast is a reference category compared to 
walks occasionally and frequently 8 Completely immobile and very limited is reference category compared to slightly limited 
and no limitations 9 Constantly and often moist is reference category compared to occasionally and rarely moist; 10 Very 
poor and probably inadequate is reference category compared to adequate and excellent; 11 Problem and potential 
problem is reference category compared to no problem; 12 Geriatric ward is reference category; 13 One-stage ALPAM is  
reference category compared to Multi-stage ALPAM 
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Table 2  Potential predictive factors in all patients and comparison of predictive factors between 
patients developing a pressure ulcer category II-IV and remaining pressure ulcer free 
 Total (n=610) 
median (IQR1) 
% (n) 
No PU (n=575) 
median (IQR1) 
% (n) 
PU (n=35 ) 
median (IQR1) 
% (n) 
Mann-Whitney 
U/χ² ;   
p-value 
Age 80 (71-86) 80 (71-86) 79 (73-84) p=0.52 
Weight (kg) 65 (55-76) 65 (55.0-75.7) 65 (56.0-78.0) p=0.87 
Length (cm) 165 (159-173) 165 (159-173) 168.5 (160-178) p=0.08 
BMI 
Systolic blood pressure 
Diastolic blood pressure 
Braden 
23.6 (21.0-26.6) 
130 (120-140) 
70 (61-80) 
14 (12-15) 
23.6 (21.1-26.7) 
130 (120-143.5) 
70 (60.5-80) 
14.0 (12.0-15.0) 
23.2 (20.0-26.1) 
130 (120-140) 
70 (64-77) 
13.0 (10.0-15.0) 
p=0.39 
p=0.54 
p=0.71 
p<0.05 
Braden-Mobility 
Completely immobile 
Very limited 
Slightly limited & no 
impairment 
 
14.5 (88) 
70.4 (428) 
15.1 (92) 
 
14.1 (81) 
70.5 (404) 
15.4 (88) 
 
20.0 (7) 
68.6 (24) 
11.4 (4) 
 
Χ²=1.17; 
 p=0.76 
Braden-Activity     
Bedbound 27.5 (167) 26.7 (153) 40.0 (14) Χ²=3.44; 
Chairbound 61.3 (373) 61.8 (354) 54.3 (19) p=0.33 
Walks occasionally/frequently 11.2 (68) 11.5 (66) 5.7 (2)  
Braden-Sensory perception 
Completely & very limited 
Slightly limited & no 
impairment 
Braden-Moisture 
Constantly & often moist 
 
28.6 (174) 
71.4 (434) 
 
 
44.6 (271) 
 
28.3 (162) 
71.7 (411) 
 
 
44.5 (255) 
 
34.3 (12) 
65.7 (23) 
 
 
45.7 (16) 
 
Χ²=0.58; 
p=0.45 
 
 
Χ²=0.02; 
Occasionally & rarely moist 55.4 (337) 55.5 (318) 54.3 (19) p=0.89 
Braden-Nutrition 
Very poor & probably 
inadequate 
Adequate & excellent 
Braden-Friction & Shear 
Problem & potential problem 
No problem 
 
52.1 (316) 
 
47.9 (291) 
 
96.2 (585) 
3.8 (23) 
 
51.4 (294) 
 
48.6 (278) 
 
96.0 (550) 
4.0 (23) 
 
62.9 (22) 
 
37.1 (13) 
 
6.0 (35) 
0.0 (0) 
 
 
Χ²=1.74;  
p=0.19 
 
Χ²=1.46;  
p=0.23 
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Table 2  Potential predictive factors in all patients and comparison of predictive factors between 
patients developing a pressure ulcer category II-IV and remaining pressure ulcer free 
 Total (n=610) 
median (IQR1) 
% (n) 
No PU (n=575) 
median (IQR1) 
% (n) 
PU (n=35 ) 
median (IQR1) 
% (n) 
Mann-Whitney 
U/χ² ;   
p-value 
Body temperature 
Fever (>38°Celcius) 
36.5 (36.1-36.9) 
7.1 (44) 
36.5 (36.1-36.9) 
6.8 (39) 
36.8 (36.4-37.3) 
11.4 (4) 
p< 0.01 
χ²=1.08;  
p=0.30 
Gender 
Male 
Female 
 
39.5 (241) 
60.5 (369) 
 
39.1 (225) 
60.9 (350) 
 
45.7 (16) 
54.3 (19) 
 
Χ²=0.60; p=0.44  
Incontinence 
Urinary 
Fecal 
Urinary & fecal 
 
66.3 (389) 
53.9 (318) 
49.5 (302) 
 
66.6 (369) 
53.5 (298) 
49.6 (285) 
 
60.6 (20) 
60.6 (20) 
48.5 (17) 
 
χ²=0.50.; p=0.48 
χ²=0.63; p= 0.42 
χ²=0.01; p=0.91 
Urinary catheter 19.9 (119) 18.8 (106) 38.6 (13) χ²=7.60; p <0.01 
Ward type 
Internal medicine 
Geriatrics 
 
67.7 (413) 
32.3 (197) 
 
63.1 (385) 
31.1 (190) 
 
4.6 (28) 
1.1 (7) 
 
χ²=2.57; p=0.11 
Primary diagnosis 
Pulmonary disorder 
Cardiovascular disorder 
Neurological disorder 
Locomotor disorder 
Gastroenterological disorder 
Urogenital disorder 
Endocrinological disorder 
Immunological disorder 
Sensorial perception disorder 
Dermatological disorder 
 
21.3 (130) 
10.7 (65) 
28.9 (176) 
23.6 (144) 
14.4 (88) 
4.1 (25) 
2.5 (15) 
1.6 (10) 
0.2 (1) 
1.8 (11) 
 
21.2 (122) 
10.6 (61) 
28.7 (165) 
24.0 (138) 
14.8 (85) 
3.7 (21) 
2.4 (14) 
1.7 (10) 
0.2 (1) 
1.9 (11) 
 
22.9 (8) 
11.4 (4) 
31.4 (11) 
17.1 (6) 
8.6 (3) 
11.4 (4) 
2.9 (1) 
0 (0) 
0 (0)  
0 (0) 
 
χ²=0.05; p=0.82 
χ²=0.02; p=0.88 
χ²=0.12; p=0.73 
χ²=0.86; p=0.35 
χ²=1.03; p=0.31 
F.E.4; p<0.05 
F.E.4; p=0.59 
F.E.4, p=1.00 
F.E.4, p=1.00 
F.E.4, p=1.00 
Diabetes 22.1 (135) 21.7 (125) 28.6 (10) χ²=0.89.; p=0.34 
Paralysis 11.6(71) 11.5 (66) 14.3 (5) F.E.4, p=0.59 
Medication 
Sleep medication/ 
tranquilizers 
Corticosteroids (oral/IV) 
 
48.5 (288) 
 
12.5 (76) 
 
48.6 (272) 
 
12.9 (74) 
 
47.1 (16) 
 
5.7 (2) 
 
χ²=0.03; p=0.86 
 
χ²=1.55 ; p=0.21 
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Table 2  Potential predictive factors in all patients and comparison of predictive factors between 
patients developing a pressure ulcer category II-IV and remaining pressure ulcer free 
 Total (n=610) 
median (IQR1) 
% (n) 
No PU (n=575) 
median (IQR1) 
% (n) 
PU (n=35 ) 
median (IQR1) 
% (n) 
Mann-Whitney 
U/χ² ;   
p-value 
Preventive measures 
ALPAM Type 1² 
ALPAM Type 2³ 
 
48.9 (298) 
51.1 (312) 
 
48.9 (281) 
51.1 (294) 
 
48.6 (17) 
51.4 (18) 
 
χ²=0.001; p=0.97 
 
Non-blanchable erythema at 
the start of the study 
15.4 (94) 13.9 (80) 40.0 (14) χ²=17.22; p<0.001 
IAD at the start of the study5 6.4 (39) 5.9 (34) 14.3 (5) F.E.4; p=0.064 
 
 
 
 
4.3 PREDICTIVE FACTORS FOR THE DEVELOPMENT OF SUPERFICIAL (CATEGORY 
II) AND SEVERE PRESSURE ULCERS (CATEGORY III-IV) 
Admission to an internal medicine ward (OR = 4.16; 95% CI 1.2 - 7.5), IAD (OR 
= 2.99; 95% CI 1.20- 7.5), non-blanchable erythema (OR = 3.73; 95% CI 1.5 - 
9.1), and the Braden score (OR = 0.79; 95% CI 0.7 - 0.9) were independent 
predictive factors for the development of category II pressure ulcers. The 
predictors included in the model explained 18% of the variance for the 
development of superficial pressure ulcers (Nagelkerke R² = 0.18) (Table 3).  
For the patients on an internal medicine ward, a trend towards being bed- and 
chairbound (90.5%, n= 372) was found compared to patients on a geriatric ward 
(85.3%, n= 168), but the difference was not significant (p = 0.055). More patients 
on an internal medicine ward had paralysis (14.8%, n = 61) and had a urinary 
catheter (22.8%, n = 92), compared to the patients on a geriatric ward (5.19%, n 
= 10, p < 0.001 and 13.8%, n = 27, p = 0.012 respectively). 
The development of superficial sacral pressure ulcers was significantly 
associated with the presence of IAD.  It was present in 44.4% of the patients 
who developed a superficial sacral pressure ulcer compared to 12.2% of the 
patients who did not (Fisher’s Exact, p = 0.001). The development of heel 
1 IQR= Interquartile Range; ² ALPAM Type 1 = Alternating Low Pressure Air Mattress with gradual inflation and 
deflation of the air cells; 3 ALPAM Type 2 = Alternating Low Pressure Air Mattress with one steep inflation and 
deflation of the air cells; 4 F.E. = Fisher’s Exact test; 5IAD at the start of the study= Incontinence-associated 
Dermatitis at the start of the study 
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pressure ulcers was not significantly associated with the presence of IAD 
(Fisher’s Exact, p = 0.431). 
 
Non-blanchable erythema (OR = 25.95; 95% CI 3.2 - 212.3), diabetes (OR = 
7.62; 95% CI 2.0 - 28.8), and having a urinary catheter (OR = 3.72; 95% CI 1.0 - 
13.7) were found to be significantly associated with the development of severe 
pressure ulcers. The predictors included in the model explained 34% of the 
variance for the development of severe pressure ulcers (Nagelkerke R² = 0.34), 
but the confidence intervals of the odds ratios indicated that this model was 
probably less reliable. 
 
Table 3  Multivariate analysis  with patients with pressure ulcers of varying severity as dependent 
variable and risk factors as independent variables 
Patients with pressure ulcer category II-IV as dependent 
variable 
 
OR (1) 
 
95% CI 
 
p-value 
Non-blanchable erythema²  
Urogenital diagnosis 3 
Body temperature 
5.36 
3.76 
1.65 
(2.40-11.99) 
(1.03-13.70) 
(1.02-2.66) 
<0.001 
0.044 
0.041 
Urinary catheter 4 2.00 (0.92-4.37) 0.081 
IAD7 2.15 (0.92-4.37) 0.079 
Braden score 0.87 (0.75-1.01) 0.074 
Patients with superficial pressure ulcer4 as dependent 
variable 
 
OR (1) 
 
95% CI 
 
p-value 
Internal medicine ward6 4.16 (1.20-7.52) 0.027 
IAD7 2.99 (1.20-7.52) 0.019 
Non-blanchable erythema²  3.73 (1.53-9.11) 0.004 
Braden score 0.79 (0.67-0.94) 0.009 
 
  
1 OR: odds ratio; 2 Absence of non blanchable erythema is reference category; 3 Absence of the 
diagnosis is reference category; 4 Urinary catheter; 5 superficial pressure ulcer: pressure ulcer 
category II; 6Geriatrics is reference category; 7Absence of IAD (Incontinence-associated dermatitis) 
is reference category. 
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5. DISCUSSION 
Once patients are found to be at risk for pressure ulcer development, preventive 
care is needed. Despite preventive measures, a proportion of these patients still 
develop a pressure ulcer (Demarré et al., 2012a; Nixon et al., 2006b; Theaker et 
al., 2005; Vanderwee et al., 2005). The identification of these ‘high risk’ patients 
is crucial for improved quality of care. The aim of this study was to identify 
factors that independently predicted the development of a pressure ulcer in an at 
risk population who received standardised preventive care. All patients in this 
study were allocated to an alternating low-pressure device when lying in bed and 
they all had a static air cushion when seated. The presence of non-blanchable 
erythema, having a urogenital disorder, and higher body temperature were found 
to be predictive factors associated with the development of a pressure ulcer.  
 
5.1 PREDICTIVE FACTORS FOR THE DEVELOPMENT OF PRESSURE ULCERS 
(CATEGORY II-IV) 
Previous studies found that non-blanchable erythema was an independent 
predictive factor for developing pressure ulcers (Nixon et al., 2007; Reed et al., 
2003; Vanderwee et al., 2009; Coleman et al., 2013; Allman et al., 1995; NPUAP 
& EPUAP, 2009). The findings of this study illustrate that non-blanchable 
erythema is  a high-risk indicator,  even when patients receive preventive care 
(Nixon et al., 2006a). Although it is not clear to what extent non-blanchable 
erythema would have been reversible, this predictive factor indicates the risk for 
pressure ulcer deterioration and signifies that current preventive measures must 
be further tailored.   
 
In the present study, body temperature was also found to be an independent 
predictor of pressure ulcer development. Increased body temperature influences 
tissue metabolism (Maklebust et al. 1987 cited in Defloor et al. 1999, Patel et al. 
1999), as well as tissue stiffness (Patel et al., 1999). Increased body 
temperature will lead to an increased metabolism (Maklebust et al. 1987 cited in 
Defloor et al. 1999) and subsequent increased oxygen need. If the oxygen 
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supply to the tissue no longer matches the needs, the risk of pressure ulcers 
increases (Defloor, 1999). Furthermore the effect of temperature may differ for 
muscle tissue, subcutaneous fat, and skin tissue (Lachenbruch et al., 2013). 
Lachenburg and colleagues suggested there is a need to manage skin 
temperature, as well as pressure, to reduce the risk of ischemia (Lachenbruch et 
al., 2013). 
 
Increased body temperature also influences tissue stiffness (Patel et al., 1999). 
Tissue stiffness allows tissue to resist deformation (Arokoski et al., 2005; 
Iivarinen et al., 2011); stiffness depends on the type of tissue and is influenced 
by numerous factors including past or present injuries (Gefen et al., 2005; 
Gefen, 2007; Levy et al., 2013). For example, stiffness of different tissues 
influences overall tissue deformation and minimising tissue deformation 
decreases the chance of developing a deep tissue injury (Loerakker et al., 
2013). However, the relation between temperature, tissue stiffness, and 
pressure ulcer development is complex, and requires further study.  
 
Detailed information on the specific diagnosis of patients classified with a 
urogenital disorder was not collected. Further research should include data 
which is based on (inter)national diagnostic classification systems, such as the 
International Classification of Diseases (ICD), to enhance clarity and allow  
benchmarking with other studies. 
Generally, patients admitted with a urogenital disorder on a geriatric or internal 
medicine ward have a diagnosis of (suspected) urinary tract infection or 
urosepsis. None of the baseline characteristics collected in this study could 
explain the increased risk for patients with a urogenital disorder to develop a 
pressure ulcer compared to those without.  A possible reason for the finding may 
be, that as the urogenital disorders referred to a diagnosis of infection, they may 
be related to severe illness and/or organ failure. Severe illness may be 
insufficiently measured by the variables included in the present study, such as 
temperature and fever. Further research might collect data on the severity of 
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illness index, sepsis, and organ failure to examine their association with the 
process of pressure ulcer development.  
 
5.2 PREDICTIVE FACTORS FOR THE DEVELOPMENT OF SUPERFICIAL (CATEGORY 
II) AND SEVERE PRESSURE ULCERS (CATEGORY III-IV) 
IAD was found to be associated with a higher risk of developing a superficial 
pressure ulcer. More specifically, IAD was significantly associated with the 
development of superficial sacral pressure ulcers, but not associated with 
superficial heel ulcers.  
The presence of a skin lesion (Nonnemacher et al., 2009), as well as 
incontinence for urine and feces (Brandeis et al., 1994; Marchette et al., 1991; 
Ooi et al., 1999), and moist skin (Bates-Jensen et al., 2007; Compton et al., 
2008; Sanada et al., 2007) have been described as factors associated with 
pressure ulcer development (Coleman et al., 2013). The association between 
IAD and pressure ulcers has not been previously examined.  The skin may be 
more susceptible to shear and pressure when it is moist (Antokal et al., 2012). 
The strength of the stratum corneum is affected, thereby increasing the risk of 
skin damage (Hagisawa and Shimada, 2005).  
Patients hospitalised on an internal medicine ward had a higher risk of 
developing a pressure ulcer compared to patients admitted to a geriatric ward. 
The reason for this finding could not be explained by the multivariate analyses. 
The most plausible explanation is that these patients were more severely ill and 
less mobile compared to patients admitted to a geriatric ward. Patients admitted 
to an internal medicine ward may be burdened with a combination of several 
potential risk factors which were not significantly associated when assessed 
separately.   
 
5.3 STUDY LIMITATIONS 
The main limitation of this study was the low event rate, which mainly affected 
the multivariate analyses for severe pressure ulcers. Only 11 severe pressure 
ulcers occurred, leading to wide confidence intervals of the potentially predictive 
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factors for developing a severe pressure ulcer.  Sample size calculation of this 
study was guided by the sample size calculation of the original study, an RCT to 
compare the effectiveness of two ALPAMs. Sample size calculations for 
multivariable analyses, as conducted in these risk factor analyses, can be 
informed by the ‘rule of thumb’. This rule of thumb states that ten events or 
pressure ulcers per variable in the multivariate model are needed (Coleman et 
al. 2012; Peduzzi et al. 1995). Therefore, the results for superficial and severe 
pressure ulcers presented in the subanalyses, need to be interpreted with 
caution. 
 Due to ethical considerations, the participation of a patient in the study was 
ended when a pressure ulcer category II-IV developed, but superficial pressure 
ulcers may have evolved to a more severe lesion if follow-up had been 
continued.  
Another limitation of the study is the length of the follow-up. A follow-up period of 
14 days may have been too brief to observe the development of a pressure ulcer 
in patients during a lengthy hospital stay (Theisen et al., 2012). A 14-day study 
period was chosen because for the majority of the patients this length of follow-
up would include a full hospitalisation. The mean length of stay in Belgian 
hospitals was 6 days on internal medicine wards and 18 days on geriatric wards 
(Flemish Agency for Care and Health cited in Trybou, 2011). This follow-up 
period was chosen to optimize the probability of capturing the moment patients 
developed a pressure ulcer, with regard to the limited availability of the study’s 
standardised preventive measures. 
 
6. CONCLUSION 
Non-blanchable erythema, a urogenital disorder, and higher body temperature 
were found to be significantly associated with the development of pressure 
ulcers despite preventive measures. Predictive factors may differ between 
anatomical locations. Health care professionals as well as health care 
institutions continuously aim to provide pressure ulcer prevention tailored to the 
needs of the individual patient. Their goal is to improve resource use and reduce 
expenditures, while maintaining or improving the quality of care. Risk 
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assessment scales and scores are frequently used in daily care to tailor 
preventive measures to a specific patient, although there is no evidence that risk 
assessment scores can differentiate risk levels among patients (Beeckman et 
al., 2013a). The use of factors predicting pressure ulcers as found in this study 
may therefore be more appropriate to tailor preventive measures based on a 
stepped-care model. In this stepped-care model preventive measures will be 
adjusted in steps when patients’ risk profile is changing or the current preventive 
measures fail. It also aims to encourage health care providers to continuously 
reassess the patients’ needs and adapt the provided preventive measures on a 
regular basis. Further research should examine the effectiveness of stepped-
care prevention. 
Even if prevention is provided, continuous tailoring to the patients’ needs 
remains necessary. The results of this study point out the importance of regular 
skin observation and timely detection of non-blanchable erythema in daily 
practice. The new finding of this study is the identification of IAD as a possible 
predictive factor for superficial sacral pressure ulcers. Therefore, further 
research is needed to assess the effect of including daily skin observation to 
detect non-blanchable erythema, as well as IAD as part of the patients’ risk 
assessment. The possibility and nature of the relationship between superficial 
sacral pressure ulcers and IAD and the impact of prevention and treatment of 
IAD in the effectiveness of pressure ulcer prevention needs further exploration.  
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A SYSTEMATIC REVIEW OF THE COST OF PREVENTION 
AND TREATMENT OF PRESSURE ULCERS 
Based on the article of Demarré L, Verhaeghe S, Van Hecke A, Grypdonck M, 
Lemey J, Annemans L & Beeckman D. A systematic review of the cost of 
prevention and treatment of pressure ulcers.  Under Review. 
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ABSTRACT 
Introduction: Pressure ulcers impose a substantial financial burden. The need for 
high-quality health care while expenditures are constrained entails the interest to 
calculate the cost of preventing and treating pressure ulcers and their impact on 
patients, healthcare, and society. 
Aim: The aim of this paper is to provide insight into the economic impact of 
pressure ulcer prevention and treatment in an adult population. 
Methods: A systematic literature review was performed conform the Cochrane 
Collaboration guidelines for systematic reviews. The search strategy contained 
index terms and key words related to pressure ulcers and cost. The search was 
performed in Medline, CINAHL, Web of Science, The Cochrane Library, 
Embase, and EconLit covering articles up to September 2013. Reference lists 
and conference abstracts were screened. Articles were eligible if they reported 
on direct medical cost of pressure ulcer prevention or treatment, and provided 
national cost estimates, cost per patient, or cost per patient per day. The 
Consensus on Health Economic Criteria checklist was used to assess 
methodological quality of the included studies.  
Results: In total, 3396 articles were retrieved. After assessing eligibility, 33 
articles were included. Ten articles reported on the cost of prevention as well as 
treatment, seven articles reported on cost of prevention, and 16 articles reported 
on the cost of pressure ulcer treatment. All articles were published between 
1991 and 2013.  
Cost of pressure ulcer prevention per patient at risk varied between €2.65 and 
€87.57 per day. Cost of pressure ulcer treatment ranged from €1.73 to €812.92 
per patient per day. The methodological heterogeneity among studies was 
considerable, and encompassed differences regarding type of health economic 
design, cost components, and health outcomes.  
Conclusion: Cost of pressure ulcer prevention and treatment differed 
considerable between studies. The cost to provide pressure ulcer prevention to 
patients at risk was higher in hospitalised patients compared to patients in home 
care or nursing homes. Cost of treatment tended to increase with pressure ulcer 
severity. Methodological heterogeneity among studies identified the need to use 
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the available, study design specific methodological guidelines to conduct health 
economic studies, and the need for additional pressure ulcer specific 
recommendations. 
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1. INTRODUCTION 
Pressure ulcers impose a considerable burden. Besides their impact on the 
patients’ overall well-being (physical, psychological, functional and social), 
pressure ulcers also entail a substantial financial concern for all involved parties 
(Gorecki et al., 2009; Hopkins et al., 2006; Langemo et al., 2000). A growing 
awareness of the economic impact of pressure ulcers is related to constrained 
public and healthcare finances. The scarce financial resources cannot meet all 
current health care needs (Posnett and Franks, 2008). Therefore it is important 
to provide insight in the cost related to the treatment of mainly avoidable events, 
such as pressure ulcers. Several studies have provided insight into the 
economic burden of pressure ulcers for society and health care payers, such as 
patients, health services, and insurers (Larg and Moss, 2011; Rice, 1967). 
These insights can help policymakers and health service management to identify 
the cost drivers for pressure ulcer prevention and treatment. Furthermore, it may 
guide the decision making of health care institutions about allocating healthcare 
resources such as materials and nursing staff.  
Health economic studies can comprise direct and indirect costs, as well as 
medical and non-medical costs (Annemans, 2008; Rice, 1967). Direct medical 
costs are defined as disease related costs, such as prevention, detection, 
treatment, and rehabilitation, which are paid by the patient, healthcare institution, 
insurances, and/or government (Annemans, 2008; Rice, 1967). Direct non-
medical costs are disease related costs, which are not part of the health 
services, such as travel costs to the health care provider, or costs related to the 
time that significant others spent to provide care for the patient. Indirect medical 
costs are future costs of general healthcare, such as the healthcare costs arising 
from living longer (Annemans, 2008). Indirect non-medical costs include costs 
related to reduced work productivity due to morbidity or premature death 
because of illness (Annemans, 2008). In general, indirect costs are often more 
difficult to measure objectively, and less easy to attribute to a specific disease 
(Dagenais et al., 2008).  
A number of published studies have described the costs associated with 
pressure ulcer prevention and treatment. Summarising the costs of pressure 
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ulcer prevention is important for the government and health care payers to 
assess the impact of prevention on their budget (Schuurman et al., 2009; 
Severens et al., 2002) and when considering the expenditures of new preventive 
strategies (Xakellis et al., 1996b; Makai et al., 2010). Insights in the cost of 
pressure ulcer prevention and treatment may stimulate the attention for 
systematic risk assessment, and encourage investing in risk assessment 
research which improves the ability of correctly identifying patients at risk for 
pressure ulcer development. Moreover, insight in the cost of pressure ulcer 
treatment can motivate to focus more on prevention (Moore et al., 2013) and 
facilitate decision making regarding investment in new treatment options (Allman 
et al., 1987; Baxter, 2000).  
Studies summarising the available data on cost of pressure ulcer prevention and 
treatment focussed on cost data in the United Kingdom (National Institute for 
Clinical Excellence, 2005) or did not aimed to perform a systematic search 
(Spetz et al., 2013). A systematic review summarising the available evidence on 
the cost of pressure ulcer prevention and treatment is however lacking. 
 
2. AIM 
The aim of this paper is to provide insight into the economic impact of pressure 
ulcer prevention and treatment in an adult population. 
 
3.  METHODOLOGY 
3.1 DESIGN 
A systematic review was performed. The Cochrane Collaboration guidelines for 
systematic reviews of interventions incorporating economic evidence were 
applied (The Cochrane Collaboration, 2008).  
 
3.2 SEARCH STRATEGY 
The search strategy contained index terms and key words related to pressure 
ulcers and cost (Table 1). The search string for pressure ulcer prevention and 
treatment was based on the search string of the Belgian Health Care Knowledge 
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Centre (KCE) Pressure Ulcer Report (Beeckman et al., 2013a). The search 
string for cost was based on the search string used in systematic reviews 
performed by the Cochrane Collaboration and KCE (Maher et al., 2012; 
McKinlay et al., 2006; Vrijens et al., 2009).  The search was performed in six 
electronic databases: Medline, Cumulative Index to Nursing and Allied Health 
Literature (CINAHL), Web of Science, The Cochrane Library, Embase, and 
Econlit. Data retrieval was completed in September 2013. The following 
conference proceedings were screened: proceedings of the Annual European 
Pressure Ulcer Advisory Panel Meetings (2005-2013), and of the European 
Wound Management Association meetings (2001-2013). If appropriate, the 
authors of relevant conference proceedings were contacted to request additional 
information. The reference lists of the included articles were screened. 
 
3.2 STUDY ELIGIBILITY  
Title and abstract of all retrieved records were independently screened for 
eligibility by two researchers (IG & LD). Following criteria were used: (1) written 
in English, French or Dutch; (2) providing monetary data of at least the direct 
medical cost of pressure ulcer prevention or treatment; (3) retrieved from original 
research (except case studies), or health economic modelling using data from 
international literature; and (4) targeting an adult hospital, long term care/nursing 
home or home care population.  
All types of health economic studies were eligible for inclusion if at least data 
were provided on direct medical cost of pressure ulcer prevention or treatment. 
 
Records were excluded if: (1) there was a focus on a specific subpopulation, 
such as spinal cord injury patients or a specific pressure ulcer severity; (2) there 
was a focus on one specific preventive measure or one aspect of pressure ulcer 
prevention (such as mattresses or repositioning) and not on pressure ulcer 
prevention as a whole; (3) there was a focus on one specific treatment or one 
aspect of pressure ulcer treatment (such as dressings) and not on pressure 
ulcer treatment as a whole; or if (4) the preventive measures or treatments under 
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study were not in line with the recommendations of the  NPUAP/ EPUAP 
guidelines (NPUAP & EPUAP, 2009).  
Table 1  Search strategy  
Concept Search terms 1 
Cost 1. Cost and Cost Analysis [Mesh] 
2. Cost.tw 
3. Cost-benefit.tw 
4. Cost-effectiveness.tw 
5. Economic*.tw 
Pressure ulcer 6. Pressure ulcer (MeSH) 
7. Pressure ulcers.tw 
8. Ulcer pressure.tw 
9. Ulcers pressure.tw 
10. Bedsore.tw 
11. Bedsores.tw 
12. Pressure sore.tw 
13. Pressure sores.tw 
14. Bed sore.tw 
15. Bed sores.tw 
16. Sore bed.tw 
17. Decubitus.tw 
Cost AND Pressure ulcer 18. OR/1 –5 
19. OR/6 – 17 
20. AND/18 – 19 
 
 
Differences in assessment about the inclusion of the records were discussed 
until consensus was obtained. In case of doubt, the full text article was retrieved 
and screened in detail. Potentially interesting records were screened in full by 
one reviewer (LD). The reasons for exclusion of title, abstracts and full texts 
were documented (Moher et al., 2010) (Figure 1).  
 
3.3 DATA EXTRACTION 
A data extraction form was developed prior to the search and refined after pilot 
testing. Data extraction included the name of the authors, the year of publication, 
1 Search terms were used in the MEDLINE search strategy and adapted for each database 
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the type of health economic study (cost-of-illness study, cost-effectiveness 
study, cost-utility analysis, or cost-benefit analysis, cost analyses, cost-
description and cost-outcome description studies), the economic perspective 
specifying the chosen focus of the group baring the costs (societal, health care 
payer, institutional, patient’s or mixed, the latter consisting of patient, institution, 
insurance perspective), the method of cost calculation (bottom-up/person-based 
approach, top-down/population-based approach), population (hospital, nursing 
home/long term care, and home care), intervention (prevention, treatment, 
inclusion of secondary prevention), costs (cost, currency, year of data collection, 
cost components incorporated), time horizon (timeframe used for health-related 
and cost outcomes), discounting (adjusting for future costs and effects that need 
to be included in the current calculations), analyses of uncertainty, data sources 
of health outcomes and cost components, and limitations. Data extraction was 
performed by one reviewer (LD). A second reviewer (JL) independently 
extracted data based on the data extraction form of a random sample of 15% of 
the articles. Only minor differences in data extraction occurred. These 
differences were discussed between both reviewers until consensus was 
reached.  
3.4 QUALITY ASSESSMENT 
The methodological quality of the included articles was assessed using an 
adapted version of Evers’ Consensus on Health Economic Criteria (CHEC-) 
checklist (Evers et al., 2005). This checklist was recommended by the Cochrane 
Collaboration to perform a critical appraisal of full (cost-effectiveness, cost-utility, 
and cost-benefit) and partial (cost analyses, cost-description, and cost-outcome 
description) economic studies (The Cochrane Collaboration, 2008). The 
methodological quality was assessed by one reviewer (LD) and a random 
sample of 15% of the articles was double checked by a second reviewer (JL). 
The Cohen’s Kappa correlation was calculated to determine the level of 
agreement between both assessors (Rousson et al., 2002) (ᴋ=0.625). 
Disagreements in quality assessment were discussed until consensus was 
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reached. Because of the explorative nature of this review, the methodological 
quality of the studies was not set as a criterion for exclusion. 
3.5 DATA SYNTHESIS 
Data on national cost estimates, cost per patient, and the cost per patient per 
day were extracted from the included studies. Original data were changed to one 
single currency (Euro) and adjusted according to the inflation rates until 2013 
based on the health index (FOD Economie and PF Economie, 2014). If the 
authors did not report the reference year of the data or the year of data 
collection, the year before the article was published was used as reference. Due 
to the methodological heterogeneity, results were synthesised narratively and no 
meta-analysis was performed.  
 
4. RESULTS 
4.1 GENERAL STUDY CHARACTERISTICS AND QUALITY ASSESSMENT 
The literature search yielded 3396 articles (Medline: 845, CINAHL: 971, Web of 
Science: 980, The Cochrane Library: 154, Embase: 414, Econlit: 32), of which 
1244 were duplicates. Title and abstract were screened, resulting in 110 
potentially relevant articles. Based on full-text screening, 33 articles were 
withheld. Ten articles provided outcomes on both cost of prevention and 
treatment, seven only on cost of prevention and 16 articles exclusively on cost of 
treatment. No additional articles were included from reference list screening or 
reviewing conference proceedings (Figure 1). 
An overview of the quality assessment is provided in Table 3. Articles on cost of 
pressure ulcer prevention included cost data from North America (US and 
Canada) and Europe (UK, Spain and The Netherlands). Several types of health 
economic studies were included. In six studies, a cost-effectiveness analysis 
was performed (Lyder et al., 2002; Makai et al., 2010; Padula et al., 2011; 
Xakellis et al., 1996b; Xakellis, Jr. et al., 1998; Foglia et al., 2012), other studies 
used a cost-of-illness design (Severens et al., 2002; Chan et al., 2013), a cost 
minimization design (Schuurman et al., 2009), or an economic impact model 
(Bayoumi et al., 2008). Two studies did not report on the health economic design
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References identified through database searching 
(n = 3396) 
• Medline (n=839) 
• CINAHL (n= 971) 
• Web of Science (n=980) 
• The Cochrane Library (n= 154) 
• Embase (n=414) 
• Econlit (n= 32) 
 
Duplicates (n =1244) 
References excluded (n = 2042) 
• Language (n= 49) 
• No focus on pressure ulcers and cost (n = 1867) 
• Focus on part of prevention (n = 28 )  
• Focus on part of treatment (n = 45 )  
• Focus on wounds in general (n =  14) 
• Focus on population in developing country (n= 3) 
• Focus of aspect of cost (n = 3) 
• Exclusion because of age (n = 0) 
• Exclusion because of subpopulation (n = 16) 
• Exclusion because of design (n=1 design, opinion) 
(n = 5 ) 
• Outcome cost is not valued in monetary unit (n= 12) 
Full-text articles assessed for eligibility (n = 110) 
Studies included (n = 33) 
Prevention of pressure ulcers (n = 17) 
Treatment of pressure ulcers (n = 26) 
Title and abstract screening 
(n = 2152) 
Figure 1   Flowchart of the systematic review process 
References identified through other sources 
(n = 45) 
• Reference lists searching  (n = 2)  
• Conference proceedings (n = 43)  
Duplicates (n = 3) 
Title and abstract screening 
(n = 42) 
References excluded (n = 41) 
• Language (n=0) 
• No focus on pressure ulcers and cost (n = 28) 
• Focus on part of prevention (n =4 ) 
• Focus on part of treatment (n =1 ) 
• Focus on wounds in general (n = 0 ) 
• Exclusion because of age (n =0 ) 
• Exclusion because of subpopulation (n = 2) 
• Exclusion because of design (n=1 design, opinion) 
(n = 4 ) 
• Focus on population in developing country (n= 0) 
• No details of authors available (n = 1) 
• No full-text available (n = 1) 
Full-text articles screened (n = 1 ) 
References excluded (n = 70): 
• No focus on pressure ulcers and cost (n = 11) 
• Focus on aspect of prevention (n =  19) 
• Focus on aspect of treatment (n =  5) 
• Focus on wounds in general (n =  3) 
• Focus on population in developing country (n= 0) 
• Focus of aspect of cost (n =3) 
• Exclusion because of age (n = 0) 
• Exclusion because of subpopulation (n = 9) 
• Exclusion because of design (n=1 design, opinion, 
editorial, no original study) (n = 22) 
• Outcome cost is not valued in monetary unit (n= 2) 
• Not available by author nor library request (n = 3) 
References excluded (n = 1): 
• Focus on aspect of prevention (n = 1 ) 
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being used (Beckrich et al., 1999; Berthier et al., 2005). The remaining articles 
used varying terminology referring to a cost evaluation (Agreda et al., 2007; 
Allman et al., 1999; Alterescu, 1989; Assadian et al., 2011; Baker, 1996; Bennett 
et al., 2004; Dzwierzynski et al., 1998; Frantz et al., 1991; Frantz et al., 1995a; 
Frantz et al., 2001; Haalboom, 1991; Hale, 1990; Hu et al., 1993b; Kumar et al., 
2004; Oot-Giromini et al., 1989; Rees and Bashshur, 2007; Richardson et al., 
1998; Van Den Bos et al., 2011; Xakellis et al., 1995; Xakellis et al., 1996a; 
Xakellis et al., 2001). The majority of the studies used a bottom-up approach to 
examine medical resource use (Agreda et al., 2007; Alterescu, 1989; Assadian 
et al., 2011; Bayoumi et al., 2008; Beckrich et al., 1999; Bennett et al., 2004; 
Dealey et al., 2012; Foglia et al., 2012; Frantz et al., 1991; Frantz et al., 1995a; 
Frantz et al., 2001; Gebhardt and Gebhardt, 2003; Haalboom, 1991; Hale, 1990; 
Hu et al., 1993; Lyder et al., 2002; Makai et al., 2010; Oot-Giromini et al., 1989; 
Padula et al., 2011; Rees and Bashshur, 2007; Richardson et al., 1998; 
Schuurman et al., 2009; Severens et al., 2002; Xakellis et al., 1995; Xakellis et 
al., 1996a; Xakellis et al., 1996b; Xakellis et al., 2001; Xakellis, Jr. et al., 1998), 
in six studies a top-down approach was used (Allman et al., 1999; Baker, 1996; 
Berthier et al., 2005; Dzwierzynski et al., 1998; Kumar et al., 2004; Van Den Bos 
et al., 2011). The articles were published between 1991 and 2013. The time 
horizon ranged from one day up to 5 years.  
4.2 COST OF PRESSURE ULCER PREVENTION 
The main study characteristics of the articles and their reported cost of pressure 
ulcer prevention are outlined in Table 3. 
The cost calculations were related to a variety of preventive measures and 
methods. In two studies the cost calculation of preventive measures was based 
on a model created from best practice guidelines (Bennett et al., 2004; Dealey et 
al., 2012), and in six studies on a model based on findings from the literature 
(Bayoumi et al., 2008; Haalboom, 1991; Hu et al., 1993; Makai et al., 2010; 
Padula et al., 2011; Severens et al., 2002). In four studies cost calculation of 
preventive measures was based on real practice, collecting data alongside the 
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health economic study (Richardson et al., 1998; Schuurman et al., 2009; 
Xakellis et al., 2001; Xakellis, Jr. et al., 1998). 
National annual cost of pressure ulcer prevention 
The impact of cost of pressure ulcer prevention on the national annual budget 
was described in two studies from the Netherlands (Haalboom, 1991; 
Schuurman et al., 2009). In these studies, the annual cost of pressure ulcer 
prevention was estimated between €33.20 million and €160.4 million (Haalboom, 
1991; Schuurman et al., 2009), or between €197,030 and €951,900 per 100,000 
inhabitants. In the study by Haalboom (1991), a decision analytical model was 
used. In this model, the medical resource use was based on expert opinion and 
consensus (Haalboom, 1991). Schuurman et al. (2009) used a bottom-up cost 
minimization analysis assessing resource use from patients’ study files and 
records (Schuurman et al., 2009).  
 
Cost of pressure ulcer prevention per patient at risk 
The cost of pressure ulcer prevention varied between €167.83 and €7,988.47 
per hospitalised patient (Haalboom, 1991; Padula et al., 2011; Schuurman et al., 
2009; Bennett et al., 2004; Dealey et al., 2012).  
The time horizon in long-term care differed between studies (Bayoumi et al., 
2008; Makai et al., 2010; Richardson et al., 1998; Xakellis et al., 1995; Xakellis 
et al., 1996a; Xakellis et al., 1996b; Xakellis et al., 2001; Xakellis, Jr. et al., 
1998). Bayoumi et al. calculated the cost of prevention using a time horizon of 5 
years and found an attributable cost between €53.66 and €111.04 to provide 
pressure ulcer prevention in residents at risk (Bayoumi et al., 2008). Xakelis et 
al. found a cost ranging between €273.33 and €613.33 using a time horizon of 3 
months (Xakellis et al., 1995; Xakellis et al., 1996b), and ranging between 
€94.79 and €156.39 using a time horizon of 6 months (Xakellis et al., 2001; 
Xakellis, Jr. et al., 1998). 
In two studies no differentiation was made between hospitalised patients and 
residents in long-term care (Bennett et al., 2004; Dealey et al., 2012), resulting  
  
Table 2  Quality appraisals based on CHEC checklist (Evers et al.2005) 
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Agreda et al (2007) + na + + + + + [+] + na [+] + na na - + + - + 
Allman et al (1999) [+] na + + + + [+] [+] [+] + + +  na + - + - - [+] 
Allterescu et al (1989) + na + + + + + + [+] + [+] [+] na na - + + - + 
Assadian et al (2011) + na + + + + [+] [+] [+] na  [+] [+]  na na -  + [+] + + 
Baker J. (1996) + na + + + + + + [+] [+] + [+] na na - [+] - - - 
Bayouimi et al. (2008) + + + + + + + + + + + [+] + + + + + - + 
Beckrich et al (1999) [+] na + [+] + -  [+] [+]  [+] [+] + + na na + [+] - - + 
Bennet et al (2004) [+] na + + + + + [+] + + + + na na + + +  +  + 
Berthier et al (2005) + na + [+] + + + + [+] + + + na na - + [+] - [+] 
Chan et al (2013) [+] + + + + + + + [+] + [+] [+] na na - + [+] - + 
Dealey et al (2012 + na + + + + + [+] + + + + na na [+] + + + + 
Foglia et al (2012) [+] - + + [+] + [+] [+] + - [+] [+] + + + + + - + 
Frantz et al (1991) + na + + + + + [+] + + + + na na - + + - + 
Frantz et al. (1995) + na + + + + + [+] + + + + na na - + + - + 
Frantz et al. (2001) + na + + + + + [+] + + + + na na - + + - + 
Haalboom (1991) + na + [+] [+] + [+] [+] + [+] + + na na - + [+] - + 
Hale (1990) - na + - + - - - - - - + na na - + - - - 
Hu et al. (1993) [+] na + [+] + + [+] [+] [+] + - + na na - + + - + 
                    
                    
                    
  
Table 2  Quality appraisals based on CHEC checklist (Evers et al.2005) 
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Kumar et al. (2004) + na + + + + [+] [+] + + [+] [+] na na - + + - + 
Lyder et al. (2002) - + + [+] + + [+] [+] [+] + - [+] - na - + - [+] - 
Makai et al. (2010) + + + + + + [+] [+] [+] + [+] [+] + - + + + + + 
Oot-Giromini (1989) - - + + + - - - - - - - - - - - - - - 
Padula et al. (2011) + + + + + + + [+] + + + + + + + + + - + 
Rees et al. (2007) - [+] + [+] + [+] [+] [+] [+] + [+] [+] - na - + + - + 
Richardson et al 
(1998) + na + + + + + [+] [+] + + [+] na na - [+] - - + 
Schuurman et al 
(2009) + + + + + + + [+] [+] + + [+] na na + + + - + 
Severens et al. (2002) [+] na + + + + + [+] - + + + na na [+] + [+] - [+] 
Van den Bos et al. 
(2011) - na + + + + + + + [+] + [+] na na - + - - + 
Xakellis et al. (1995) + na + + [+] + + [+] + + + + na na - + - - + 
Xakellis & Frantz 
(1996a) - na + + + + + [+] + + + + na na - + + - + 
Xakellis et al (1996b) + + + + + + [+] [+] - + [+] [+] - na - + [+] - [+] 
Xakellis et al (1998) + + + + + + + [+] [+] [+] [+] [+] na na + + + - [+] 
Xakellis et al (2001) + + + + + + + [+] [+] [+] [+] [+] - na + + + - [+] 
+: present, [+] partly present, na: not applicable, - absent 
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in a cost between €1,524 and €1,676 per patient at risk using a time horizon of 
28 days. 
 
Cost of pressure ulcer prevention per patient at risk per day 
Cost of pressure ulcer prevention per patient per day was calculated for acute 
hospital care (Bennett et al., 2004; Dealey et al., 2012; Haalboom, 1991; Hu et 
al., 1993; Oot-Giromini et al., 1989; Padula et al., 2011; Schuurman et al., 2009; 
Severens et al., 2002), long-term care (Bayoumi et al., 2008; Bennett et al., 
2004; Dealey et al., 2012; Hu et al., 1993; Lyder et al., 2002; Richardson et al., 
1998; Severens et al., 2002; Xakellis et al., 1995), and home care setting 
(Severens et al., 2002).  
Cost of pressure ulcer prevention per patient at risk per day varied between 
€5.39 and €87.57 in hospitals (Haalboom, 1991; Hu et al., 1993; Oot-Giromini et 
al., 1989; Padula et al., 2011; Schuurman et al., 2009; Severens et al., 2002). 
Cost per day for pressure ulcer prevention in long-term care residents varied 
between €2.65 and €19.69 (Hu et al., 1993b; Lyder et al., 2002; Richardson et 
al., 1998; Severens et al., 2002; Xakellis et al., 1995). The average cost of 
prevention for patients in long-term care and hospitals ranged between €53.69 
and €59.84 (Bennett et al., 2004; Dealey et al., 2012). The cost of prevention per 
patient per day in home care ranged between €7.75 and €13.78 (Severens et 
al., 2002).  
  
       
Reference Country 
Currency 
Fiscal year of 
data 
Study population/ 
Number 
Study design Type of 
prevention 
Type of reported  
data 
Direct costs 
Converted & inflated cost (original cost) 
National 
 
Per Capita 
 
Per capita/day 
 
Bayoumi et al. 
(2008) 
Canada 
CAD 
2008 
 
Long term care 
homes  
 
Number:  
National 
 
Economic and 
health impact 
model based on 
decision analytic 
modelling  
Intervention 1: 
alternate foam 
mattress 
Intervention 2: 
Alternate foam + 
4-hourly 
repositioning 
Control: standard 
care  
Incremental 
lifetime cost 
Intervention 1: 
€12.58 million 
(C$17.34 million) 
Intervention 2: 
€14.32 million 
(C$19.75 million) 
Control group: 
€16.27million 
(C$77.60 million) 
 
Intervention 1: €53.66 
(C$80) 
Intervention 2: €58.01 
(C$74) 
Control group: €111.04 
(C$153,14) 
 
- 
Bennet et al. 
(2004) 
UK 
GBP 
UK NHS unit 
costs at 2000 
prices 
 
Hospital or long 
term care and 
community care  
Number: National 
Bottom-up cost 
evaluation 
 
Protocols 
reflecting good 
clinical practice 
At risk= PU cat 1 
-Treatment cost 
per episode of 
care and per 
patient 
  
- Cat.1: €1,675.53 (£1,064) 
 
Cat. €1:59.84 (£38) 
 
Dealey et al. 
(2012) 
UK 
GBP 
UK NHS unit 
costs at 2011 
prices 
 
Hospital or long 
term care and 
not admitted for 
pressure ulcer. 
Number: National 
Bottom-up cost 
evaluation 
 
 
Protocols 
reflecting good 
clinical practice 
At risk= PU cat 1 
Treatment cost 
per episode of 
care per patient 
 Per severity  
 Per level of 
complications 
- Cat 1: €1,524.95  
(£1213.58) 
 
Cat 1: €53.69 
(£42.73) 
 
Haalboom (1991) The Netherlands 
NLG 
Hospital Economic 
evaluation based 
Prevention = 
- extra nursing 
Cost of 
prevention for 
€160.4 million 
(ƒ223 million) 
€808.29 (ƒ1,123.74) 
 
€67.36 (ƒ93.65) 
 
Table 3  Articles on Cost of Pressure Ulcer prevention  
  
       
Reference Country 
Currency 
Fiscal year of 
data 
Study population/ 
Number 
Study design Type of 
prevention 
Type of reported  
data 
Direct costs 
Converted & inflated cost (original cost) 
National 
 
Per Capita 
 
Per capita/day 
 
Year not reported Number: National  on modelling 
 
care (in total 83 
min/day) 
- physiotherapy 
- nutritional 
support 
- support surface 
 
patient at risk 
(per day or per 
admission) 
 
Hu et al. (1993) US 
USD 
1991 
 
Hospital and 
nursing home 
 
Number: 
Hospital (n= 20): 
hip fracture 
(n=9); paraplegia 
(n=3);  
intensive care 
(n=7) 
 (n=8) 
Nursing home 
(n= 8)  
cost evaluation 
based on case 
studies 
 
Prevention and 
guideline 
implementation 
- Cost of 
prevention and 
early treatment of 
stage I pressure 
ulcers 
- Cost of 
guideline 
implementation. 
 
- - Hip fracture patient: 
€19.09 - €20.08 
($17.11- $18.0) 
Paraplegia patient: 
€39.35 - €40.88 
($35.27- :$36.64) 
Intensive care 
patients: €47.97 - 
€50.28 ($43.00-
$45.07) 
Nursing home 
resident: €13.61 -
€16.88 ($12.20-
$15.13) 
 
Lyder et al. US Nursing home cost evaluation Prevention  after Costs of - -  €17.73 ($19.17) 
Table 3  Articles on Cost of Pressure Ulcer prevention  
  
       
Reference Country 
Currency 
Fiscal year of 
data 
Study population/ 
Number 
Study design Type of 
prevention 
Type of reported  
data 
Direct costs 
Converted & inflated cost (original cost) 
National 
 
Per Capita 
 
Per capita/day 
 
(2002) USD 
1999 
 
residents 
Number: n=20 
based on 
modelling 
 
guideline 
implementation 
 
prevention of PU:  
 
Makai et al. 
(2010) 
The Netherlands 
EUR 
November 2007 
 
Nursing homes; 
Number: n=88  
 
 
Full economic 
analysis (CEA) 
based on a non-
controlled pre 
post design and 
modelling 
(Markov model) 
 
Control group: 
before  
implementation 
of quality 
improving 
program 
Intervention: 
quality improving 
program 
 
Cost 
effectiveness of 
quality improving 
program. 
 
- Control group: €15.27 
(€13.15) 
QIC: €44.73 (€38.52); excl. 
cost of implementation  
 
Oot-Giromini et 
al. (1989) 
US 
USD 
Year not reported 
 
Hospital 
Number:  not 
reported (random 
sample) 
 
Economic 
evaluation based 
on a prospective 
bottom up design 
DS: supplies 
based on 
patients bills 
Prevention 
(hospital 
standards of 
care)  
direct costs 
(labour + 
material cost) 
 
- - €5.39 ($4.83) 
Padula et al. 
(2011) 
US 
USD 
Hospital 
Number: not 
full-economic 
analyses based 
Intervention 1: 
prevention (full 
Cost of 
prevention per 
- Intervention 1: €5,781.50 
($7276.35) 
Intervention 1: 
€43.43 ($54.66) 
Table 3  Articles on Cost of Pressure Ulcer prevention  
  
       
Reference Country 
Currency 
Fiscal year of 
data 
Study population/ 
Number 
Study design Type of 
prevention 
Type of reported  
data 
Direct costs 
Converted & inflated cost (original cost) 
National 
 
Per Capita 
 
Per capita/day 
 
2009 (corrected 
for inflation to 
2009 US$) 
 
applicable 
(model) 
 
on Semi-Markov 
model simulating  
 
prevention  
defined by Reddy 
assumed) 
Standard care  
patient per day, 
per patient  
 
Standard care: €7,988.47 
($10,053.95) 
Standard care: not 
reported 
Richardson et al. 
(1998) 
US 
USD 
1996 
 
Long term care.  
Number: n=30 
(excl. of one 
patient with low-
air-los rental) 
 
Economic 
evaluation as 
part of a 
comparative 
prospective 
descriptive study 
 
Cost of 
prevention was 
calculated for 4 
Prevention: 
Risk assessment 
labour 
Mattress support 
surfaces,  
Chair support 
surfaces,  
Repositioning 
labour 
 
Total cost for 
each subject: 
summing across 
categories, and 
cost per day. 
 
- €498.94 ($497.52)   €5.57 ($5.55)  
 
Schuurman et al 
(2009) 
The Netherlands 
EUR 
2001- 2004 
Hospital 
Number:  
n= 149  
(TA: n=94; HA: 
n= 55) 
Bottom- up 
economic 
evaluation  
 
Intervention 1: 
technological 
approach 
Intervention 2: 
human approach  
Cost of 
prevention  
-Technical 
approach (TA) 
-Human 
TA: €33.20 
million (€27.5 
million)  
HA: €76.79 
million (€63.6 
million)  
TA: €167.83 (€139) 
HA: €387.59 (€321) 
 
TA: €15.70 (€13)  
HA: €28.98 (€24)  
Table 3  Articles on Cost of Pressure Ulcer prevention  
  
       
Reference Country 
Currency 
Fiscal year of 
data 
Study population/ 
Number 
Study design Type of 
prevention 
Type of reported  
data 
Direct costs 
Converted & inflated cost (original cost) 
National 
 
Per Capita 
 
Per capita/day 
 
 approach (HA)  
Severens et al. 
(2002) 
The Netherlands 
USD 
Year not reported 
 
 
Home care, 
nursing homes, 
university and 
general 
hospitals. 
 
Number: 
National 
Cost of illness 
 
High risk (for 
some respondent 
identical to 
patients with Pu 
stage I) 
 - - Home Care: €7.75 
- €13.78 ($8.38 -
$14.90) 
Nursing Home: 
€2.65 - €19.69 
($2.87-$21.29) 
General hospital: 
€8.32 - €11.03 
($8.99-$11.92) 
University hospital:  
€54.85 - €87.57 
($59.29-$94.67) 
 
 
Xakellis et al. 
(1995) 
US 
USD 
1991 
 
Long term care 
Number: n=539 
Cost evaluation 
of attributable 
cost of PU 
prevention 
 
Prevention 
(turning, 
mattresses, 
cushions and 
protective 
devices) 
Equipment for 
PU prevention, 
nursing care, 
- €273.33 ($245) over 3 
months 
€3.32 ($2.98) 
Xakellis et al. 
(1996a) 
US 
USD 
1992-1993 
Long term care  
 
Number: 
Secondary data 
analyses of study 
Prevention in 
patients with 
pressure  ulcers 
Support surfaces 
and repositioning 
- €613.33 ($550) over 3 
months 
 
- 
Table 3  Articles on Cost of Pressure Ulcer prevention  
  
       
Reference Country 
Currency 
Fiscal year of 
data 
Study population/ 
Number 
Study design Type of 
prevention 
Type of reported  
data 
Direct costs 
Converted & inflated cost (original cost) 
National 
 
Per Capita 
 
Per capita/day 
 
 N=30 (developed 
45 PU) 
of Frantz 1995: 
retrospective 
descriptive 
analysis of 
additional cost of 
pressure ulcer 
treatment 
 
category II-IV  
Xakellis et al. 
(1996b) 
UK and US 
USD 
Intervention 
1:1960 
Intervention 2: 
1991 
 
 
Hospital 
Number: 
Intervention 1: 
n=250  
Intervention 2: 
N=420  
 
Cost 
effectiveness 
analysis 
 
Intervention1: no 
prevention 
Intervention 2: 
prevention by 
repositioning; 
mattresses, 
cushions, heel  
protectors 
Cost= cost of 
prevention & 
treatment 
- Intervention 1:  
$0  
Intervention 2:  
€262.18 ($235) over 3 
months 
- 
Xakellis et al. 
(1998) 
US 
USD 
1994- 1995 
 
 
Long term care 
Number: 
Pre-protocol: 
n=69 
Post-protocol: 
n=63  
 
Quasi 
experimental pre-
post-test design. 
 
Pre protocol: no 
systematic 
preventive 
method 
Post protocol: 
Protocol based 
on AHCPR 
guidelines 
Cost of 
assessing, Cost 
of prevention 
Cost of treatment  
- Pre protocol: $0 
Post protocol: €94.79 
($91.56) over 6 months 
- 
Table 3  Articles on Cost of Pressure Ulcer prevention  
  
       
Reference Country 
Currency 
Fiscal year of 
data 
Study population/ 
Number 
Study design Type of 
prevention 
Type of reported  
data 
Direct costs 
Converted & inflated cost (original cost) 
National 
 
Per Capita 
 
Per capita/day 
 
 
Xakellis et al. 
(2001) 
 
 
US 
USD 
1994- 1995 
& 1997 
 
Long term care 
 
Number: 
Pre-protocol: 
n=69  
Post-protocol: 
n=63  
Post-protocol 2: 
n=71  
Quasi 
experimental pre-
post-test design. 
 
Pre protocol: no 
systematic 
prevention 
Post protocol: 
based on 
AHCPR 
guidelines 
Post protocol 2 : 
2 years after data 
collection 
 Xakellis et al. 
1998 
- Pre protocol: $0 
Post protocol 1: 
€132.53 ($130) 
Post protocol 2 : 
€156.39 ($158) 
over 6 months 
- 
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Reference Country 
Currency 
Fiscal year of data 
Study population/ 
Number 
Study design/ 
Data sources 
PU severity Type of reported  
data 
Direct costs 
Converted & inflated cost (original cost) 
National Per Capita Per capita/day 
Agreda et al. 
(2007) 
Spain 
EUR 
2006 
 
National (hospital, 
residential and 
primary care) 
 
Number:  
Primary care: 
n=704 572 (1.86% 
of 37,880,215 
beds) 
Hospital: n= 8466  
(6.61% of 128,082 
beds) 
Residential care: 
n=10761 (4.05% of 
265,712 beds) 
 
Bottom-up cost of 
illness study 
 
 
PU 1-4 (per PU 
severity 
category) 
-weekly treatment 
costs per patient 
(recalculated to cost 
per day) 
-cost per episode of 
care and  
-national cost of 
pressure ulcer 
treatment by PU 
grade and treatment 
setting 
 
€535.37million 
(€461 million)  
Primary care: 
€121.44 million 
(€104.57 million) 
Hospital: €140.57 
million (€121.04 
million) 
Residential Care: 
€273.83 million 
(€235.79 million) 
 
Primary care  
Cat. 1: €125.42 
(€108) 
Cat.2: €225.49 
(€220)  
Cat.3: €760.67 
(€655) 
Cat.4: €3,330.69 
(€2,868) 
Hospital:  
Cat.1: €19.74 
(€17) 
Cat.2: €84.78 
(€73) 
Cat.3: €625.96 
(€539)  
Cat.4: €922.09 
(€794) 
Residential care: 
Cat.1: €15.10 
(€13) 
Cat.2: €358.58 
(€309) 
 
Cat.3: €409.95 
(€353) 
Primary care Cat.1: 
€4.48 (€3.857) 
Cat.2: €8.46 
(€7.286) 
Cat.3: €12.61 
(€10.857)  
Cat.4= €33.35 
(€28.714) 
Hospital:  
Cat.1: €2.82 
(€2.429)  
Cat.2: €12.11 
(€10.429)  
Cat.3: €89.42 
(€77) 
Cat.4: €131.73 
(€113.429) 
Residential care: 
Cat.1: €2.16 
(€1.857)  
Cat.2: €51.26 
(€44.143)  
 
Cat.3: €58.56 
(€50.429)  
Cat.4: €63.71 
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Reference Country 
Currency 
Fiscal year of data 
Study population/ 
Number 
Study design/ 
Data sources 
PU severity Type of reported  
data 
Direct costs 
Converted & inflated cost (original cost) 
National Per Capita Per capita/day 
Cat.4: €445.95 
(€384) 
 
(€54.857) 
Allman et al. 
(1999) 
US  
USD 
Converted to 
prices: dec 1988 – 
june 1991 
 
Hospital  
Number:  
N=286  (>55 years 
of age, confined to 
bed/ chair or with 
hip fracture) 
Bottom-up 
economic 
evaluation, based 
on prospective 
cohort study 
 
 
PU 2-4  
 
Hospital costs using 
category-specific cost 
to charge ratios.  
- €16,990.04 
($15,229)  
 
€812.66 
($728.66)  
Alterescu et al 
(1989) 
US 
USD 
November 1, 1986-
31 January 1987 
 
Hospital (one 
community 
teaching hospital) 
 
Number: n=23 
(all patients with 
PU referred to 
enterostomal 
Therapy Nurse 
between 1 Nov 
1986 and 31 Jan 
1987) 
 
Economic 
evaluation study, 
based on 
retrospective study 
PU 1-4 
 
Total costs (mean per 
patient/day) 
 
-  €99.91 ($80.42) 
 
Assadian et al. 
(2011) 
Germany 
EUR 
January 2001 
Hospitals (3 
community 
hospitals) 
Bottom-up 
prospective 
economic 
PU 2-4 Total cost per 
day/patient  
 
- €1,255.89 (€991) 
 
€65.90 (€52) 
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Reference Country 
Currency 
Fiscal year of data 
Study population/ 
Number 
Study design/ 
Data sources 
PU severity Type of reported  
data 
Direct costs 
Converted & inflated cost (original cost) 
National Per Capita Per capita/day 
  
Number: n=35 (=all 
patients admitted 
with PU diagnosis 
PU besides 
primary diagnosis) 
evaluation 
 
Baker et al. (1996) 
 
US 
USD 
1988-1990 
 
Hospital 
Number= 814 
(residents with 
hospital admission) 
 
Top-down budget 
impact analyses 
based on 
retrospective 
analysis of data 
from Medicaid 
patient claims 
Not reported Additional cost of 
claim for 
reimbursement based 
on cost of hospital 
stay associated and 
not associated with 
PU  
- €2,998.84 ($2,688)  - 
         
Beckrich  & 
Aronovitch 
(1999) 
US 
USD 
Year not reported 
(based on 
Alterescu et al. 
1989 & Allman et 
al 1995) 
 
Hospital 
Number: 
n=373,560  
Economic 
evaluation based 
on literature data  
Hospital 
acquired PU 1-4 
Annual Cost of 
hospital-acquired PU  
Cost of hospital-
acquired PU per ulcer 
Cost of OR acquired 
PU 
€2,468.865 million 
($2,212.958 
million) 
€1,535.12 ($1,376)  
Cat. 1-2: €139.45 - 
€228.71 ($125- 
$205);  
Cat. 3-4: 
€15,641.28 -
€25,575.05 
($14,020- $22,925)  
 
 
Bennet et al. 
(2004) 
UK 
GBP 
Hospital or long 
term care and 
Bottom-up cost 
evaluation 
PU 1-4 (per PU 
severity 
-Treatment cost per 
episode of care and 
€2.79bn (£1.77bn) Cat. 1: €1,675.53 
(£1,064) 
Cat. 1: €59.84 
(£38) 
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Reference Country 
Currency 
Fiscal year of data 
Study population/ 
Number 
Study design/ 
Data sources 
PU severity Type of reported  
data 
Direct costs 
Converted & inflated cost (original cost) 
National Per Capita Per capita/day 
NHS unit costs at 
2000 prices 
 
community 
nursing/care of GP 
 
Number: National 
 category & level 
of complication) 
per patient 
-Total cost of health 
and social care 
system in UK 
Cat. 2: €6,217.11-
€32,143.76 
(£3,948-  
£20,412) 
Cat. 3: €9,999.65- 
€35,926.30 
(£6,350-£22,814) 
Cat. 4: €12,204.30- 
€38,130.95 
(£7,750-£24,214) 
 
Cat. 2: €66.14- 
€308.65 (£42 - 
£196)  
 
Cat.  3: €78.74- 
€308.65 (£50-
£196) 
Cat.  4: €78.74-
€308.65 (£50-
£196) 
Berthier et al. 
(2005) 
France 
EUR 
2003 
 
Hospital 
Number: n = 73  
 
Budget impact 
analyses 
examining the 
effect of the 
“Associated 
Complication and 
Morbidity” pressure 
ulcer coding 
defect. 
 
PU 1-4 
(average) 
 
Cost of stay in 
hospital for patients 
identified with PU 
based on existing 
MDG (Major 
Diagnostic Group  
code  
- €429.53 (€350) 
(Adjusted for 
extreme cases) 
_ 
Chan et al (2013) Canada 
CAD 
2002-2006 
Hospital 
Number: n=3874 
(>65 years) 
Cost-of-illness 
based on top down 
matched controlled 
cases 
PU 2-4 (per PU 
severity 
category) 
Cost of hospital 
acquired and pre-
admission PU 
including direct and 
overhead costs 
- Hospital acquired 
PU: 
Cat. 2: €33,786.17 
(C$43,930) 
Cat. 3: €52,544.30 
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Reference Country 
Currency 
Fiscal year of data 
Study population/ 
Number 
Study design/ 
Data sources 
PU severity Type of reported  
data 
Direct costs 
Converted & inflated cost (original cost) 
National Per Capita Per capita/day 
(C$68,320) 
Cat. 4: €69,472.00 
(C$90,330) 
Unstageable: 
€36,585.66 
(C$47,570) 
Pre-admission PU: 
Cat.2: (C$10,810) 
Cat.3: €11,613.28 
(C$15,100) 
Cat.4: €14,243.57 
(C$18,520) 
Unstageable: 
€6,387.30 
(C$8,305) 
 
 
 
Dealey et al. 
(2012) 
UK 
GBP 
UK NHS unit costs 
at 2011 prices 
 
Institutional setting 
(hospital of long 
term care) but not 
admitted solely for 
PU care. 
Number: National 
 
Bottom-up cost 
evaluation 
 
 
PU 1-4 (per PU 
severity 
category) 
Treatment cost per 
episode of care and 
per patient fir PU of 
different severity and 
different level of 
complications 
- Cat. 1:   
€1,524.95 
(£1213.58) 
Cat.2:  
€5527,40-
€45048,02 
(£4,398.79 
-£35,849.90) 
Cat.1: €53.69 
(£42.73) 
 
Cat. 2: €58.93-
€470.49 (£46.90- 
374.42) 
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Reference Country 
Currency 
Fiscal year of data 
Study population/ 
Number 
Study design/ 
Data sources 
PU severity Type of reported  
data 
Direct costs 
Converted & inflated cost (original cost) 
National Per Capita Per capita/day 
Cat. 3:  
€9088,71-
€48,609.33 
(£7,232.93-
£38,684.04) 
Cat. 4:  
€11,036.29- 
€50,556.92 
(£8,782.85-
£40,233.96) 
Cat. 3: €71.34-
€470.49 (£56.77-
£374.42) 
 
 
Cat.4: €71.34-
€470.49 (£56.77 -
£374.42) 
 
Foglia et al. (2012) Italy 
EUR 
2010 (discounted 
from 2008) 
 
Home care  
Number: Advanced 
dressings group: 
n=201 
Simple dressings 
group: n=150  
Health Technology 
assessment model  
 
Not reported Treatment cost per 
month (recalculated 
to cost per day)  
 - Simple dressings: 
€12.53 (€11.70)  
Advanced 
dressings: €9.18 
(€8.573)  
Frantz et al. (1991) US 
USD 
November 1, 1983- 
October 31,1988. 
(salary of 1988 by 
adjusting the 1984 
salary data) 
 
Long term care 
residents 
Number: n=155 
(240 PU) 
Retrospective 
descriptive 
analysis of 
additional cost of 
pressure ulcer 
treatment 
 
PU 1-4 (per PU 
severity 
category) 
Number of PU, 
location of PU and 
corresponding 
treatments,  
 
- - 
 
€6.57 ($5.35) 
Cat. 1: €8.87 
($7.22)  
Cat. 2: €3.64 
($2.96)  
Cat. 3: €2.16 
($1.76)  
Cat. 4: €5.88 
($4.79)  
Table 4  Articles on Cost of Pressure Ulcer treatment 
  
Reference Country 
Currency 
Fiscal year of data 
Study population/ 
Number 
Study design/ 
Data sources 
PU severity Type of reported  
data 
Direct costs 
Converted & inflated cost (original cost) 
National Per Capita Per capita/day 
 
Frantz et al. (1995) US 
USD 
January 1, 1992 – 
December 31, 
1992 
 
Long term care 
residents. 
 
Number: n= 50 (81 
PU) 
 
Retrospective 
descriptive 
analysis of 
additional cost of 
pressure ulcer 
treatment 
 
 
PU 1-4 (per PU 
severity 
category) 
Location and number 
of PU, PU treatment, 
treatment duration, 
skill level of nursing 
personnel, number of 
days of treatment, 
frequency of 
treatment 
 
 
- €671.15 ($601.58) 
 
€4.17 ($3.74)  
Cat. 1: €1.73 
($1.55)  
Cat. 2: €4.07 
($3.65) 
Cat. 3: €4.98 
($4.46) 
Cat. 4: €6.73 
($6.03)  
Frantz et al. (2001) US 
USD 
September 1, 1996 
– August 31, 1997 
 
Long term care 
residents 
Number: n= 31 (46 
PU) 
 
Economic 
evaluation based 
on retrospective 
descriptive 
analysis  
PU 2-4 
(facility acquired 
open PU) 
Location and number 
of PU, PU treatment, 
treatment duration, 
skill level of nursing 
personnel, number of 
days of treatment, 
frequency of 
treatment, use of 
support surfaces and 
repositioning 
 
- €401.85 ($406) 
 
€4.76 ($4.81)  
Cat. 2: €3.88 
($3.92)  
Cat. 3: €7.14 
($7.21)  
Cat. 4: €7.07 
($7.14)  
Unstageable: 
€14.57 ($14.72)  
Haalboom (1991) The Netherlands 
NLG 
Year not reported 
Hospital 
Number: national 
 
Economic 
evaluation based 
on modelling 
PU 1-2 and 
PU 3-4 
Cost of treatment 
 
€338.07 million 
(ƒ470 million)  
- Cat. 1 or 2: €95.92 
(ƒ133.35) 
Cat. 3 or 4: 
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Reference Country 
Currency 
Fiscal year of data 
Study population/ 
Number 
Study design/ 
Data sources 
PU severity Type of reported  
data 
Direct costs 
Converted & inflated cost (original cost) 
National Per Capita Per capita/day 
 €93.11-€125.79 
(ƒ129.45-ƒ174.88)  
Hale (1990) UK 
GBP 
June 1989 
 
Hospital and 
community centres  
 
Number: n=27 
patients with a PU 
Economic 
evaluation of cost 
of treatment. 
 
 
Not reported Estimates of cost of 
used materials and 
nurses’ time during 
treatment. 
 
- - €106.49 (£ 53.95) 
 
Kumar et al.(2004) US 
USD 
2000 $-values 
 
Hospital, rural 
health, outpatient 
hospital, federally 
qualified health 
clinic, home care 
health 
Number: NR 
2683 skin ulcers 
patients  (PU, 
chronic ulcer, leg 
ulcer, ulcer of the 
lower limb) 
 
 
 
Top down 
economic 
evaluation based 
on retrospective 
analysis of claim 
database 
 
 
Not reported Median and mean 
annual cost of 
hospital, physician 
visits and 
prescriptions per 
patient. 
Total annual cost for 
each of the 5 study 
period years. 
 
 
-  1994: €11.67 
($12.28) 
1995: €23.15 
($24.36) 
1996: €22.38 
($23.55) 
1997: €17.96 
($18.90) 
1998: €22.77 
($23.96) 
 
Oot-Giromini et al. 
(1989) 
US 
USD 
Hospital 
Number:  NR 
Economic 
evaluation based 
PU 1-4  Direct costs (labour & 
material cost) 
- - €13.34 ($11.96)  
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Reference Country 
Currency 
Fiscal year of data 
Study population/ 
Number 
Study design/ 
Data sources 
PU severity Type of reported  
data 
Direct costs 
Converted & inflated cost (original cost) 
National Per Capita Per capita/day 
Year not reported (random sample) 
 
on a prospective 
bottom up design 
 
 
Rees et al. (2007) US 
USD 
2004-2005 
 
Homebound 
patients 
Number:  
N= 38 (group1: 
homebound 
patients with 
chronic pressure 
ulcer (n=19)  
group 2: historical 
cohort (n= 19) 
Economic 
evaluation based 
on prospective 
research and 
retrospective chart 
analyses 
 
Not reported 
(Chronic PU) 
Use of service (ED 
visits, outpatient clinic 
visits outpatient clinic 
contact, 
hospitalisations, LOS, 
level of outpatient 
visit acuity and 
financial costs) 
- Inpatient/2years: 
€4,185.44-
€13,600.95 
($4,852-$15,767) 
Outpatient/2years: 
€1,751-€1,248.21 
($2,030-$1,447) 
 
Inpatient: 
€5.73-€18.60 
($6.65-$213.38) 
Outpatient: 
€2.40-€1.71 
($2.78-$1.98) 
Schuurman et al 
(2009) 
The Netherlands 
EUR 
2001-2004 
Hospital 
Number:  
n= 84  
(Technical 
approach: n=26 ; 
Human approach: 
n= 58) 
Bottom- up 
economic 
evaluation  
 
PU 1-4 (per PU 
severity 
category) 
Cost of treatment 
using technical 
approach (TA) or 
human approach 
(HA) per day; per 
patient. annual 
expenditures for the 
Dutch national health 
system by 
extrapolating from 
previously published 
national admission 
TA: €215.89 million  
(€178.8 million)  
HA: €210.70 
million (€174.5 
million) 
 
Cat. 1:  
TA: €510.75 
(€423)  
HA: €425.02 
(€352)  
Cat.2: 
TA: €840.38 
(€696)  
HA: €603.72 
(€500)  
Cat.3:  
TA: €988.89 
Cat. 1:  
TA: €56.75 (€47)  
HA: €38.64 (€32) 
 
 
Cat. 2: 
TA: €70.03 (€58) 
HA: €60.37 (€50) 
 
 
Cat.3:  
TA: €76.07 (€63) 
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Reference Country 
Currency 
Fiscal year of data 
Study population/ 
Number 
Study design/ 
Data sources 
PU severity Type of reported  
data 
Direct costs 
Converted & inflated cost (original cost) 
National Per Capita Per capita/day 
data and data on 
prevalence of PU 
(€819) 
HA: €1,487.57 
(€1,232)  
Cat. 4:  
TA: €1,553.98 
(€1,287)  
HA: €2,079.21 
(€1,722) 
HA: €106.25 (€88) 
 
 
Cat. 4: 
 TA: €119.54 (€99)  
HA: €148.52 
(€123)  
 
Severens et al. 
(2002) 
The Netherlands 
USD 
Year not reported 
Home care, 
nursing homes, 
university and 
general hospitals. 
 
Number: 
National 
Cost of illness 
 
PU 1-4 (per PU 
severity 
category) 
Volume of care 
parameters: time 
investment of 
personnel, use of 
medical materials, 
diagnostic and 
therapeutic 
interventions, 
extended length of 
home care of 
institutional care 
€334.86 million -
€2.59 billion ($362 
million -$2.8 billion) 
- Cat. 1 
Home Care: 
€9.37-€15.55 
($10.14-$16.81) 
Nursing Home: 
€8.49-€29.74 
($9.18-$32.15) 
General hospital: 
€8.45-€10.57 
($9.13-$11.43) 
University hospital: 
€57.74-€91.21 
($62.42-$98.60) 
Cat. 2 
Home Care: 
€75.08-€97.65 
($81.16-$105.56) 
Nursing Home: 
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Reference Country 
Currency 
Fiscal year of data 
Study population/ 
Number 
Study design/ 
Data sources 
PU severity Type of reported  
data 
Direct costs 
Converted & inflated cost (original cost) 
National Per Capita Per capita/day 
€27.54-€63.47 
($29.77-$68.61) 
General hospital: 
€28.52-€30.25 
($30.83-$32.70) 
University hospital: 
€86.20-€132.57 
($93.19-$143.31) 
Cat.  3 
Home Care: 
€106.68-€142.68 
$115.33-$154.24 
Nursing Home: 
€53.92-€108.98 
($58.29-$117.81) 
General: hospital: 
€49.16-€59.68 
($53.14-$64.52) 
University hospital: 
€110.01-€174.05 
($118.93-$188.15) 
Cat. 4 
Home Care: 
€138.27-€190.47 
($149.48-$205.91) 
Nursing Home: 
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Reference Country 
Currency 
Fiscal year of data 
Study population/ 
Number 
Study design/ 
Data sources 
PU severity Type of reported  
data 
Direct costs 
Converted & inflated cost (original cost) 
National Per Capita Per capita/day 
€108.37-€170.43 
($117.15-$184.24) 
General: hospital: 
€103.43-€109.71 
($111.81-$118.60) 
University hospital: 
€137.68-€209.35 
($148.84-$226.32) 
Van den Bos et al. 
(2011) 
US 
USD 
2008 
 
In- and outpatients 
Number: National 
 
Top-down cost 
study based on 
actuarial approach 
trough medical 
claim data 
 
 
Not reported Elements of actuarial 
analysis: marginal 
costs, by period of 
time following the 
event, adjusted for 
survival and 
discounting 
€2,615.69 million 
($3,273 million) 
€6,976.78 ($8,730)   
Xakellis et al. 
(1996a) 
US 
USD 
1992-1993 
 
Long term care 
patients followed 
across multiple 
health care 
settings 
Number: 
n=30 (45 PU) 
Secondary data 
analyses of study 
of Frantz 1995: 
retrospective 
descriptive 
analysis of 
additional cost of 
pressure ulcer 
treatment 
 
PU 2-4 Number of PU, 
location of PU and 
corresponding 
treatments,  
 
- €1,432.48 ($1,284) 
over 3 months  
 
Incl. hospital costs: 
€5,184.38 ($4,647) 
over 3 months  
 
- 
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PU = Pressure Ulcer; Cat. = Category/Grade/Stage 
Reference Country 
Currency 
Fiscal year of data 
Study population/ 
Number 
Study design/ 
Data sources 
PU severity Type of reported  
data 
Direct costs 
Converted & inflated cost (original cost) 
National Per Capita Per capita/day 
Xakellis et al. 
(1996b) 
UK and US 
USD 
Intervention 1:1960 
Intervention 2: 
1991 
 
Hospital 
Number: 
Intervention 1: 
n=250  
Intervention 2: 
n=420  
CEA 
DS: identical to 
Xakellis et al 1995 
Cost of treatment 
from Frantz et al. 
1995 
Superficial and 
severe PU 
Cost= cost of 
secondary prevention 
+ treatment 
 
Intervention 1: no 
secondary prevention 
Intervention 2: 
prevention by 
repositioning; 
mattresses, cushions, 
heel protectors 
 
- Intervention 1:  
€186.31 ($167) 
Intervention 2:  
€273.33 ($245) 
over 12 weeks  
- 
Xakellis et al. 
(1998) 
US 
USD 
1994-1995 
 
Long term care 
Number: 
Pre-protocol: n=16 
(26 PU)  
Post-protocol: n=3 
( 5 PU) 
Quasi 
experimental pre-
post-test design. 
reimbursable 
charge, 
PU 1-4 
 
PU frequency 
Types of PU 
treatment 
Time needed to heel 
PU 
cost of treatment  
- Pre-protocol: 
€502.20 ($487) 
Post-protocol: 
€188.43 ($182) 
over 6 months 
- 
Xakellis et al. 
(2001) 
 
 
US 
USD 
1994- 1995 & 1997 
 
 
 
Long term care 
Number: 
Pre-protocol: n=16 
(26 PU)  
Post-protocol: n=3 
(5 PU) 
2 Years post-
protocol: n=10  
Quasi 
experimental pre-
post-test design. 
  
PU 1-4  
 
Cfr. Xakellis 1998 - Pre protocol: 
€660.60 ($648) 
Post protocol: 
€234.47 ($230) 
2 Years post-
protocol: €138.57 
($140) over 6 
months 
- 
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4.3 COST OF PRESSURE ULCER TREATMENT 
The main study characteristics and their reported costs of pressure ulcer 
prevention are outlined in Table 4.  
Cost components included in the treatment cost varied widely between studies. 
The total treatment cost included the cost of materials for dressing changes, 
nursing time, surgery and debridement, (incremental) length of stay, medication, 
laboratory tests, radiology, secondary prevention (measures to prevent further 
deterioration, occurrence or recurrence  of pressure ulcers), complications, 
physician visits, emergency room visits, and clinic contacts. Eight studies 
included secondary prevention (Bennett et al., 2004; Dealey et al., 2012; Frantz 
et al., 2001; Haalboom, 1991; Hu et al., 1993; Lyder et al., 2002; Schuurman et 
al., 2009; Severens et al., 2002), and five studies did not (Agreda et al., 2007; 
Assadian et al., 2011; Foglia et al., 2012; Hale, 1990; Oot-Giromini et al., 1989). 
One study reported on the cost of the cost of secondary prevention separate 
from the treatment cost (Xakellis et al., 1996a), and nine studies partially 
included cost of secondary prevention (Allman et al., 1999; Alterescu, 1989; 
Baker, 1996; Berthier et al., 2005; Dzwierzynski et al., 1998; Frantz et al., 1991; 
Frantz et al., 1995a; Kumar et al., 2004; Van Den Bos et al., 2011). In two 
studies it was not clear if secondary prevention was included (Beckrich et al., 
1999; Van Den Bos et al., 2011). 
 
National annual cost of pressure ulcer treatment 
The national annual cost of pressure ulcer treatment was examined in Europe 
(Agreda et al., 2007; Bennett et al., 2004; Haalboom, 1991; Schuurman et al., 
2009; Severens et al., 2002), and in the United States (Beckrich et al., 1999; 
Van Den Bos et al., 2011). National annual cost to treat all pressure ulcers 
varied between €334 million and €2.79 billion (Agreda et al., 2007; Bennett et 
al., 2004; Severens et al., 2002).   
 
Cost of pressure ulcer treatment per patient 
The cost of pressure ulcer treatment in hospitals varied between €19.74 for 
treating a category I pressure ulcer (non-blanchable erythema (NPUAP & 
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EPUAP, 2009)) without providing secondary prevention up to an average cost of 
€6,9471.99 for treating a pressure ulcer category IV (Agreda et al., 2007; 
Allman; Alterescu, 1989; Assadian et al., 2011; Baker, 1996; Beckrich et al., 
1999; Berthier et al., 2005; Dzwierzynski et al., 1998; Schuurman et al., 2009). 
In long term care, costs ranged between €15.10 to treat a category I pressure 
ulcer without providing secondary prevention and €1,432.48 to treat a pressure 
ulcer category II-IV (Agreda et al., 2007; Frantz et al., 1995a; Frantz et al., 2001; 
Xakellis et al., 1996a; Xakellis et al., 2001). The cost of pressure ulcers in home 
care varied between €125.42 to treat a category I pressure ulcer without 
providing secondary prevention up to €3,330.69 to treat a category IV ulcer 
(Agreda et al., 2007). 
 
Cost of pressure ulcer treatment per patient per day 
Overall, average cost of pressure ulcer (category I-IV/II-IV) treatment ranged 
from €2.16 (Alterescu, 1989) to €812.66 per patient per day, including cost of 
prolonged length of stay (Allman et al. , 1999).  
The cost of a category I pressure ulcer varied between €1.73 in long term care 
without incorporating costs of secondary prevention and €59.84 in hospitalised 
patients taking into account secondary prevention (Agreda et al., 2007; Bennett 
et al., 2004; Dealey et al., 2012; Frantz et al., 1991; Frantz et al., 1995a; Frantz 
et al., 2001; Schuurman et al., 2009; Severens et al., 2002). The cost for treating 
a category II pressure ulcer ranged between €3.64 in long term care residents 
and €470.49 in patients and residents with osteomyelitis (Agreda et al., 2007; 
Bennett et al., 2004; Dealey et al., 2012; Frantz et al., 1991; Frantz et al., 1995a; 
Frantz et al., 2001; Schuurman et al., 2009; Severens et al., 2002). The cost to 
treat a category III pressure ulcer varied between €2.16 in long term care 
patients and €470.49 in patients and residents with osteomyelitis (Agreda et al., 
2007; Bennett et al., 2004; Dealey et al., 2012; Frantz et al., 1991; Frantz et al., 
1995a; Frantz et al., 2001; Schuurman et al., 2009; Severens et al., 2002). The 
cost to treat a category IV pressure ulcer ranged from €11.13 in long term care 
patients to €470.49 in patients and residents with osteomyelitis (Agreda et al., 
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2007; Bennett et al., 2004; Dealey et al., 2012; Frantz et al., 1991; Frantz et al., 
1995a; Frantz et al., 2001; Schuurman et al., 2009; Severens et al., 2002). 
 
5. DISCUSSION 
The aim of this review was to systematically assess and summarise the 
literature on the economic impact of pressure ulcer prevention and treatment in 
an adult population. Seven studies addressing cost of pressure ulcer prevention 
and 16 studies considering cost of pressure ulcer treatment were included. Ten 
studies included cost data on both, prevention and treatment of pressure ulcers. 
The most frequently reported cost outcome was the cost per patient per day.  
The results were reported in a narrative way because of the methodological 
heterogeneity of the extracted data. Substantial heterogeneity was found in the 
health economic designs being used, the included costs, setting, samples, 
methods for cost calculation, time horizon, economic perspective, and cost 
outcomes. Besides this substantial methodological heterogeneity, lack of 
transparency in data reporting hindered the correct interpretation of the data.  
 
5.1 METHODOLOGICAL DISCUSSION 
The majority of the studies did not specify the type of health economic design 
they applied, but used varying terminology for cost evaluation. The type of health 
economic design can significantly influence the results and thus the conclusions 
of a study (Larg and Moss, 2011; van Gils et al., 2010). The lack of clear 
rationale for the health economic designs may have caused the wide variation in 
included costs and the methods to measure these costs. Studies without a 
clearly defined health economic design will not be in line with the available 
methodological guidelines. Further research that examines the economic impact 
of pressure ulcer prevention or treatment should use the available guide or 
guidelines corresponding to the chosen health economic design (Larg and Moss, 
2011). The use of the available guide can significantly improve the 
methodological quality, the validity of the results, as well as the transparency of 
reporting. Besides a generic guide, additional tailored recommendations for 
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pressure ulcer specific research are needed. These tailored recommendations 
can enhance (inter)national benchmarking of outcomes by advising on cost 
components that need to be included and the cost outcomes that need to be 
reported in pressure ulcer related cost-of-illness studies.  
 
Generally, direct as well as indirect cost need be taken into account in health 
economic studies (Larg and Moss, 2011; Rice, 1967), but all studies in this 
review reported only direct medical costs. The economic impact of indirect costs 
on the total societal expenditures may be marginal for pressure ulcers because 
the cost of productivity loss due to pressure ulcer development in a mainly 
elderly population will probably be limited.  
 
In this review, the most reliable variable to compare costs between different 
countries and settings was the cost per patient per day. This was due to less 
influencing factors affecting the cost outcomes, compared to the national annual 
cost or cost per patient. These influencing factors included the number of 
inhabitants, number or patients at risk, number patients with a pressure ulcer for 
the national annual cost of pressure ulcers, and included the length of stay, the 
time horizon, and loss to follow-up for the cost per patient. Furthermore, when 
providing the cost per patient per day as outcome measure, an average length 
of stay and/or healing times should be provided.  
 
5.2 COST OF PRESSURE ULCER PREVENTION AND TREATMENT 
One day of prevention for a patient or resident at risk costs between €3.26 and 
€107.45 per day (Haalboom, 1991; Padula et al., 2011; Schuurman et al., 2009; 
Bennett et al., 2004; Dealey et al., 2012; Bayoumi et al., 2008; Makai et al., 
2010; Richardson et al., 1998; Xakellis et al., 1995; Xakellis et al., 1996a; 
Xakellis et al., 1996b; Xakellis et al., 2001; Xakellis, Jr. et al., 1998). Prevention 
provided to hospitalised patients (€8.01-€107.45) was more costly than for long 
term care residents (€3.26-€24.16) and in home care (€9.51-€16.91). One day of 
pressure ulcer treatment costs between €2.86 to €1,277.82 per patient or 
resident. These major differences were related to pressure ulcer severity. The 
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cost to treat a pressure ulcer complicated by cellulitis or osteomyelitis with need 
for surgical procedures and prolonged hospitalisation will significantly increase 
the estimated costs (Bennett et al., 2004; Dealey et al., 2012). Besides 
treatment cost per day, it was important to examine the cost of pressure ulcer 
treatment until the wound was completely healed, which was provided by the 
treatment cost per patient (€15.10-€26,706.52). Insight in these costs may help 
to draw the attention of government and health care institutions to pressure ulcer 
prevention. Treatment costs were usually provided for one specific healthcare 
setting (Allman et al., 1999; Alterescu, 1989; Baker, 1996; Beckrich et al., 1999; 
Berthier et al., 2005; Dzwierzynski et al., 1998; Frantz et al., 1991; Frantz et al., 
1995a; Frantz et al., 2001; Oot-Giromini et al., 1989; Schuurman et al., 2009; 
Xakellis et al., 1996a; Xakellis et al., 2001), but patients or residents may move 
between healthcare settings during a treatment episode. Moreover, not all 
patients were followed until complete healing occurred. Therefore the provided 
cost is probably an underestimation of the real cost of treatment per patient.  
 
5.3 STUDY LIMITATIONS  
The majority (n=20) of the studies were published more than ten years ago and 
therefore may have become less relevant for the current healthcare situation. 
Treatment, and to a lesser extent prevention of pressure ulcers has evolved and 
changed over the last ten years (Baranoski and Ayello, 2012; Effraim, 2010). 
Wound dressings, wound closure methods, and insights on wound healing have 
changed and possibly even influenced time of healing, number of dressing 
changes, or nursing time. Furthermore, only direct medical costs were included 
in the studies. None of the studies included explored the impact of indirect 
medical costs or direct and indirect non-medical costs.  
 
6. CONCLUSION 
Cost of pressure ulcer prevention and treatment differed considerable between 
studies. The cost to provide pressure ulcer prevention to patients at risk seems 
to be higher in hospitalised patients compared to patients in home care or 
nursing homes. Cost of treatment tended to increase with pressure ulcer 
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severity. Methodological heterogeneity among studies identified the need to use 
the available, study design specific methodological guidelines to conduct health 
economic studies, and the need for additional pressure ulcer specific 
recommendations. 
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CHAPTER 6 
 
THE COST OF PREVENTION AND TREATMENT OF 
PRESSURE ULCERS IN FLANDERS: A COST-OF-
ILLNESS STUDY 
Based on the article of Demarré L, Verhaeghe S, Van Hecke A, Grypdonck M, 
Annemans L & Beeckman D. The cost of prevention and treatment of pressure 
ulcers in hospitals and nursing homes in Flanders.  Under Review. 
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ABSTRACT 
Introduction: The economic impact of pressure ulcer prevention and treatment is 
high. The results of cost-of-illness studies can assist the planning, allocation and 
priority setting of healthcare expenditures to improve the allocation of preventive 
measures. Data on the cost of current practice of pressure ulcer prevention or 
treatment in Flanders (Belgium) is lacking.  
Aim: To examine the cost of pressure ulcer prevention and treatment in an adult 
population in hospitals and nursing homes from a mixed perspective.  
Design: A cost-of-illness study was performed using a bottom-up approach. 
Methods: Data were collected in a series of multicentre cross-sectional studies 
between 2008 and 2013. Data collection included data on risk assessment, 
pressure ulcer prevalence, preventive measures, unit cost of materials for 
prevention and treatment, nursing time measurements for activities related to 
pressure ulcer prevention and treatment, and nursing wages. The cost of 
pressure ulcer prevention and treatment in hospitals and nursing homes was 
calculated as annual cost for Flanders, per patient, and per patient per day. 
Results: The cost for pressure ulcer prevention was €7.88 per hospitalised 
patient at risk per day and €2.15 per nursing home resident at risk per day. The 
cost of pressure ulcer prevention for patients and residents identified not at risk 
for pressure ulcer development was €1.44 per day in hospitals and €0.50 per 
day in nursing homes. The main cost driver was the cost of labour, responsible 
for 79% to 85% of the cost of prevention. The average cost of local treatment 
per patient per day varied between €2.34 and €77.36 in hospitals, and between 
€2.42 and €16.18 in nursing homes. 
Conclusions: Related to methodological differences between studies, the cost of 
pressure ulcer prevention and treatment in hospitals and nursing homes in 
Flanders was found to be low compared to other international studies. Pressure 
ulcer specific recommendations as part of methodological guidelines to conduct 
cost-off-illness studies, are needed. A reliable risk assessment policy and a 
continuous monitoring of preventive measures to the patients’ needs may 
decrease healthcare expenditures by lowering the costs of pressure ulcer 
incidence.
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1. INTRODUCTION 
Pressure ulcers are defined as localised injuries of the skin and/or underlying 
tissue over a bony prominence due to pressure and shear (NPUAP & EPUAP, 
2009). Pressure ulcers are internationally considered as important quality 
indicators, and most pressure ulcers are avoidable (National Pressure Ulcer 
Advisory Panel, 2011; Van Den Bos et al., 2011). Besides an impact on the 
patients’ overall well-being, pressure ulcers have a financial implication for 
society, patients, health care organisations, and insurances (Gorecki et al., 
2009; Hopkins et al., 2006; Langemo et al., 2000; National Institute for Clinical 
Excellence, 2005; Spetz et al., 2013).  
A recent systematic review pointed out that the cost of pressure ulcer prevention 
per patient at risk varied between €2.65 and €87.57 per day. The average cost 
of pressure ulcer treatment ranged between €1.73 and €812.92 per patient per 
day (Chapter 5). The majority of the studies were conducted more than a 
decade ago and the review included cost data collected in North America (US 
and Canada) and Europe (UK, Spain and The Netherlands) (Chapter 5).  
 
Cost of pressure ulcer prevention and treatment is driven by labour cost, 
prolonged hospitalisation, pressure ulcer complications, and cost for materials 
(Dealey et al., 2012; Haalboom, 1991; Schuurman et al., 2009). Several studies 
indicated the significant weight of the cost of nursing labour compared to the 
cost of materials (Dealey et al., 2012; Frantz et al., 2001; Xakellis et al., 2001). 
Nursing times can vary as a result of the methodology used to estimate the 
duration of these times. This variation in study methodology can significantly 
influence the estimated total cost. Several studies used subjective time 
measurements, such as expert opinion or Delphi method, to estimate the 
duration of nursing activities related to pressure ulcer prevention and treatment 
(Agreda et al., 2007; Alterescu, 1989; Assadian et al., 2011; Bayoumi et al., 
2008; Frantz et al., 1995b; Hale, 1990; Severens et al., 2002). Nursing times 
measured through direct observation by a researcher were found to result in 
smaller estimates than when measured using a Delphi method (Boudt, 2013; 
Burke et al., 2000). When measuring average time spend on an activity related 
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to pressure ulcer prevention and treatment the method of direct observation is 
most accurate (Burke et al., 2000).  The main limitation of this method is the high 
cost of direct observation for extended periods, therefore transparently and 
detailed reported results of such time measurements will enhance the quality of 
cost-of-illness studies and can be used in future cost-of-illness studies.  
 
The results of cost-of-illness studies can assist policy makers and health care 
service managers in planning, allocating and prioritising expenditures in order to 
improve the allocation of preventive measures (Larg and Moss, 2011). 
Furthermore, insights into the cost-of-illness can emphasize the need for 
pressure ulcer prevention, thereby improving the quality of care (Moore et al., 
2013), diminishing costs for treatment and prolonged hospitalisation.  
 
The implementation of international guidelines in care as usual is not always 
successful. Inadequate, incomplete or lacking preventive measures were 
observed in the majority of patients at risk in several studies (Baumgarten et al., 
2010; Beeckman et al., 2013; Gunningberg, 2005; van Gaal et al., 2011; 
Vanderwee et al., 2011). On the other hand, an important part of the patients 
assessed as not at risk received (some) preventive measures. In Belgian 
hospitals more than 70% of the patients not at risk received preventive 
measures (Vanderwee et al., 2011). Most studies have calculated the cost of 
preventive measures based on models or algorithms of prevention which were 
created from best practice guidelines or based on findings from the literature 
(preventive measures under highly standardised conditions) (Chapter 5). In 
these model-based cost calculations, the cost of prevention in patients not at risk 
is not included in the total cost and the cost of patients at risk will probably be 
higher compared to cost calculations based on care as usual (this is the care 
provided to patients without interference of research/researchers). Model-based 
cost calculations can be useful to provide insight in the cost of evidence based 
prevention and/or treatment, but only cost calculations based on usual care can 
reflect the actual expenditures and economic impact of pressure ulcer 
prevention and treatment in current practice. 
Chapter 6 
161 
For Flanders (Belgium), no data on the cost of pressure ulcer prevention or 
treatment are available.  
 
2. AIM 
The aim of this study is to calculate the cost of pressure ulcer prevention and 
treatment in an adult hospitals and nursing homes population using a mixed 
perspective. This mixed perspective, which specifies the chosen focus of the 
group bearing the cost, consists of the perspective of the patient, institution, and 
insurances.  
 
3. METHODOLOGY 
3.1 DESIGN 
A cost-of-illness study was performed using a bottom-up approach (person-
based approach calculating the resources used in individuals receiving pressure 
ulcer prevention or treatment). A cost-of-illness study was chosen to identify the 
disease-attributable costs that occur concurrently with pressure ulcer prevention 
and treatment to assess the total current economic burden of prevention and 
treatment of this health problem. A bottom-up approach calculating costs by 
directly tracing resources was used to quantify resource use solely attributable 
to pressure ulcer prevention and treatment. The cost of medical resource use 
was based on data from hospitals and nursing homes collected by direct 
observation.  
Data were collected in a series of multicentre cross-sectional studies (Table 1). 
Data collection was performed between 2008 and 2013.  
 
3.2 DATA SOURCES  
An overview of the data collected in hospitals and nursing homes is provided in 
Table 1.  
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Hospitals:  
Data on risk assessment (Braden scale or presence of a pressure ulcer), 
pressure ulcer prevalence, and prevention being applied were retrieved from the 
2008  Belgian prevalence study (Vanderwee et al., 2011).  
The unit cost (per day) of materials for prevention and treatment were collected 
in a random sample of ten hospitals. To calculate the treatment cost, 78 
treatments were observed.  
Nursing time measurements were performed for activities related to risk 
assessment, patient repositioning, the application of materials, local wound 
treatments (cleansing, use of topical agents, dressing changes), and 
documentation. A sample size of 15 observations for each activity was pursued  
(Van Goubergen, 2005).  In total, 1717 measurements were performed in 753 
patients admitted to a convenience sample of 15 hospitals in Flanders. 
The nursing labour cost per second was calculated by multiplying the nursing 
time of each activity with the nursing wages. The nursing wages were based on 
the manual for cost-based pricing of hospital interventions of the Belgian Health 
Care Knowledge Centre (Swartenbroekx, 2012).  
 
Nursing homes 
Data on risk assessment (Braden scale or presence of pressure ulcer), pressure 
ulcer prevalence, and prevention being applied were collected using the 
European Pressure Ulcer Advisory Panel (EPUAP) minimum dataset and 
EPUAP methodology to collect the data (Vanderwee et al., 2007a; Vanderwee et 
al., 2011).  
The unit cost (per day) of materials for prevention and treatment were collected 
in a sample of 20 nursing homes, drawn from the 84 nursing homes of the 
prevalence study. To calculate the treatment cost, 59 treatments were observed.  
Nursing time measurements were performed for similar activities as in hospitals.  
In total, 1052 measurements were performed in 198 residents admitted to a 
convenience sample of 20 nursing homes. 
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3.2 COSTS CALCULATIONS 
The total cost of pressure ulcer prevention and pressure ulcer treatment was 
calculated as annual cost for Flanders, per patient, and per patient per day in 
hospitals and nursing homes. The formulas used to calculate the cost of 
pressure ulcer prevention and treatment were provided in Table 2. 
All costs were provided in Euro and adjusted to the inflation rate in 2013 based 
on the health index (FOD Economie and PF Economie, 2014).  
 
3.2 SENSITIVITY ANALYSES  
The results of the study are subject to uncertainty, which was handled by a 
sensitivity analysis. Sensitivity analyses were performed to examine the 
influence of variance due to device related uncertainties (lifespan of materials; 
viscoelastic foam as a standard mattress in an organisation). 
 
3.3 ETHICAL CONSIDERATIONS 
The study was approved by the Ethics Review Committee of Ghent University 
Hospital, and the Ethics Review Committees of all participating hospitals and 
nursing homes (B/67020083249, B/670201213428, B/670201214217, 
B/670201215256). 
  
Table 1  Overview of the data collected in hospitals and nursing homes in Flanders: type of data, data sources, setting and sample 
Type of data Data source/Reference 
Hospitals 
Data source/Reference 
Nursing homes 
Setting and sample  
Hospitals 
Setting and sample  
Nursing Homes 
Prevalence data: 
• Demographic data 
• Risk assessment 
(Braden Scale or 
presence of a 
pressure ulcer) 
• Pressure ulcer 
prevalence 
category I-IV 
• Preventive 
measures in bed 
and chair1 
Vanderwee et al. (2011) 
Data of frequency of risk 
assessment and skin assessment 
was adopted from Gunningberg et 
al. (2011) 
 
Data collected by teams of two 
observers (including one nurse 
from the ward being surveyed, and 
one nurse from a different ward) 
using the EPUAP minimum 
dataset 
Data of frequency of skin 
assessment adopted from 
Gunningberg et al.  (2011). No 
further risk assessment was 
assumed 
Hospitals  
Wards  
Patients  
 
n=48 
n=454 
n=11 792 
 
Nursing 
homes  
Wards 
Residents  
n=84 
 
n=294 
n=8008) 
  
Cost of materials  
• Pressure ulcer 
prevention 
o mattresses 
o cushions 
• Local treatment  
o dressings 
o wound cleaning 
solutions, 
o disinfectants 
o sets 
o consult of general 
practitioner 
o consult of surgeon  
o surgery 
o medication 
o nutritional 
supplements 
o contact precaution 
materials 
Hire/purchase prices of preventive 
devices from resources manager 
Lifespan of the devices: based on 
information of medical technology 
companies 
Type and amount of materials 
used for pressure ulcer treatment: 
direct observation by researcher 
Prices of materials: pharmacy and 
the logistics department (adjusted 
for discounts), if missing official 
prices from databases of The 
National Institute for Health and 
Disability Insurance (NIHDI) were 
used (downloaded from 
http://www.riziv.be/drug/nl/) 
Hire/purchase prices of preventive 
devices from resources manager 
Lifespan of the devices: based on 
information of medical technology 
companies 
Type and amount of materials 
used for pressure ulcer treatment: 
direct observation by researcher 
Prices of materials: pharmacy and 
the logistics department (adjusted 
for discounts), if missing official 
prices from databases of NIHDI 
were used (downloaded from 
http://www.riziv.be/drug/nl/) 
Hospitals  
Wound 
treatments  
 
n=10 
 
n=78 
 
Nursing 
homes  
Wound  
treatments  
 
n=20 
 
n=59 
 
Nursing times for activities 
related to prevention and 
treatment 
Data collected through direct 
observation by the researcher 
(LD), using a chronometer 
Data collected through direct 
observation by the researchers 
(LD, DB, HD), using a 
chronometer 
Hospitals  
Patients  
Time 
measurements  
n=15 
n=753 
n=1717 
Nursing 
homes 
Residents  
Time 
measurements  
n=20 
 
n=198 
n=1052 
Table 1  Overview of the data collected in hospitals and nursing homes in Flanders: type of data, data sources, setting and sample 
  
< 
 
 
 
Labour cost Cost of nursing wages based 
manual for cost-based pricing of 
hospital interventions of the 
Belgian Health Care Knowledge 
Centre (Swartenbroekx, 2012) 
Cost of the wages provided by the 
organisations and based on NIHDI  
 
Data retrieved 
from  manual 
for cost-based 
pricing of 
hospital 
interventions 
of the Belgian 
Health Care 
Knowledge 
Centre 
(Swartenbroek
x, 2012) 
 Nursing 
homes  
n=20 
1 Preventive measures in bed and chair: including primary prevention and secondary prevention (measures to prevent further deterioration, occurrence or recurrence  of 
pressure ulcers) 
Table 1  Overview of the data collected in hospitals and nursing homes in Flanders: type of data, data sources, setting and sample 
  
 
Table 2  Formulas to calculate the cost of pressure ulcer prevention and treatment 
Prevention 
 
Hospitals Nursing homes 
Cost of prevention per patient or 
resident per day 
 
Unit cost devices/day/patient + labour cost 
prevention/ patient/day1 
Unit cost devices/resident/day + labour cost prevention/ 
resident/day1 
Cost of prevention per patient  Cost/patient/day x 7.57 (the average length of stay 
in hospitals) ² 
 
 Not applicable (no data on average length of stay in nursing 
homes available) 
Annual cost of prevention Patient at risk= (% of patients at risk x cost/patient 
at risk/day x 8.52 million (number of care days per 
year³)) 
 
Patient not at risk= (% of patients not at risk x 
cost/patient not at risk/day x 8.52 million (number of 
care days per year³)) 
Resident at risk= (% of resident at risk x cost/resident at 
risk/day x 69 902 (number of residencies4) x 365) 
 
Resident not at risk= (% of resident not at risk x cost/resident 
not at risk/day x 69 902 (number of residencies4) x 365) 
 
Local treatment 5 
 
Hospitals Nursing homes 
Cost of treatment per patient or 
resident per day 10 
Unit cost materials/patient/ day + labour 
cost/patient/ day  
Unit cost materials/resident/ day + labour cost/resident/ day 
Cost of treatment per patient or 
resident 10 
PU6 category I= Cost /patient /day x 7.57 (average 
length of stay)  
PU category II-IV= Cost /patient/day x (7.57 
(average length of stay²) +  (4.31 (extra length of 
stay due to pressure ulcer5)x  €366.85 
PU category I= Cost / resident/day x  28 days (healing time PU 
category I) 9; PU category II= Cost / resident/day x  94 days 
(healing time PU category II) 9; PU category III= Cost / 
resident/day x  127 days (healing time PU category III) 9; PU 
category IV= Cost / resident/day x  155 days (healing time PU 
  
1Type, amount and frequency of preventive measures per patient or resident were used from the prevalence data; ²Average length of stay in hospitals of 7.57 
days adopted from Trybou (2011); 3 Number of care days adopted from Flemish Institution for Health Care downloaded from http://www.zorg-en-
gezondheid.be/Cijfers/Zorgaanbod-en-verlening/Ziekenhuizen/Bezettingsgraad-en-verblijfsduur-Vlaamse-ziekenhuizen/; 4 Number of residencies adopted from 
Flemish Institution for Health Care downloaded from http://www.zorg-en-gezondheid.be/programmatiewoonzorgcentra/; 5Cost of secondary prevention (measures 
to prevent further deterioration, occurrence or recurrence  of pressure ulcers) was provided separately from cost of local treatment to avoid double counting of 
preventive measures; 6PU: pressure ulcer; 7 Extra length of stay controlled for comorbidities of 4.31 days adopted from Graves et al. (2011) controlling for 
comorbidities; 8 Hospitalisation cost per day in a hospital in Flanders was retrieved from the from databases of the National Institute for Health and Disability 
Insurance (NIHDI) (http://www.riziv.be/); 9Average healing time per pressure ulcer severity category adopted from Dealey et al. (2012); 10 Calculated per PU 
severity category I-IV 
 
 
 
  
(hospitalisation cost/day 7) category IV) 9 Local treatment 5 
 
Hospitals Nursing homes 
Annual cost of treatment ((% of patients with a PU category I x cost/patient 
PU category I x 8.52 million (number of care days 
per year³)) + (% of patients with a pressure category 
II x  cost/patient PU category II x 8.52 million ) + (% 
of patients with a pressure category III x  
cost/patient PU category III  x 8.52 million) + (% of 
patients with a pressure category IV x  cost/patient 
PU category IV x 8.52 million (number of care days 
per year³)) 
((% of residents with a PU category I x cost/resident/day PU 
category I x 69 902 (number of residencies4) x 365) + (% of 
residents with a PU category II x cost/resident/day PU category II x 
69 902 (number of residencies4) x 365) + (%of residents with a PU 
category III x cost/resident/day PU category III x 69 902 (number of 
residencies4) x 365) + (% of residents with a PU category IV x 
cost/resident/day PU category IV x 69 902 (number of residencies4) 
x 365) 
Table  2  Formulas to calculate the cost of pressure ulcer prevention and treatment 
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4. RESULTS 
4.1 DEMOGRAPHIC DATA AND PRESSURE ULCER PREVALENCE 
In hospitals, 38% (n=4482) of the patients were younger than 70 years, 55% 
(n=6517) were female, and 29% (n=3453) were at risk. Non-blanchable 
erythema was present in 6.3% (n=738) of the patients. Pressure ulcer 
prevalence category II, category III and category IV was respectively 3.6% 
(n=426), 2.5% (n=294), and 1.6% (n=192). 
 
In nursing homes, 52% (n=4169) of the residents were aged between 80 and 89 
years, and 29% (n=2284) was older. Seventy five percent (n=6052) were 
female, and 37% (n=2993) of the residents were at risk. Non-blanchable 
erythema was present in 10.5% (n=840) of the nursing home residents. 
Pressure ulcer prevalence category II, category III and category IV was 
respectively 2.9% (n=230), 1.9% (n=152), and 1.1% (n=87). 
 
4.2 COST OF PRESSURE ULCER PREVENTION 
Hospitals 
The average cost of pressure prevention for patients at risk was €7.88 
(SD=8.21), consisting of 79% cost for labour and of 21% cost for devices (Table 
5). An overview of the nursing times related to activities for prevention and 
treatment is provided in Table 3. The average cost per activity for repositioning 
of a bedridden patient was €1.98 and €3.82 for a not-bedridden patient.  An 
overview of the cost of devices for prevention is provided in Table 4. The 
average cost per day was €4.89 for an alternating device, €0.09 for a 
viscoelastic foam mattress and €0.05 for a viscoelastic foam cushion.  
Some of the patients not at risk received prevention, resulting in an average cost 
of €1.44 (SD=4.26) per patient per day (Table 5). 
 
The average cost for a patient at risk was €59.65 per hospitalisation, and €10.90 
for a patient not at risk.   
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The annual cost of pressure ulcer prevention in hospitals was €28.34 million, 
consisting of €19.67 million for patients at risk and €8.67 million for patients not 
at risk.  
 
Nursing homes 
The average cost of pressure prevention for a residents at risk was €2.15 
(SD=3.10), consisting of 85% cost for labour and 15% cost for devices (Table 5). 
The average cost per activity for repositioning of a bedridden resident was €0.86 
and €3.44 for a not-bedridden resident (Table 3).  The average cost per day was 
€0.71 for an alternating device, €0.10 for a viscoelastic foam mattress, and 
€0.04 for a viscoelastic foam cushion (Table 4). 
Some of the residents not at risk received preventive measures, resulting in an 
average cost of €0.50 (SD=1.61) per nursing home resident per day (Table 5). 
 
The annual cost of pressure ulcer prevention in nursing homes was €17.53 
million, consisting of €9.54 million for residents at risk and €7.99 million for 
residents not at risk. 
 
4.3 COST OF PRESSURE ULCER TREATMENT 
Table 6 provides an overview of the cost for the local treatment of pressure 
ulcers and the cost for secondary prevention in hospitals and nursing homes. 
The results are given for each pressure ulcer category. 
 
Hospitals 
The average cost of treatment per patient per day varied between €2.34 
(SD=1.14) to treat a category I pressure ulcer up to €77.36 (SD=35.95) to treat a 
category IV pressure ulcer. The average cost per day for secondary prevention 
varied between €6.83 (SD=8.16) per patient with a pressure ulcer category I and 
€10.74 (SD=8.46) per patient with a pressure ulcer category IV.  
  
 
Table 3  Nursing time and costs related to nursing activities for prevention 
  Hospitals  Nursing homes 
Activity Mean time 
(s)/activity 
Mean cost 
(€) 
% (n) patients 
receiving the activity 
Mean time 
(s) /activity 
Mean cost 
(€) 
% (n) patients 
receiving the activity 
Risk assessment                 63.71 0.61 N.A. 1 106.48 1.03 N.A.1 
Repositioning in bed (bedridden) 200.28 1.98 4.2 (504) 88.67 0.86 1.2 (101)) 
Repositioning in bed (not-bedridden) 236.10 2.55 13.7 (1628) 192.93 2.11 9.1 (735) 
Repositioning in chair 99.56 0.98 8.8 (1039) 55.88 0.54 9.6 (779) 
Registration of repositioning 9.90 0.09 N.A.2 1.98 0.02 N.A.2 
Heel offloading 29.23 0.58 22.9 (2695) 5.23 0.05 13.1 (1053) 
1 Frequency of risk assessment was not included in the data collection. Data of frequency of assessing risk was used from Gunningberg et al. (2011); 
 ² Frequency of registration of  repositioning was not included in the data collection, a frequency of once per shift was assumed 
 
  
Table 4  Cost of mattresses and cushions per day based on a variable lifespan  
 Hospital Nursing home 
 Mean cost/day (€) for minimum/mean/maximum lifespan Mean cost/day (€) for minimum/mean/maximum lifespan 
Device 
 
Min. 
Lifespan 
(years) 
Min. 
Cost/day  
Mean 
 (Min, Max) 
Mean 
Lifespan 
(years) 
Mean  
Cost/day  
Mean 
(Min, Max) 
Max. 
Lifespan 
(years) 
Max. 
Cost/day  
Mean 
 (Min, Max) 
Min. 
Lifespan 
(years) 
Min. 
Cost/day  
Mean 
 (Min, Max) 
Mean 
Lifespan 
(years) 
Mean  
Cost/day  
Mean 
(Min, Max) 
Max. 
Lifespan 
(years) 
Max. 
Cost/day  
Mean 
 (Min, Max) 
Viscoelastic foam 
mattress                
5  0.13,  
0.09-0.17 
7 0.09 
0.06-0.12 
9 0.07 
0.05-0.09 
5 0.14 
0.08-0.24 
7 0.10 
0.06-0.17 
9 0.08 
0.05-0.13 
Alternating mattress1 5  5.11 
0.85-16.94 
7 4.89 
0.16-16.94 
9 4.76 
0.47-16.94 
5 0.87 
0.34-3.86 
7 0.71 
0.24-3.86 
9 0.62 
0.19-3.86 
Static air mattress 1  0.51 
0.40-0.67 
2 0.25 
0.20-0.33 
3 0.17 
0.13-0.22 
1 0.45 
0.41-0.50 
2 0.22 
0.20-0.25 
3 0.15 
0.13-0.17 
Viscoelastic foam 
cushion              
3  0.08 
0.03-0.17 
5 0.05 
0.02-0.10 
7 0.04 
0.01-0.07 
3 0.07 
0.04-0.15 
5 0.04 
0.03-0.09 
7 0.03 
0.02-0.06 
Static air 1 0.50 
0.17-1.28 
2 0.25 
0.09-0.64 
3 0.16 
.06-0.43 
1 0.19 
0.14-0.24 
2 0.09 
0.07-0.12 
3 0.06 
0.05-0.08 
Gel cushion 1 0.45 
0.12-0.78 
3 0.15 
0.04-0.26 
5 0.09 
0.02-0.16 
1 0.45² 
0.12-0.78 
3 0.15² 
0.04-0.26 
5 0.09² 
0.02-0.16 
  
 
 
  
 Hospital  Nursing home 
 Mean cost/day (€) for minimum/mean/maximum lifespan Mean cost/day (€) for minimum/mean/maximum lifespan 
Device 
 
Min. 
Lifespan 
(years) 
Min. 
Cost/day  
Mean 
 (Min, Max) 
Mean 
Lifespan 
(years) 
Mean  
Cost/day  
Mean 
(Min, Max) 
Max. 
Lifespan 
(years) 
Max. 
Cost/day  
Mean 
 (Min, Max) 
Min. 
Lifespan 
(years) 
Min. 
Cost/day  
Mean 
 (Min, Max) 
Mean 
Lifespan 
(years) 
Mean  
Cost/day  
Mean 
(Min, Max) 
Max. 
Lifespan 
(years) 
Max. 
Cost/day  
Mean 
 (Min, Max) 
Heel cushion 3 0.10 
0.03-0.27 
5 0.06 
0.02-0.16 
7  0.04 
0.02-0.12 
3 0.09 
0.05-0.13 
5 0.05 
0.03-0.08 
7 0.04 
0.02-0.05 
Ring cushion 1 0.24 
0.08-0.40 
2 0.15 
0.04-0.26 
3 0.05 
0.02-0.16 
1 0.02 2 0.03 3 0.02 
1 In hospitals 50% of the alternating devices was rented and 50% was purchased, in nursing homes 11% of the alternating devices was rented and 89% was purchased; ² Missing in 
nursing homes; data used  from  the cost of devices in hospitals 
Table 4  Cost of mattresses and cushions per day based on a variable lifespan 
  
Table 5  The cost of pressure ulcer prevention per patient per day in hospitals and nursing homes in Flanders 
Cost per patient /day Total  
€/day (SD) 
Material  
€/day (SD) 
Labour  
€/day (SD) 
Hospitals    
Patient at risk 7.88 (8.21) 1.68 (2.25) 6.21 (7.51) 
Patient not at risk 1.44 (4.26) 0.25 (0.85) 1.19 (4.04) 
Nursing homes    
Residents at risk 2.15 (3.10) 0.32 (0.30) 1.83 (3.01) 
Resident not at risk 0.50 (1.61) 0.10 (0.13) 4.4 (1.58) 
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The average cost for the local treatment of a pressure ulcer category I summed 
up to €17.71 per hospitalisation. The average cost to treat a pressure ulcer 
category II, category III, and category IV summed up to respectively, €1709.54, 
€1,784.86, and €2,500.16 per hospitalisation (not including the cost of 
secondary prevention). The annual cost for pressure ulcer treatment was 
€165.75 million (Table 6). 
 
Nursing homes 
The average cost of treatment per resident per day varied between €2.42 
(SD=1.15) to treat a category I pressure ulcer up to €16.18 (SD=4.93) to treat a 
category IV pressure ulcer in nursing homes. The average cost for secondary 
prevention varied between €2.14 (SD=3.19) up to €3.49 (SD=3.97) per resident 
per day (Table 6). 
 
The average cost to heal a pressure ulcer category I, category II, category III, 
and category IV summed up to €67.76, €368.48, €1,276.35, and €2,507.90 (not 
including the cost of secondary prevention), assuming a healing time of 
respectively 28, 94, 127, and 155 days (Dealey et al., 2012). 
The annual cost for pressure ulcers in nursing homes was €18.80 million, based 
on 69,902 residencies per year (Table 6).   
Overall, this accounts for a cost of pressure ulcer prevention and treatment of 
€36.13 per inhabitant of Flanders. 
 
4.4 SENSITIVITY ANALYSES  
Analysis of uncertainty concerning the lifespan of preventive devices (minimum 
versus maximum lifespan)  
In hospitals, minimum lifespan of preventive devices resulted in 3% higher cost 
of pressure ulcer prevention per day for a patient at risk compared to the 
maximum lifespan (€7.80; SD=8.18 - €8.02; SD=8.27), and 6% per day for a 
patient not at risk (€1.41; SD=4.25) - €1.50; SD=4.29).  
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In nursing homes, minimum lifespan of preventive devices resulted in 32% 
higher cost of pressure ulcer prevention per day for a resident at risk compared 
to maximum lifespan (2.10€; SD=3.08 - 2.78; SD=3.21), and 21% per day for a 
resident not at risk (0.48€; SD=1.60 - 0.58€; SD=1.66).  
 
Analysis of uncertainty concerning the use of viscoelastic foam mattresses as 
standard mattress 
If a viscoelastic foam mattress was not included in the cost of prevention, the 
average cost of pressure ulcer prevention reduced with 18% per hospitalised 
patient at risk per day (€6.49; SD=7.59), and 15% per hospitalised patient not at 
risk (€1.23; SD=4.07).  
 
In nursing homes, the cost of pressure ulcer prevention reduced with 2% per 
resident at risk per day (€2.10; SD=3.10), and with 14% per resident not at risk 
(€0.43; SD=1.61).  
 
5. DISCUSSION 
The aim of this study was to examine the cost of pressure ulcer prevention and 
treatment in an adult hospitals and nursing home population using a mixed 
perspective. The cost for pressure ulcer prevention is €7.88 per hospitalised 
patient at risk per day and €2.15 per nursing home resident at risk per day. The 
cost of pressure ulcer prevention for patients and residents identified not at risk 
for pressure ulcer development was €1.44 per day in hospitals and €0.50 per 
day in nursing homes. The main cost driver was the cost of labour, responsible 
for 79% to 85% of the cost of prevention. The average cost of local treatment 
per patient per day varied between €2.34 (category I) and €77.36 (category IV) 
in hospitals, and between €2.42 (category I) and €16.18 (category IV pressure 
ulcer) in nursing homes. 
 
  
Table 6  The cost of pressure ulcer treatment per day, per episode, and per year in hospitals and nursing homes in Flanders 
Hospitals  Treatment  Secondary prevention 
Cost per patient/resident 
Mean cost  
(€)/day (SD) 
Mean material 
(€)/day (SD) 
Mean labour cost 
(€)/day (SD) 
Mean cost  
(€)/day (SD) 
Mean material cost 
(€)/day (SD) 
Mean labour 
cost (€)/day 
(SD) 
Category I 2.34 (1.14) 0.47 (0.23) 0.88 (1.49) 6.83 (8.16) 1.46 (2.15) 5.39 (7.54) 
Category II 10.81 (4.25) 2.90 (1.14) 7.91 (3.11) 8.86 (8.90) 2.14 (2.36) 6.46 (8.12) 
Category III 17.15 (7.33) 7.91 (3.38) 9.24 (3.95) 9.84 (8.78) 2.68 (2.41) 7.16 (7.92) 
Category IV 77.36 (35.95) 68.42 (31.79) 8.94 (4.16) 10.74 (8.46) 2.88 (2.39) 7.86 (7.92) 
Nursing homes       
Category I 2.42 (1.15) 0.16 (0.07) 2.26 (1.07) 2.14 (3.19) 0.32 (0.30) 1.82 (3.09) 
Category II 3.92 (1.33) 1.93 (0.65) 2.00 (0.67) 2.56 (3.14) 0.42 (0.33) 2.14 (3.05) 
Category III 10.05 (2.81) 3.73 (1.04) 6.32 (1.77) 3.35 (3.42) 0.55 (0.30) 2.79 (3.32) 
Category IV 16.18 (4.93) 9.09 (2.77) 7.08 (2.16) 3.49 (3.97) 0.52 (0.31) 2.97 (3.91) 
Hospital Length of stay 
 
Cost extra length of stay 
Mean total cost/episode 
of care  
Pressure ulcer 
prevalence  
Episodes of care/year 
Annual cost of 
treatment 4 
Category I 7.57 days1 N.A. €17.71 6.3% 1,125,3701 €1,255,609 
Category II 11.88 days2 €1,581.12 3 €1,709.54 3.6% 1,125,3701 €69,259,141 
Category III 11.88 days2 €1,581.12 3 €1,784.86 2.5% 1,125,3701 €50,215,697 
Category IV 11.88 days2 €1,581.12 3 €2,500.16 1.6% 1,125,3701 €45,017,680 
Total cost treatment 
 
  
 
 €165,748,128 
 
 
 
 
 
 
 
 
 
 
  
Table 6  The cost of pressure ulcer treatment per day, per episode, and per year in hospitals and nursing homes in Flanders 
 
Nursing homes 
Healing times 
Total cost/episode of care 
Mean 
Pressure ulcer 
prevalence 
Number of residencies 
Annual cost of 
treatment 4  
Category I 28 days 5 €67.76  10.5% 69,9021 €6,483,166  
Category II 94 days 5 €368.48 2.9% 69,9021 €2,900,458  
Category III 127 days5 €1,276.35 1.9% 69,9021 €4,871,942  
Category IV 155 days 5 €2,507.90 1.1% 69,9021 €4,541,023  
Total cost of treatment 
 
  
 
€18,796,589  
1 Flemish Institution for Health Care; 2Graves et al. 2005; 3 Dealey et al. 2012; 4Secundary prevention  not  included; 5 Cost per extra length of stay: 366.85€/day in a hospital in 
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5.1 COST OF PRESSURE ULCER PREVENTION 
The cost of pressure ulcer prevention in hospitals and nursing homes was low 
compared to other studies. A systematic review reported a cost for pressure 
ulcer prevention per patient at risk per day varying between €5.39 and €87.57 in 
hospitals, and between €2.65 and €19.69 in nursing homes (Chapter 5). Several 
reasons may account for this finding. The present study used the cost of 
preventive measures based on care as usual, whereas calculations the study of 
Dealey et al (2012), Bayoumi et al (2008), and Bennet et al (2004), and others 
were based on prevention provided compliant to guidelines (Chapter 5). As a 
result, the average cost of prevention per patient per day measured in the 
present study was lower than when prevention compliant to the guidelines was 
provided. Another reason for the low cost may be related to the collection of time 
measurements by direct observation. This more accurate method may have 
lowered the costs of prevention given the high share of labour cost in the total 
cost.  
 
This study points out that the cost of prevention for patients who are considered 
not at risk is high. This is partly linked with our decision to include the cost of a 
viscoelastic foam mattress as an attributable cost related to pressure ulcer 
prevention. However, we observed that in some hospitals and nursing homes in 
Belgium, a viscoelastic foam mattress is used as a standard mattress for each 
patient for comfort purposes. Considering the results of the sensitivity analyses, 
this was not the main reason for the cost of prevention in patients not at risk.  
In the present study, the majority of the patients did not receive the correct 
preventive measures compliant to the guideline. This was less than needed for 
patients at risk and more than needed for patient not at risk. A structured risk 
assessment policy, consisting of accurate and consistent screening as well as 
continuously monitoring and adaptation of the preventive measures can lead to 
reducing the health care expenditures related to pressure ulcer prevention. 
Decreasing pressure ulcer incidence related costs as well as decreasing costs of 
inadequate and incomplete prevention can generate cost savings. Further 
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research should focus on the extent of the possible costs savings per averted 
case.  
The study pointed out that the cost of prevention provided to patients perceived 
not at risk was high (€8.67 million in hospitals and €7.99 million in nursing 
homes). Device related costs, for example created by late or forgotten 
removal/relocation of mattresses or cushions in patients that were once at risk 
but already recovered, can give cause to cost savings. The vast majority of the 
cost for patients not at risk was labour related. Legitimate reasons for this labour 
cost in patients perceived as not at risk can be related to the cost of risk 
assessment in all patients, and to differences in risk assessment method that 
may have led to the identification of other patients at risk. If activities related to 
prevention were provided to patients that are not in need of these preventive 
measures, this labour cost can be seen as an opportunity cost because this 
nursing time is not available to do other patient activities. Although this may not 
directly lead to health care savings for institutions and government, due to the 
nursing shortage a correct allocation of nursing time is needed. Because 
healthcare resources for pressure ulcer prevention (labour and materials) are 
limited, attention must be given to use the available resources as efficient as 
possible. 
 
5.2 COST OF PRESSURE ULCER TREATMENT 
Compared to other studies, the cost of pressure ulcer treatment was low. A 
systematic review reported on a cost of pressure ulcer treatment per patient per 
day varying between €1.73 and €812.92 (Chapter 5). As for pressure ulcer 
prevention, data on the type and amount of materials used to treat a pressure 
ulcer were collected by direct observation, and not based on expert opinion. Also 
labour time was measured by direct observation, which was found to be an 
accurate method for measuring the duration of nursing activities (Burke et. al, 
2000), but may provide conservative aggregated nursing times because the time 
related to activities,  such as ordering wound dressings, education and training, 
shift hand-over and patient transport was not included in the total nursing time. 
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Finally, the observed treatments of pressure ulcers were mainly conservative 
treatments. Surgical treatments or complications were included, but rarely 
observed. Medical resource use was based on prevalence data and observed 
one or two days per hospital. Pressure ulcers category IV or pressure ulcers with 
severe complications are less common than superficial or non-complicated 
pressure ulcers, in this study respectively 1.1% - 1.6% for pressure ulcer 
category IV and 1.9% - 10.5% for pressure ulcers category III or less. Therefore, 
there may have been an under-observation of these events. Due to the high cost 
of complications in severe pressure ulcers (Dealey et al., 2012) the cost of local 
pressure ulcer treatment presented in this study are conservative. Further 
research needs to include data about medical resource use to treat a category 
IV pressure ulcer during the full hospitalisation period or until complete healing 
to provide more accurate cost estimates. 
 
The cost of pressure ulcer treatment per day was remarkably lower in nursing 
homes compared to hospitals, even when the cost of extra length of stay was 
not included. The type and materials used to treat a pressure ulcer in nursing 
homes differed from those used in hospitals. Financial implications for the 
nursing home resident were known to the nurse providing wound treatment, and 
often explicitly weighted when treating pressure ulcers in nursing homes. 
Whereas in hospitals, the costs of materials are less known to the nurse 
providing the wound treatment. Furthermore the availability of materials was 
more restricted in nursing homes compared to hospitals. More insight in the cost 
of materials, such as dressings, sets and cleaning solutions need to be provided 
to all nurses involved in pressure ulcer treatment to enable them in a 
conscientious examination of costs and benefits of treatment options.  
Another important reason for higher cost of pressure ulcer treatment is that 
specialised pressure ulcer treatment, such as surgery or re-evaluation of non-
healing wounds, is provided in hospitals. Although seldom observed in this 
study, such a specialised treatment led to higher costs in hospitals, whereas 
follow-up treatment and monitoring were associated with lower costs. The latter 
treatment was usually provided in nursing homes.  
Chapter 6 
182 
5.3 LIMITATIONS 
Besides the above mentioned underestimation of the cost of severe pressure 
ulcers and their complications, this study has encompassed several other 
limitations. No empirical data were available on the percentage of overlay 
mattresses versus matrass replacements. Therefore the mathematical mean of 
all alternating devices was used.  
Furthermore, no data were available on extra length of stay related to pressure 
ulcer risk or treatment. It is not clear whether pressure ulcer risk leads to extra 
length of stay. The current calculations of the cost of pressure ulcer treatment 
assume no attributable length of stay for patients with a Braden score of 16 or 
less and patients with a pressure ulcer category I, which may be an 
underestimation of the true cost.  Furthermore, no data were available on the 
extra length of stay for each separate pressure ulcer category. Therefore, an 
overall extra length of stay for pressure ulcers category II-IV was used. This may 
have led to an overestimation of the cost of superficial pressure ulcers (category 
II-III) and an underestimation of the cost of severe pressure ulcers (category IV). 
The percentage of patients in which risk assessment is done, is not known for 
the Belgian hospital or nursing home population. Gunningberg et al. (2011) 
reported that 6.0% to 10.7% of the patients in general hospitals, and 60.1% to 
60.5% of the patients in a teaching hospital received respectively, a risk 
assessment and skin assessment (Gunningberg et al., 2011). These 
percentages were used to calculate the cost for pressure ulcer prevention in 
hospitals. For nursing homes, the assumption that skin assessment was 
performed in 6% of the residents was adopted. It is not clear to what extent 
these figures accurately reflect the risk and skin assessment in care as usual in 
Flanders.  
 
6. CONCLUSION 
The cost for pressure ulcer prevention was €7.88 per hospitalised patient at risk 
per day and €2.15 per nursing home resident at risk per day. The cost of 
treatment per hospitalised patient per day varied between €2.34 and €77.36, 
and between €2.42 and €16.18 in nursing homes residents. The cost of pressure 
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ulcer prevention and treatment in hospitals and nursing homes in Flanders was 
found to be low compared to other international studies, mainly due to 
methodological differences between studies. There is need for pressure ulcer 
specific recommendations as part of methodological guidelines to conduct cost-
off-illness studies.  A decrease of health care expenditures may be achieved by 
implementing a reliable screening policy and a continuous monitoring of 
preventive measures to the patient’s needs by lowering the costs of pressure 
ulcer incidence. 
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The aim of this chapter is to discuss and to reflect on the main findings of this 
thesis. Following topics will be addressed: key findings, contributions to risk 
assessment, the relation between pressure ulcer aetiology and preventive 
measures, and the impact of pressure ulcers on quality of care and budgets. In a 
separate section, some methodological issues will be addressed. In a final 
section, recommendations for practice, and further research will be discussed.  
 
1. KEY FINDINGS 
1.1 EFFECTIVENESS OF ALTERNATING DEVICES 
To compare the effectiveness of several types of alternating devices, two studies 
were conducted. First an RCT was conducted to compare the effectiveness of 
multi-stage and one-stage ALPAMs. No significant difference in cumulative 
pressure ulcer incidence between multi-stage and one-stage ALPAMs was 
found. Secondly, secondary data analyses on a pooled database were 
conducted to compare the effectiveness of APAM overlays with multi-stage and 
one-stage ALPAMs. Fewer pressure ulcers developed on multi-stage ALPAMs 
compared to APAM overlays, but no difference was found between one-stage 
ALPAMs and APAM overlays. Time to develop ulcers did not differ by mattress 
type. 
Similar to the study of Nixon et al. (2006a), the results from our study found no 
differences in effectiveness between APAM overlays and one-stage ALPAMs. A 
significantly lower pressure ulcer incidence was found in the multi-stage ALPAM 
group compared to the APAM overlay group (Demarré et al., 2013). This finding 
was based on non-randomised comparative analyses of patient data from two 
separate studies. Therefore, prudency is advised in the interpretation of these 
findings. It is difficult to determine the relative contribution of each of the 
numerous differences in mattress design that could explain these findings. The 
hypothesis is that a combination of features of the mattresses was associated 
with lower pressure ulcer incidences on multi-stage ALPAMs compared to 
APAM overlays. This combination of features includes lower inner air cell 
pressures, the use of a sensor which continuously measures weight distribution 
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and adjusts the pressure in the cells, and the gradual inflation and deflation of 
the air cells. One feature on itself, working on one specific etiological factor of 
pressure ulcer development, could not empirically be demonstrated to have a 
surplus value (Demarré et al., 2012a; Nixon et al., 2006a). An RCT is needed to 
confirm if multi-stage ALPAMs, including a combination of features and acting on 
different etiological mechanisms at once, are more effective than APAM 
overlays. 
 
Although pressure ulcer incidences in our study were in line with the 
international literature (McInnes et al., 2012), they are still high for adverse 
events that are considered avoidable. One of the possibilities for further 
decreasing pressure ulcers is the improvement of prevention of heel pressure 
ulcers. No pressure or shear is applied to the heel when they are really 
offloaded. Pressure ulcer prevention provided at the heels differed between 
study groups. Patients on a one-stage and multi-stage ALPAM had no additional 
heel offloading. The one-stage ALPAM contained low alternating pressure air 
cells at the heels, whereas the multi-stage ALPAM included an ultra-low 
continuous pressure zone at the heels. For the APAM overlay group, a pillow 
under the legs was used to support the heels. However, in all groups heel 
pressure ulcers still occurred. Vanderwee et al. (2006) suggested from their 
findings, comparing heel offloading with a pillow on viscoelastic foam as well as 
on an APAM overlay, that the support surface underneath influenced the 
pressure ulcer development at the heels (Vanderwee et al., 2005). When 
patients pushed away or relocated the pillow under their legs, or if bottoming out 
of the pillow occurred, the heels touched the support surface underneath. A 
meta-analysis of Nicosia et al. (2007) found that pressure redistributing 
mattresses were associated with a lower incidence of heel pressure ulcers 
compared to a standard mattress, both without heel offloading. Nevertheless, 
offloading the heels remains the most appropriate and effective way to prevent 
heel pressure ulcers (Huber et al., 2008), because only then 0mm/Hg can be 
achieved at the heels. The meta-analyses of 2007 found insufficient evidence 
that one heel offloading device outperformed another (Nicosia et al., 2007), but a 
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2009 pooled database study by Heyneman et al. (2009) found that a wedge-
shaped cushion was more effective in offloading the heel than a regular pillow 
(Heyneman et al., 2009). Due to the methodological limitations related to pooled 
database studies, an RCT is needed to confirm these findings. When using a 
pillow, continuous attention and efforts must be made to educate both patients 
and nurses to provide correct heel offloading. Further research should also focus 
on the development of devices that are simultaneously effective and well 
tolerated by patients.  
 
1.2 PRESSURE ULCER RISK FACTORS IN PATIENTS WHO RECEIVE PREVENTIVE 
MEASURES 
Factors predicting the development of pressure ulcers in hospitalised patients 
who receive preventive measures were identified using secondary data analyses 
of the ALPAM study. Non-blanchable erythema, presence of a urogenital 
disorder, and higher body temperature were associated with the development of 
pressure ulcers category II-IV. Models identifying predicting factors associated 
with superficial and severe pressure ulcers need to be prudently interpreted. 
Due to the low event rate in the sub-analyses, these multivariate models may 
lack accuracy and power. 
 
There is an evident need to consistently and correctly identify the patients who 
are at risk to develop pressure ulcers while receiving standardised preventive 
measures. Methods to identify these patients are essential to provide tailored 
preventive measures, only to those patients who will benefit from it, and to use 
the limited health care resources for pressure ulcer prevention (labour and 
materials) most effectively. Many studies addressed risk assessment methods to 
predict pressure ulcer development (Beeckman et al., 2013a; Coleman et al., 
2013; Balzer et al., 2007; Balzer et al., 2014), but only a few addressed this 
issue in patients who already receive preventive measures (Manzano et al., 
2013; Nixon et al., 2006a). Risk assessment scales, such as the Braden scale, 
aim to correctly identify patients at risk for pressure ulcer development, but were 
found to predict the development of pressure ulcers only to some extent 
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(Schoonhoven et al., 2002). Furthermore, the findings in our study indicated that 
the lower range of the Braden scale (between 6 and 16) was unable to identify 
those patients who were at risk of pressure ulcer development while receiving 
preventive measures. On-going research will hopefully lead to the development 
of new accurate tools that can be adopted in a clinical setting, to identify patients 
at risk while receiving preventive measures (Gefen et al., 2013; Aliano et al., 
2014). Much is expected from research on the use of ultrasound findings and the 
measurement of biochemical markers which can be diagnosed from blood or 
urine samples when tissue is damaged (Gefen et al., 2013; Aliano et al., 2014). 
Until then, the predictive factors identified in our study can help health care 
professionals to recognize these patients at risk of developing pressure ulcers 
even when preventive measures are applied. 
 
1.3 COST OF PRESSURE ULCER PREVENTION AND TREATMENT 
In Chapter 5 a systematic review on cost of pressure ulcer prevention and 
treatment in an adult population was performed, providing a robust overview of 
the economic impact of pressure ulcer prevention and treatment. The cost of 
pressure ulcer prevention per patient at risk varied between €2.65 and €87.57 
per day. The cost of pressure ulcer treatment ranged from €1.73 to €812.92 per 
patient per day. The studies encompassed a considerable methodological 
heterogeneity in terms of the type of health economic design, health economic 
perspective, the cost components, and the health outcomes. This overview of 
the available evidence can facilitate benchmarking with future economic 
evaluations of measures for prevention or treatment of pressure ulcers. 
 
For the first time a study was conducted giving insight in the cost of pressure 
ulcer prevention and treatment as provided in usual care in Flemish hospitals 
and nursing homes. The cost of pressure ulcer prevention and treatment in 
Flanders was examined using a cost-off-illness design with a mixed perspective. 
In hospitals, a cost for pressure ulcer prevention of €7.88 per patient at risk per 
day was found. In nursing homes, a cost of €2.15 per resident at risk per day 
was calculated. The cost of pressure ulcer prevention for patients and residents 
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perceived not at risk for pressure ulcer development was €1.44 per day in 
hospitals and €0.50 per day in nursing homes. The main cost driver was found 
to be the cost of labour, rather than the cost of devices. The average cost of 
local treatment per patient per day varied from €2.34 (category I) to €77.36 
(category IV) in hospitals, and from €2.42 (category I) to €16.18 (category IV 
pressure ulcer) in nursing homes. 
Direct cost of pressure ulcer prevention and treatment depends on the unit cost 
of resources, type and frequency of complications and cost of labour. Several 
studies indicated that nursing time cost accounted for a major share in the total 
cost of pressure ulcer prevention and treatment compared to the resource cost 
(Richardson et al., 1998; Schuurman et al., 2009; Frantz et al., 1995a; 
Haalboom, 1991; Schuurman et al., 2009). However, the methodological rigour 
to report on time measurements is often low. The method used for measuring or 
estimating nursing time related to pressure ulcer prevention or treatment 
included a Delphi procedure (Alterescu, 1989; Foglia et al., 2012), 
questionnaires (Agreda et al., 2007; Hu et al., 1993), interviewing researchers or 
experts (Makai et al., 2010; Severens et al., 2002), workload measurements 
(Frantz et al., 1995a; Lyder et al., 2002; Richardson et al., 1998; Xakellis et al., 
1995), self-recording by nurses (Schuurman et al., 2009), but was also 
frequently not reported (Agreda et al., 2007; Assadian et al., 2011; Bayoumi et 
al., 2008; Bennett et al., 2004; Oot-Giromini et al., 1989). These differences in 
measurement methods, may have led to varying time estimation results in the 
cost calculations of pressure ulcer prevention and treatment. In our study, direct 
observation was used to measure the average time of activities, thereby 
enhancing the quality of the cost estimates. Direct observation was found to be 
an accurate method for measuring the duration of nursing activities (Burke et. al, 
2000), but may provide conservative aggregated nursing times because the time 
related to activities,  such as ordering wound dressings, education and training, 
shift hand-over, and patient transport was not included in the total nursing time. 
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2. CONTRIBUTIONS TO INSIGHTS INTO PRESSURE ULCER RISK ASSESSMENT  
Risk assessment aims to accurately and consistently identify patients at risk for 
pressure ulcer development, and distinguish them from those who are not 
(Balzer et al., 2013; Defloor and Grypdonck, 2004).  None of the existing 
methods for risk assessment, such as the sole use of risk assessment scales, 
clinical judgement based on key risk factors, and skin observation, appropriately 
identify patients at risk. There is no sound evidence supporting the superiority of 
one risk assessment method over the others (Beeckman et al., 2013a).  
International guidelines recommend a structured risk assessment procedure 
combining all of the previously described methods (Beeckman et al., 2013a; 
NPUAP & EPUAP, 2009).  Risk assessment should be performed at the first 
contact with the patient, and reassessment needs to be undertaken at regular 
time intervals, tailored to the patients’ needs (Beeckman et al., 2013a).  
The identification of patients who are still at risk for pressure ulcer development 
despite receiving prevention did not get much research attention. These ‘high 
risk’ patients, however, need preventive measures adjusted to their increased 
vulnerability. Braden (2012) addressed levels of risk for pressure ulcer 
development based on the Braden scale risk scores: scores between 15 and 18 
would indicate some risk, 13 or 14 moderate risk, between 10 and 12  high risk, 
and ≤ 9 very high risk (Braden, 2012). Evidence to link the results of risk 
assessment scores to successive preventive measures is, however, lacking 
(Balzer et al., 2013; NPUAP & EPUAP, 2009). Our study confirmed that the 
lower range of the Braden scale (between 6 and 16) did not identify the patients 
who were still at risk to develop a pressure ulcer despite receiving prevention. 
Therefore, alternative approaches for risk assessment to identify high risk 
patients are clearly needed. The specific factors identified in this thesis, the 
presence of non-blanchable erythema, a urogenital disorder, and higher body 
temperature, can contribute to identify ‘high risk’ patients, and thus support 
health care professionals in adapting preventive measures.  
As tissue damage can develop in the underlying tissue before visible changes of 
the skin (Berlowitz and Brienza, 2007; Gefen, 2009), a comprehensive risk 
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assessment to identify ‘high risk’ patients, must include the assessment of all 
(direct and indirect) risk factors and not only those detectable at the level of the 
skin. 
  
On-going research may lead to the development of new accurate tools 
identifying patients at risk while receiving preventive measures (Gefen et al., 
2013; Aliano et al., 2014). Promising research about ultrasound and biochemical 
markers may support risk assessment using blood or urine samples to diagnose 
(invisible) tissue damage (Gefen et al., 2013; Aliano et al., 2014). 
 
Risk assessment can importantly impact health care expenditures. The 
identification of those patients who will benefit from prevention can lead to a 
more targeted and effective use of the limited health care resources. The 
available evidence about predictive factors for pressure ulcer development, 
complemented with factors emerging from further research, can assist health 
care professionals to identify ‘high risk’ patients. 
 
3. PRESSURE ULCER AETIOLOGY AND PREVENTIVE MEASURES  
Pressure ulcer aetiology is complex. Several interacting mechanisms result in 
skin and/or tissue damage. Loerakker et al. (2011) proposed, in a study that 
focused on the effects of tissue deformation, ischemia, and reperfusion in the 
development of deep tissue injuries, hypotheses linking aetiological mechanisms 
with different types of preventive measures (Loerakker et al., 2011). Preventive 
measures that increase the contact area may prevent damage related to 
deformation by keeping the internal tissue deformations below the deformation 
threshold. Patient repositioning and the use of alternating devices may prevent 
damage related to ischemia and ischemia-reperfusion injury by limiting the 
period of ischemia (Loerakker et al., 2011). Furthermore, gradual reperfusion of 
ischemic tissue is reported as a possible method to prevent an ischemic 
reperfusion injury (Okamoto et al., 1986; Unal et al., 2001).  
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In this thesis two studies were included that compare the effectiveness of 
several types of alternating devices. In the first study the effect of an ALPAM 
with a gradual, multi-stage inflation and deflation cycle was compared to an 
ALPAM with a one-stage steep inflation and deflation cycle of the air cells.  No 
significant difference in cumulative pressure ulcer incidence was found between 
patients allocated to a multi-stage ALPAM and patients allocated to a one-stage 
ALPAM (Demarré et al., 2012a). In a subsequent study, the patient data from 
the two previously conducted RCTs were pooled (Demarré et al., 2012a; 
Vanderwee et al., 2005). A significantly lower pressure ulcer incidence on multi-
stage ALPAMs compared to APAM overlays, and no difference between APAM 
overlays and one-stage ALPAMs was found (Demarré et al., 2013). The findings 
from our study were based on non-randomized comparative analyses on a 
pooled database. Therefore, prudency is needed in the interpretation of these 
findings. Our preliminary evidence, suggesting that less pressure ulcers develop 
on multi-stage ALPAMs compared to APAM-overlays, could not be explained by 
one specific feature in mattress design. It is difficult to determine the relative 
contribution of each of the differences between both mattresses and to associate 
them with possible aetiologic mechanisms. A hypothesis can be proposed that 
the combination of features may be responsible for our findings. These features 
consisted of lower inner air cell pressures and the use of a sensor which 
continuously measures weight distribution and adjusts the pressure in the cells, 
thus preserving internal tissue deformation below the threshold, and the gradual 
inflation and deflation of the air cells, thus decreasing damage related to 
ischemia-reperfusion. One feature by itself, influencing one specific aetiological 
factor of pressure ulcer development, could not empirically be demonstrated to 
be clinical effective (Demarré et al., 2012a), but a combination of all these 
features, acting on different aetiological mechanisms at the same time may 
explain why multi-stage ALPAMs were associated with a lower pressure ulcer 
incidence (Demarré et al., 2013). 
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4. PRESSURE ULCERS: IMPACT ON QUALITY OF CARE AND BUDGETS  
The results of this thesis point out the need for more emphasis on pressure ulcer 
prevention in daily practice. As described above, the implementation of pressure 
ulcer prevention compliant to guidelines should include a systematic, recurrent 
risk-assessment on regular time intervals, the allocation of preventive measures 
compliant to guidelines in patients at risk, as well as intensified prevention in 
patients at high risk (Vanderwee et al., 2011; Demarré et al., 2012a; Demarré et 
al., 2012b). Implementation of prevention guidelines and quality improvement 
can be guided by regular feedback of monitored results. This feedback can 
encourage health care professionals and can provide follow-up on the 
improvements in usual care towards best practices. These improvements can 
significantly influence patient safety and the quality of care (Gunningberg et al., 
2012). Pressure ulcer prevalence and incidence figures have been recognised 
as indicators of quality and safety of healthcare services. Other meaningful 
indicators of quality of care include the proportion of patients receiving risk 
assessment and concordance of the preventive measures with the guidelines 
(Pinkney et al., 2014; Gunningberg et al., 2012). The results of previous 
research in Flanders (Demarré et al., 2012b; Vanderwee et al., 2011) are in line 
with the international findings demonstrating that, in a majority of the patients at 
risk, pressure ulcer prevention is incomplete, inadequate or absent 
(Gunningberg et al., 2012; Vanderwee et al., 2011). 
 
Improvement can be achieved by further focussing on the implementation of 
guidelines and by increasing the overall quality of care in health care settings. A 
multi-facetted and multi-disciplinary approach, consisting of the implementation 
of ‘care bundles of best practices’, awareness campaigns, staff education, and 
clinical monitoring and feedback can improve the implementation of guidelines 
and care protocols (Beeckman et al., 2013a; Beeckman et al., 2013b). 
Healthcare services can provide in-service and on-the-job training, including 
direct feedback on risk assessment methods and the level of customised 
preventive measures to improve guideline and protocol implementation 
(Beeckman et al., 2013a; Niederhauser et al., 2012; van Gaal et al., 2011).  
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Quality of care regarding pressure ulcer prevention can be further improved 
when health care professionals listen and accurately respond to patients’ and 
carers’ observations, and when they respond promptly to clear signs that risk 
factors are present (Beeckman et al., 2011; Pinkney et al., 2014). This prompt 
response to the patient’s needs to provide pressure ulcer prevention compliant 
to guidelines, may also be influenced by nurses’ attitudes and knowledge (Grol 
& Wensing, 2004). Previous studies in Belgian hospitals and nursing homes 
found insufficient knowledge concerning pressure ulcer prevention, which may 
lead to misconceptions about preventive strategies and can result in inadequate 
prevention (Beeckman et al., 2011; Demarré et al., 2012b).  Furthermore, 
nurses’ attitudes towards pressure ulcer prevention were found to significantly 
predict their compliance with prevention guidelines. Therefore guideline 
implementation strategies should also focus on improving nurses’ knowledge 
and attitude to effectively increase the application of prevention compliant to 
guidelines (Beeckman et al., 2011; Demarré et al., 2012b). 
 
The improvement of quality of care regarding pressure ulcer prevention can be 
guided by the regular measurement of quality indicators. In Belgium, the Federal 
Council of Nursing Care Quality developed a set of pressure ulcer specific 
quality indicators for hospitals that need to be monitored at regular time 
intervals. These quality indicators include both outcome as well as process 
indicators. For nursing homes, the Flemish Agency for Care and Health 
developed a frame of reference for quality and safety of healthcare services, 
also including some pressure ulcer related indicators. These sets of indicators 
aim to improve quality and safety of care by standardising the development of a 
minimal well-considered quality policy.  
 
Monitoring of pressure ulcer specific quality indicators is mandatory for Flemish 
hospitals and nursing homes, but the results are not public nor are they coupled 
to financial incentives. Rather than prevention (labour and materials), the current 
Belgian health care services’ financing emphasizes reimbursement of treatment 
of severe pressure ulcers. In contrast to the Belgian situation and the situation in 
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many other European countries, the treatment of hospital-acquired pressure 
ulcers is financially penalised in the United States (Gunningberg et al. 2012; 
NPUAP, 2011). Changes in reimbursement policy and hospital staffing in the 
United States seem to have increased the awareness hospital-acquired 
pressure ulcers as a negative patient outcome and may have prompted more 
systematic risk assessment and a more timely start of preventive measures 
(Gunningberg et al. 2012). It is not clear to what extent the United States 
reimbursement policy has led to the allocation of preventive measures to 
patients not at risk for pressure ulcer development and associated futile costs. 
Our study on cost of pressure ulcer prevention in Flemish hospitals and nursing 
homes reported on the extent of the futile costs (of which the avoidance may 
result in cost savings) and opportunity costs (of which the avoidance may result 
in a better allocation of resources) related to the pressure ulcer prevention in 
patients not at risk. Therefore, adopting United States alike reimbursement 
policies seems not recommended at this time. Other possibilities to increase the 
awareness can be explored, such as the creation of an edifying award for 
hospitals, nursing homes and home care organisations with low nosocomial 
pressure ulcer incidences (for example “skin friendly hospital” by analogy with 
“baby friendly hospital”). 
 
Further, organisational aspects have been found to significantly influence 
pressure ulcer incidence (Park et al, 2014). In multivariate-analyses, nurse 
staffing and nurses turnover rates were found to affect pressure ulcer incidence. 
Higher turnover negatively affected the quality of patient care and this 
independently from staffing level. Higher staffing levels were associated with 
lower pressure ulcer incidences (Park et al., 2014). Investments in sufficient 
staffing levels and minimization of turnover rates may also influence pressure 
ulcer incidences. 
 
Cost savings may be achieved when pressure ulcers can be prevented through 
improved guideline implementation in clinical practice. In our study, the cost of 
local pressure ulcer treatment in Flanders varied between €2.34 and €77.36 per 
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patient per day. With an annual cost of 165 million Euro, when costs of 
prolonged hospitalisation are included, pressure ulcer treatment significantly 
impact overall health care expenditures in Flanders. Avoiding the development 
of pressure ulcers and subsequent treatment costs, can be achieved by 
focussing on pressure ulcer prevention (Beeckman et al., 2013a; van Gaal et al., 
2011).  
 
The focus on prevention must also include the re-evaluation at regular intervals 
of the current preventive measures provided to the patient. This re-evaluation 
must be based on reassessment of risk including both patients not receiving 
preventive measures and those who currently do. Some patients identified not at 
risk receive pressure ulcer preventive measures, creating futile costs. Our cost 
study found that futile cost for prevention in hospitals and nursing homes in 
Flanders counted up to 8.67 million Euro. The resources should be used more 
effectively, because healthcare resources for pressure ulcer prevention (labour 
and materials) are limited. 
 
5. METHODOLOGICAL ISSUES 
5.1 RCTS AND SAMPLE SIZE 
Well designed and sufficiently powered RCT-designs are considered the golden 
standard to determine the most effective intervention, and this also holds true for 
pressure ulcer preventive measures (The Cochrane Collaboration, 2008). An 
RCT is characterised by experimentation, control, and randomisation (Polit and 
Beck, 2008). If randomisation is successful, the effect of experimental 
treatments, such as multi-stage and one-stage ALPAMs, can be determined 
without it being influenced by differences in baseline characteristics of the 
patients (Polit and Beck, 2008). Large-scale RCTs in pressure ulcer prevention 
are difficult to carry out and very time consuming. In the ALPAM-study 20 
months were needed to collect data in five hospitals. Furthermore, the ability to 
carry out an RCT largely depends on the willingness of the institutions, health 
care professionals, and patients to participate in the study. The quality of the 
data collection partly depends on the nurses’ dedication to the study when 
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involved in the inclusion and the follow-up of patients and this quality may 
diminish with longer periods of data collection. A major problem in conducting 
these types of RCTs is the low event rate and the subsequent need for large 
sample sizes.  In our ALPAM study two types of pressure ulcer prevention at the 
heels were provided. Pressure ulcer incidence at the heel site was 1.9% (n=6) 
on one-stage ALPAMs compared to 1.3% (n=4) on multi-stage ALPAMs. Based 
on these figures, a sample size of almost eleven thousand patients (α=0.05; β
=0.20) is needed to find a significant difference between groups, if a true 
difference would exists.  There is a need for RCTs examining currently used and 
new devices for heel prevention that are both effective and well tolerated by 
patients, but the sample sizes needed to compare such preventive measures 
are enormous. 
 
Another example of the same problem is the need for further research about the 
implementation of tailored prevention in patients who already receive preventive 
measures. More attention is needed to perform re-evaluation of care, when 
standardised prevention is provided. This re-evaluation can be based on 
predictive factors to identify ‘high risk’ patients. Signs of changing risk or 
inadequate prevention must lead to adaptation of the patients’ preventive care 
plan. Studies examining the effectiveness of the implementation protocols will 
have a limited number of patients eligible for inclusion in the study (i.e. at risk 
while receiving preventive measures). Therefore, such a study will need to 
include patients during an extensive period of time to have a sufficiently powered 
study. 
 
Creative solutions and collaborations will be needed to tackle these problems.  
International research groups, collaborating in identifying most important 
research goals, in developing a standardised core-outcome set, and a minimum-
dataset can enhance uniformity. This uniformity can improve the methodological 
quality of original studies as well as contribute to the ability of performing 
systematic reviews, meta-analyses or pooled database analyses. These pooled 
database analyses can partly concede to the problem of the need of large 
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sample size. By pooling data, the sample size can be increased and provide 
new comparative analyses based on existing data. However, the lack of 
randomisation remains a major problem and therefore, large-scale RCTs may 
still be advised to confirm findings.  
The current finding that the annual cost of pressure ulcer treatment in Flanders 
is four times the cost of pressure ulcer prevention, may emphasise the need for 
more resources to be committed to pressure ulcer prevention research. There is 
a discrepancy between the relevance of pressure ulcer prevention and the 
availability of methodologically sound clinical studies focusing on risk 
assessment and preventive measures (Beeckman et al., 2013a). Original 
research is preferably funded by grants from independent funding agencies, but 
rigorously regulated collaboration with medical device industries may also create 
new opportunities to test innovative technologies in pressure ulcer prevention. 
 
5.2 COMPLEXITY OF RISK FACTOR STUDIES 
Findings from studies examining risk factors for pressure ulcer development 
depend on several methodological factors, including the use of prevalence or 
incidence data (and time to follow-up), the inclusion of potential risk factors in 
the model and how they are measured, the outcome, the sample size, and the 
(variation in) preventive measures. All of these methodological factors influence 
the risk factors identified to predict pressure ulcer development (Coleman et al., 
2013).  
 
In a recent review, Coleman et al. (2013) pointed out the need to include a 
comprehensive range of key risk factors in multivariate analyses. In a 
subsequent study, a risk factor minimum dataset was proposed to overcome the 
range of frequently occurring methodological problems of risk factor studies 
(Coleman et al., 2014). When using this minimum dataset in further risk factor 
research, large scale multivariate analyses and meta-analyses will be facilitated 
(Coleman et al., 2014).  When conducting our study on risk factors this minimum 
dataset was not yet available. Our risk factor study did not include data on the 
presence of shock or organ failure to examine their association with pressure 
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ulcer development, as proposed in the minimum dataset (Coleman et al., 2014), 
but a urogenital disorder was found predictive for pressure ulcer development. 
None of the baseline characteristics collected in our study could explain the 
increased risk for patients with a urogenital disorder to develop a pressure ulcer 
compared to those without. A possible reason for the finding may be that if the 
presence of urogenital disorders referred to a diagnosis of infection, the 
presence of urogenital disorders may also be related to shock and/or organ 
failure. Therefore further risk factor research should include these factors related 
to shock and organ failure. Furthermore, the minimum dataset defined by 
Coleman et al. (2014) could be complemented by factors emerging from other 
and new studies, such as the presence of IAD. 
 
Finally, Coleman’s’ minimum dataset is developed for risk factor studies 
including a broad population of patients. Further research would be needed to 
adapt the current tool to the detection of ‘high risk’ patients or to develop a 
similar minimum dataset for patients at ‘high risk’. However, conducting this 
research yielding reliable models of risk factors for the prediction of pressure 
ulcer development is challenging (Balzer et al., 2013). In our study on risk 
factors, the low event rate limited the multivariate analyses. The wide confidence 
intervals of the potentially predictive factors for developing a severe pressure 
ulcer, and to a lesser extend for superficial pressure ulcers, resulted in a lower 
reliability of these multivariate models. Therefore, again sufficient sample sizes 
are needed to ensure the statistical power (Balzer et al., 2013) and the accuracy 
of the odds ratios (Peduzzi et al., 1995). Further, the preventive measures 
provided to the ‘high risk’ patients need to be comparable and standardised in all 
patients included in a study (Balzer et al., 2013). Therefore, tailored pressure 
ulcer prevention based on the patient’s risk factors would need to be 
standardised in new prevention protocols to allow comparable and reproducible 
research. 
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5.3 PRESSURE ULCER COST STUDIES GUIDELINES 
A cost-of-illness design is appropriate to quantify the medical costs caused by 
an illness or a condition (Hodgson and Meiners, 1982; Larg and Moss, 2011). 
The majority of studies on cost of pressure ulcer prevention and treatment lack a 
clear conceptualisation of the study design, or did not include a detailed 
description of the prevention or treatment (Chapter 5). Furthermore, the costs 
items included in the total cost of prevention and treatment, and methodology or 
sources may largely affect the outcome of health economic evaluations (Larg 
and Moss, 2011; WHO, 2009).   
 
Several guidelines corresponding to several health economic designs are 
available (Larg and Moss, 2011), although the methodological rigour used to 
develop these guidelines varied. The use of the currently available guidelines 
may improve the methodological quality and the validity of the results, as well as 
the transparency of reporting. Besides generic guidelines, pressure ulcer 
specific recommendations for health economic designs are needed. These 
pressure ulcer specific recommendations must include recommendations to 
enhance quality of data collection as well as quality of data reporting, thereby 
enhancing (inter)national benchmarking of outcomes.  
 
Pressure ulcer specific recommendations for cost-of-illness studies can advise 
on costs items that need to be included and how they must be measured, as 
well as on the cost outcomes and how they must be measured. 
 
The costs included in the study will affect the cost outcome. Cost-of-illness 
studies, generally take into account both direct and indirect cost (Larg and Moss, 
2011; Rice, 1967). The economic impact of indirect costs on the total societal 
expenditures may be marginal for pressure ulcers because the cost of 
productivity loss due to pressure ulcer development in a mainly elderly 
population will probably be limited, but this low impact of indirect costs is not yet 
examined.  
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Cost of pressure ulcer prevention and treatment is mainly driven by labour cost, 
which depends on the methodology used to estimate the duration of these times. 
Direct time measurements were found to provide more accurate time estimates 
than other, more subjective measurement methods (Boudt, 2013; Burke et al., 
2000). Therefore it is recommended to use data on time measurements 
retrieved by direct observation with a minimum of 15 observations per activity 
(Van Goubergen, 2005). 
 
Pressure ulcer specific recommendations for cost-of-illness studies could 
provide a checklist of mandatory and recommended items and outcomes to 
report. 
Mandatory items could include items such as the population under study, the 
research aim, the health economic perspective used (with a clear definition), the 
included cost items to measure the cost of prevention and treatment and how 
they were measured, and the cost outcomes and how they were compiled. For 
example, in cost-of-illness studies it is recommended to report the mean costs 
instead of the median costs. Despite the skewness of the cost distribution, the 
arithmetic mean is found to be the most informative because it provides 
information about the cost of prevention and treatment in all patients. This 
positive skewness is a common issue in health economic research when 
presenting the cost per patient. Few individuals with high needs tend to use 
most of the health care resources (Graves et al., 2005; Thompson and Barber, 
2000). Health economic studies need to report on the arithmetic mean of costs 
to enhance benchmarking between study results (Thompson and Barber, 2000).  
Recommended items could include separately reporting cost for labour and 
materials. This would be of surplus value for benchmarking with other countries 
and between health care services. For example, the remarkably lower cost of 
pressure ulcer treatment per day in nursing homes compared to hospitals can 
stimulate critical review of current treatment practices.  
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6. RECOMMENDATIONS FOR PRACTICE  
Emphasis on a structured risk assessment followed by re-evaluation of the 
provided prevention is needed. Health care professionals need to be informed 
about their compliance with current prevention guidelines. Furthermore, they 
need to be aware of the impact of pressure ulcers on the patients’ well-being, 
and be informed on the monetary burden of pressure ulcer treatment for all 
parties involved. Preventive measures are sometimes provided to those not at 
risk for pressure ulcer development, creating an unnecessary cost.  
Once prevention is provided, signs of changing risk profile or inadequate 
prevention must lead to an adaptation of the patients’ preventive care plan, 
improving the allocation of the available resources (Demarré et al., 2013; 
Vanderwee et al., 2011).  
 
Training to enhance nurses’ awareness on pressure ulcer prevention must be 
included in the basic education of nurses. Enhanced awareness on prevention is 
also needed in daily practice. A multi-facetted and multi-disciplinary approach, in 
which healthcare services provide in-service and on-the-job training with a clear 
focus on re-assessment and tailoring of preventive measures, may decrease 
pressure ulcer development.  
 
One of the most important and recurrent questions of health care practitioners is 
to which patients which preventive measures should be applied. Several studies 
reported in this thesis aimed to contribute to answering this question. Our 
findings suggest that there is preliminary evidence that a multi-stage ALPAM 
may be more effective in the prevention of pressure ulcers when compared to an 
APAM overlay.  Multi-stage ALPAMs are associated with considerable costs for 
purchase and maintenance, compared to less costly APAMs. Therefore, 
prudency is advised in the allocation of these multi-stage ALPAMs. 
 
Besides the focus on cost of preventive measures, enhanced awareness in daily 
practice of the financial implications involved in pressure ulcer treatment is 
needed in daily practice. The cost of the materials used for pressure ulcer 
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treatment needs to be clear and transparently communicated to the nurses 
providing the wound treatment. Costs of materials, frequency of wound 
treatment and the patient’s comfort need to be more explicitly weighted when 
treating pressure ulcers to enhance the awareness of the total cost of pressure 
ulcer treatment for all parties involved. 
 
7. RECOMMENDATIONS FOR FURTHER RESEARCH 
Several indications for further research were presented in this thesis, but special 
attention can be drawn to the following recommendations. 
Preliminary evidence suggests that less pressure ulcers develop on multi-stage 
ALPAMs compared to APAM overlays, but multi-stage ALPAMs bring along 
considerable costs for purchase and maintenance when compared to less costly 
APAMs. Cost-effectiveness analyses can provide insight whether the costs 
related to the purchase and maintenance of these sophisticated devices are 
warranted by their possible benefits, if conducted along an RCT. Furthermore, 
RCTs are generally conducted on several wards and hospitals. Therefore, 
multilevel analyses need to be used to correct possible grouping structures on 
ward or hospital level.  
 
Currently no risk assessment methods exist or are in use to identify patients at 
risk for pressure ulcer development while receiving preventive measures. 
Approaches for risk assessment to identify high risk patients are clearly needed. 
Further research to develop new, simple, and accurate tools to identify these 
high risk patients is needed (Gefen et al., 2013; Aliano et al., 2014). Promising 
research about ultrasound and biochemical markers may support risk 
assessment, using blood or urine samples to diagnose (invisible) tissue damage 
(Gefen et al., 2013; Aliano et al., 2014). 
 
In this thesis the cost of pressure ulcer prevention of care as usual in nursing 
homes and hospitals was reported.  The majority of the observed treatments of 
severe pressure ulcers were conservative treatments and surgical treatments or 
complications were rarely observed. Medical resource use was based on 
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prevalence data and observed one or two days per hospital, which may have led 
to an under-observation of severely complicated pressure ulcers and costly 
treatments. Further research needs to include data about medical resource use 
to treat a category IV pressure ulcer during the full hospitalisation period or until 
complete healing to provide more accurate cost estimates. 
The hypothesis that cost savings may be achieved when pressure ulcers can be 
prevented through improved guideline implementation need to be examined in 
clinical practice. Further research should provide insight in the cost of pressure 
ulcer prevention compliant to guidelines and the cost per averted pressure ulcer. 
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The research outline pursued with this thesis can be divided in three parts. In the 
first part, studies to compare the effectiveness of several interventions for the 
prevention of pressure ulcers were conducted. Pressure ulcer prevention 
focusses on the reduction of the amount and duration of pressure and shear. An 
alternating device intermittently removes pressure and shear from vulnerable 
areas. It provides pressure relief via cyclic inflating and deflating air cells.  
Systematic reviews and (inter)national guidelines demonstrate inconclusive 
results as to the superiority of one specific alternating pressure device. An 
example of an active support surface is an alternating pressure air mattress 
(APAM), available as overlays or replacement mattress, and ALPAMs 
(Alternating Low Pressure Air Mattresses). Differences between several types of 
active support surfaces can be related to differences in surface characteristics, 
such as cycle time, air cell inflation sequence, and pressure amplitude. The 
inflation and deflation of the air cells of an APAM and ALPAMs are characterized 
by a steep, one-stage inflation or deflation. 
ALPAMs were designed by the medical technology industry to generate lower 
pressures compared to APAMs. More recently these ALPAMs have been 
modified so that the transition from deflated air cell to inflated air cell is more 
gradual or multi-staged. As more complex technology does not necessarily lead 
to more effective devices, the aim of the first trial was to examine the influence 
of a multi-stage inflation and deflation cycle versus a one-stage inflation and 
deflation cycle. The multi-stage ALPAM did not result in a significantly lower 
pressure ulcer incidence compared to the one-stage ALPAM. Both mattresses 
were equally effective to prevent pressure ulcers. The time to develop a 
pressure ulcer was comparable in both groups.  
 
Secondly, the effectiveness of an APAM overlay was compared with the 
effectiveness of a one-stage and a multi-stage ALPAM. A reduced incidence of 
pressure ulcers was found in the multi-stage ALPAM group compared to the 
APAM overlay group. No significant differences in pressure ulcer development 
were found between a one-stage ALPAM and an APAM overlay. The median 
time to develop a pressure ulcer was similar among groups. 
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Despite preventive measures provided in the effectiveness studies, a proportion 
of the patients developed a pressure ulcer. The identification of these ‘high risk’ 
patients is examined in the second part of this dissertation and is crucial to 
further improve the quality of care. The aim of a subsequent study was to 
identify factors that independently predicted the development of a pressure ulcer 
in an at risk population who received standardised preventive care. The 
presence of non-blanchable erythema, having a urogenital disorder, and higher 
body temperature were found to be predictive factors associated with the 
development of a pressure ulcer.  
 
In the third part of this thesis the cost of pressure ulcer prevention and treatment 
was addressed. International literature found a cost of pressure ulcer prevention 
per patient at risk varying between €2.65 and €87.57 per day. The cost of 
pressure ulcer treatment ranged from €1.73 to €812.92 per patient per day. 
These studies encompassed a considerable methodological heterogeneity in 
terms of the type of health economic design, health economic perspective, the 
cost components, and the health outcomes. In a subsequent study insight was 
provided into the cost of pressure ulcer prevention and treatment in hospitals 
and nursing homes in Flanders using a mixed perspective. In hospitals, a cost 
for pressure ulcer prevention of €7.88 per patient at risk per day was found. In 
nursing homes, a cost of €2.15 per resident at risk per day was calculated. The 
cost of pressure ulcer prevention for patients and residents perceived not at risk 
for pressure ulcer development was €1.44 per day in hospitals and €0.50 per 
day in nursing homes. The main cost driver was found to be the cost of labour, 
rather than the cost of devices. The average cost of treatment per patient per 
day varied from €2.34 (category I) to €77.36 (category IV) in hospitals, and from 
€2.42 (category I)  to €16.18€ (category IV pressure ulcer) in nursing homes. 
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Het doel van dit proefschrift was drieledig. In het eerste deel werden 
onderzoeken uitgevoerd om de effectiviteit van verschillende druk verdelende 
systemen te vergelijken in de preventie van decubitus. Adequate 
decubituspreventie wordt verkregen door een reductie in de duur en de 
intensiteit van de druk- en schuifkrachten. Een methode om de duur van druk- 
en schuifkrachten te verminderen is het gebruik van alternerende systemen. 
Deze alternerende systemen zorgen voor drukopheffing door het cyclisch 
opblazen (inflatie) en leeglaten (deflatie) van luchtcellen. Systematische reviews 
en (inter)nationale richtlijnen geven aan dat er geen klinische bewijskracht is om 
één alternerend systeem boven een ander aan te bevelen. Voorbeelden van 
alternerende systemen zijn APAMs (alternerende druk matrassen), beschikbaar 
als oplegmatras of matras vervangend systeem, en ALPAMs (alternerende lage 
druk matrassen). APAMs en ALPAMs worden gekenmerkt door een 
enkelvoudige, snelle inflatie en deflatie cyclus van de luchtcellen. 
ALPAMs zijn alternerende systemen die werden ontworpen door de medische 
industrie om een lagere druk te genereren in vergelijking met APAMs. 
Recentelijk werden deze ALPAMs aangepast om de overgang tussen inflatie en 
deflatie van een luchtcel meer gradueel of getrapt te laten verlopen. Aangezien 
complexere technologie niet noodzakelijk tot effectievere systemen leidt, was 
het doel van het onderzoek om na te gaan of er een verschil was in effectiviteit 
tussen een alternerende lage druk matras met een enkelvoudige, snelle inflatie 
en deflatie cyclus van de luchtcellen en de effectiviteit van een alternerende lage 
druk matras met een meer graduele, getrapte inflatie en deflatie cyclys van de 
luchtcellen. De ALPAM met een graduele/getrapte inflatie en deflatie cyclus 
resulteerde niet in een significant lagere incidentie van decubitus tegenover de 
ALPAM met een enkelvoudige, snelle inflatie en deflatie van de luchtcellen. 
Beide matrassen waren even effectief in de preventie van decubitus. De tijd om 
decubitus te ontwikkelen was vergelijkbaar in beide groepen.  
 
Vervolgens werd de effectiviteit van een APAM oplegmatras vergeleken met de 
doeltreffendheid van zowel een ALPAM met een graduele/getrapte inflatie en 
deflatie van de luchtcellen als een ALPAM met een enkelvoudige, snelle inflatie 
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en deflatie van de luchtcellen. De incidentie van decubitus was significant lager 
in de ALPAM groep met een graduele/getrapte inflatie en deflatie van de 
luchtcellen vergeleken met de APAM oplegmatras groep. Er werden geen 
significante verschillen gevonden in incidentie van decubitus tussen de ALPAM 
met een enkelvoudige, snelle inflatie en deflatie van de luchtcellen en de APAM 
oplegmatras. De gemiddelde tijd om decubitus te ontwikkelen was vergelijkbaar 
in beide groepen. 
 
Ondanks preventieve maatregelen in de effectiviteitsstudies, ontwikkelden een 
deel van de patiënten decubitus. De identificatie van deze hoog-risicopatiënten 
werd bestudeerd in het derde deel van het proefschrift en is van cruciaal belang 
om de kwaliteit van zorg verder te kunnen verbeteren. Het doel van dit 
onderzoek was identificeren van risicofactoren die de ontwikkeling van decubitus 
voorspellen bij patiënten die gestandaardiseerde preventieve zorg kregen. De 
aanwezigheid van niet-wegdrukbare roodheid, opname omwille van een 
urogenitale stoornis en een hogere lichaamstemperatuur bleken geassocieerd te 
zijn met de ontwikkeling van decubitus. 
 
Het derde deel van dit proefschrift onderzocht de kost geassocieerd met de 
preventie en behandeling van decubitus. Internationale literatuur vermeldt 
kosten voor preventie van decubitus variërend van €2.65 tot €87.57 per dag per 
risicopatiënt. De kosten van de behandeling van decubitus varieerden tussen 
€1.73 en €812.92 per patiënt per dag. De methodologische heterogeniteit tussen 
de verschillende studies was aanzienlijk, in termen van gebruikte 
onderzoeksdesign, gekozen gezondheid, economisch perspectief, de 
geïncludeerde kost posten en de weergegeven uitkomstmaten.  
In een vervolgonderzoek werd inzicht gegeven in de kost van preventie en de 
behandeling van decubitus in ziekenhuizen en woonzorgcentra in Vlaanderen, 
gebruik makend van een gecombineerd perspectief (patiënt, instelling en 
zorgverzekering). In ziekenhuizen bedroeg de kost voor decubituspreventie 
€7.88 per risicopatiënt per dag. In woonzorgcentra bedroeg deze €2.15 per 
bewoner met risico op het ontwikkelen van decubitus per dag. De kosten van 
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preventie van decubitus bij patiënten en bewoners zonder risico op de 
ontwikkeling van decubitus bedroegen €1.44 per dag in ziekenhuizen en €0.50 
per dag in woonzorgcentra. De belangrijkste kostenfactor bleek de loonkost, 
eerder dan de materiaalkosten. De gemiddelde behandelingskost per patiënt per 
dag varieerde tussen €2.34 (decubitus categorie I) en €77.36 (decubitus 
categorie IV) in ziekenhuizen, en tussen €2.42 (decubitus categorie I) en €16.18 
(decubitus categorie IV) in woonzorgcentra. 
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